{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "import re\n",
    "import PyPDF2 \n",
    "import textwrap\n",
    "import pdfplumber\n",
    "from PyPDF2 import PdfReader"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdin",
     "output_type": "stream",
     "text": [
      "Enter file: C:\\Users\\SRIVAA86\\OneDrive - Pfizer\\Desktop\\NLP\\New folder\\C3441021 Statistical Analysis Plan v6.3 final.pdf\n"
     ]
    }
   ],
   "source": [
    "pdf_file = input(\"Enter file:\") \n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "23\n",
      "24\n"
     ]
    }
   ],
   "source": [
    "pattern = r\"^\\d+\\.\\s([A-Z\\s\\s:]+)\"\n",
    "sections = {}\n",
    "converted_sections = {}\n",
    "\n",
    "with open(pdf_file, 'rb') as file:\n",
    "    reader = PdfReader(file)\n",
    "    num_pages = len(reader.pages)\n",
    "\n",
    "    for page_number in range(num_pages):\n",
    "        page = reader.pages[page_number]\n",
    "        content = page.extract_text()\n",
    "        matches = re.findall(pattern, content, re.MULTILINE)\n",
    "       \n",
    "        for match in matches:\n",
    "            section_name = re.sub(r\"^\\d+\\.\\s\", \"\", match)\n",
    "            section_key = re.sub(r\"\\s\", \"\", section_name.lower())  # convert to lowercase and remove spaces\n",
    "            next_integer_match = re.search(r\"\\d+\", content[content.find(match) + len(match):])\n",
    "            \n",
    "            if next_integer_match:\n",
    "                next_integer = int(next_integer_match.group())\n",
    "                sections[section_key] = next_integer\n",
    "                converted_sections[section_key] = section_name.strip()\n",
    "\n",
    "# Store the section names and integers in a dictionary\n",
    "dictionary = {section: integer for section, integer in sections.items()}\n",
    "\n",
    "# Extract start page and end page for \"analysesandsummaries\" section\n",
    "section_start = \"analysesandsummaries\"\n",
    "section_end = None\n",
    "start_page = None\n",
    "end_page = None\n",
    "\n",
    "if section_start in sections:\n",
    "    start_page = sections[section_start]\n",
    "    section_index = list(sections.keys()).index(section_start)\n",
    "    \n",
    "    if section_index < len(sections) - 1:\n",
    "        section_end = list(sections.keys())[section_index + 1]\n",
    "        end_page = sections[section_end]\n",
    "\n",
    "# Retrieve the converted section name from the converted_sections dictionary\n",
    "section_end_converted = converted_sections.get(section_end)\n",
    "\n",
    "analysis_section_start= \"analysissets\"\n",
    "analysis_section_end = None\n",
    "analysis_start_page = None\n",
    "analysis_end_page = None\n",
    "\n",
    "if analysis_section_start in sections:\n",
    "    analysis_start_page = sections[analysis_section_start]\n",
    "    analysis_section_index = list(sections.keys()).index(analysis_section_start)\n",
    "            \n",
    "    if analysis_section_index < len(sections) - 1:\n",
    "        analysis_section_end = list(sections.keys())[analysis_section_index + 1]\n",
    "        analysis_end_page = sections[analysis_section_end]\n",
    "\n",
    "analysis_section_end_converted = converted_sections.get(analysis_section_end)\n",
    "print(analysis_start_page)\n",
    "print(analysis_end_page)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "def extract_text_from_pdf(pdf_file, start_page, end_page):\n",
    "    with pdfplumber.open(pdf_file) as pdf:\n",
    "        text = \"\"\n",
    "        for page_num in range(start_page - 1, end_page):\n",
    "            page = pdf.pages[page_num]\n",
    "            page = page.crop((50.0, 70.0, 612.0, 697.0))\n",
    "            text += page.extract_text()\n",
    "    return text\n",
    "\n",
    "start_page = start_page\n",
    "end_page = end_page\n",
    "\n",
    "extracted_text = extract_text_from_pdf(pdf_file, start_page, end_page)\n",
    "# print(extracted_text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ANALYSES AND SUMMARIES\n",
      "Overview of analysis presentation:\n",
      " Continuous data will be summarized using descriptive statistics (mean, median, SD,\n",
      "minimum, maximum, and 2-sided 95% CI) Categorical data (including point estimates) will be summarized by frequency counts,\n",
      "percentages and binomial 95% CIs using the Clopper-Pearson method.\n",
      " Kaplan-Meier estimates (time-to-event distirbutions) will be presented and displayed\n",
      "graphically where appropriate, together with a summary of associated statistics\n",
      "(including HRs, 2-sided 95% CIs, and 1-sided p-values).\n",
      " There will be no adjustment for multiplicity.\n",
      "6.1. Part 1 Analyses\n",
      "6.1.1. Primary Endpoint\n",
      "Target safety events specified inTable 4will be evaluated in the Part 1 safety analysisset.\n",
      "Table 4. Target Safety Events: Part 1 (Open-Label Treatment)\n",
      "Hematologic Toxicity\n",
      "Any of the following considered possibly or probably related to talazoparib:\n",
      " Grade 4 anemia\n",
      " Grade 4 thrombocytopenia\n",
      " Grade 4 neutropenia (ANC <500/µL or <0.5 × 109/L)\n",
      " Grade 3 thrombocytopenia associated with clinically significant bleeding\n",
      " Grade 3 neutropenia or Grade 3 thrombocytopenia if daily dosing is interrupted for 7days\n",
      " Febrile neutropenia, defined as ANC <1000/µLwith a single temperature of >38.3C (>101F) or a temperature of\n",
      ">38C (100.4F) sustained over a 1-hour period\n",
      " Neutropenic infection (ANC <1000/µL or <1.0 × 109/L)\n",
      "Nonhematologic Toxicity\n",
      "Any Grade 3 adverse eventconsidered possibly or probably related to talazoparib excluding the following:\n",
      " Grade 3 laboratory abnormalities not considered clinically significant\n",
      " Grade 3 adverse event not considered clinically significant\n",
      " Grade 3 nausea or vomiting that responds to medical intervention within 72hours\n",
      " Grade 3 diarrhea that can be medically managed to Grade 2 within 72hours\n",
      " Grade 3 fatigue that improves to Grade 2 within 7 days\n",
      "Liver Toxicity\n",
      "Any of the following considered possibly or probably related to talazoparib:\n",
      " ALT or AST >3× ULNif baseline ALT or AST 3×ULN\n",
      " ALT or AST >5×ULN (a lower threshold should be considered if the ALT or AST abnormalities are\n",
      "accompanied by symptoms and signs of hepatitis ) AND 2-fold increases above baseline\n",
      " ALT or AST 3×ULN and total bilirubin ≥2×ULN\n",
      " Total bilirubin >5×ULN\n",
      "Toxicities will be classified by severity according to the National Cancer Institute Common Terminology Criteria for\n",
      "Adverse Events, version 4.\n",
      "As the targeted safety events defined above include some subjective criteria or multiple\n",
      "criteria occurring simultaneously, an assessment of whether or not event met the criteria of\n",
      "being target safety events requiring a reduction in the starting dose for Part 2 will be made\n",
      "based on a review of individual patient data, summaries of all AEs,and exposure.6.1.2. Secondary Endpoints [Pharmacokinetics]\n",
      "A record-level dataset Pharmacokinetic Analysis Set -Talazoparib will includeall\n",
      "talazoparib PK concentrations that meet thecriteria below:\n",
      " PK samples collected at Week1\n",
      " PK samples collected at Weeks 5, 9, 13, and 17 at the same dose level without any\n",
      "dose modification for at least 14 days.\n",
      "Another record-level dataset Pharmacokinetic Analysis Set -Enzalutamidewill includeall\n",
      "enzalutamideconcentrationsthat meet the criteria below:\n",
      " PK samples collected at Week 1\n",
      " PK samples collected at Weeks 5, 9, 13, and 17 for patients who did not experience\n",
      "any dose reductions or interruptions of enzalutamide.\n",
      "Pharmacokinetic Analysis Set –Talazopariband Pharmacokinetic Analysis Set –\n",
      "Enzalutamide will be used for PK parameter derivation and summary tables.\n",
      "6.1.2.1. PK Concentrations\n",
      "In Part 1, analyses of PK concentrations will include sampling at predose, 1, 2, 4, 6 and 24\n",
      "hours postdoseat Day 1 (week 1) and week 9. Additionally, blood samples for PK are\n",
      "collected at predoseand 2 hours postdoseat week 5 and predose at weeks 13 and 17.\n",
      "All planned individual patients’plasma concentration data will be listed(Pharmacokinetic\n",
      "Population). PK samples obtained beyond 10% of the planned time will be included in the\n",
      "listings and could be included in the calculation of PK parameters (based on discretion of the\n",
      "pharmacokineticist), however, will be removed from figures and tables reporting mean\n",
      "concentrations per planned sampling times. PredosePKsample collection should occur prior\n",
      "to administration of the investigational product on that day, otherwise will be excluded. In\n",
      "all data presentations (except listings), values below the limit of the assay quantification\n",
      "(BLQ) will be set to zero. In listings BLQ values will be reported as “<LLQ”, where LLQ\n",
      "will be replaced with the value for the lower limit of quantification.\n",
      "Summarystatisticswill beprovidedforplasmaconcentrations of talazopariband\n",
      "enzalutamide and its N-desmethyl metabolite at scheduled visits by time point (using the PK\n",
      "Analysis Sets for talazoparib or enzalutamide, see Section6.1.2). Plasma concentration\n",
      "values below the limit of quantitation will be treated as zero in the descriptive statistics\n",
      "calculations. Zero concentrations will be considered as missing in geometric mean\n",
      "calculations. Spaghetti plots of individual concentrations against actual time postdose\n",
      "(separate plots for each dose and scheduled visit) will be presented.\n",
      "6.1.2.2. PK Parameters\n",
      "In estimating the PK parameters, BLQ values at the beginning of the profile will be set toare embedded between BLQs, or quantifiable values occurring after two or more BLQs, may\n",
      "be set to missing at the discretion of the pharmacokineticist. Actual sampling times, rather\n",
      "than scheduled sampling times, will be used in all computations involving sampling times. If\n",
      "the actual time or dose time is missing, the scheduled time may be substituted in order to\n",
      "calculate the PK parameter. As appropriate, additional PK parameters may be calculated and\n",
      "reported.\n",
      "The following PK parameters of talazoparib and enzalutamide and its Ndesmethyl metabolite\n",
      "will be summarized usingthe Pharmacokinetic Population (specifically using the record-level\n",
      "sets called PK analysis set –Talazoparib and PK analysis set –enzalutamide) as appropriate:\n",
      "C ,C , T , AUC ,and CL /F will be summarized by dose and study visit.\n",
      "max trough max  ss\n",
      "Dose-normalized AUC , C , and C will be summarized by study visit.\n",
      " max trough\n",
      "The above mentioned PK parameters (T excluded) will be summarized by arithmetic\n",
      "max\n",
      "mean, standard deviation and CV, geometric mean, geometric CV, minimum, median,\n",
      "maximum value and the number of evaluable parameters. The PK characteristics of T will\n",
      "max\n",
      "be described utilizing the number of observations, minimum, maximum and median.\n",
      "Geometric CV% is defined as sqrt(exp(variance of log transformed data)-1)*100\n",
      "In addition, box and whisker plots for individual patient parameters AUC , C , and C\n",
      " max trough\n",
      "by dose and scheduled visit as well as for dose-normalized AUC , C , and C by\n",
      " max trough\n",
      "scheduled visit maybe be presented and overlaid with geometric means.\n",
      "For all presentations, PK data from Part 1 and Part 2 will be pooled. However, separate\n",
      "summaries of PK parameters including AUC , C , and C by dose level and scheduled\n",
      " max trough\n",
      "visit in addition to summaries of dose-normalized AUC , C , and C by scheduled visit\n",
      " max trough\n",
      "will be generated for patients in Part 1.\n",
      "6.1.3. Exploratory Endpoints\n",
      "For CTC counts, a summary of the mean (standard deviation), median, and range of\n",
      "baseline and postbaselinevalues will be provided for patients in Part 1 CTC evaluable\n",
      "population. In addition, the number and percentage of patients with CTC count ≥ 5vs. <5\n",
      "and CTC count >0vs. =0 per 7.5 mL will be presented as well.\n",
      "The analysis of CTC count conversion from 5 or more CTC per 7.5 mL at baseline to < 5\n",
      "CTC per 7.5 mL post baselinewill excludepatients with a CTC count < 5 per 7.5 mL at\n",
      "baseline. The proportion of patients withsuch a conversion will be calculated along with the\n",
      "two-sided 95% CI using Clopper-Pearson method (exact methodfor a binomial proportion).\n",
      "The analysis of CTC count conversion from detectable at baseline to 0 postbaselinewill\n",
      "exclude patients with a CTC count of 0 per 7.5 mL of blood at baseline. The proportion of\n",
      "patients with sucha conversionwill be calculated along with the two-sided 95% CIusing\n",
      "Clopper-Pearson method.The analysis of the proportion of patients with baseline CTCs <5 who show increased CTCs\n",
      "postbaselinewill excludepatients with a CTC count of ≥ 5 per 7.5 mL of blood at baseline.\n",
      "The proportion of patients with such a conversion will be calculated along with the two-sided\n",
      "95% CI using the Clopper-Pearson method.\n",
      "A separate analysis plan will be provided to describe analyses of molecular profiling of\n",
      "tumor tissue remaining after genomic testing for eligibility and of saliva and ctDNA.\n",
      "Although not specifically listed as exploratory objectives,analyses of efficacy including\n",
      "rPFS, ORR in patient with soft tissue measurable disease at baseline, PSA response, and time\n",
      "to PSA progression may be evaluated during the course of the study and will be reported at\n",
      "the time of the final analysis of rPFS in all-comers, if not sooner. Derivations will follow the\n",
      "same rules outlined in section 6.2for Part 2. Summaries will be descriptive and not\n",
      "inferential. Specifically summaries of time to event endpoints will be limitedto medians and\n",
      "rates at specific timepoints of interest. Summaries of response rates will include number and\n",
      "percentage. Summaries will be provided regardless of mutation status or starting dose.\n",
      "Mutation status (where available) and starting dosewill be provided in data listings.\n",
      "6.2. Part 2 Analyses\n",
      "6.2.1. Primary Endpoint--rPFS\n",
      "The primary efficacy analysis will compare rPFS based on BICR between talazoparib in\n",
      "combination with enzalutamide vs. talazoparib-matching placebo in combination with\n",
      "enzalutamide, and will be performed using anone-sided stratified log-rank test forthe all-\n",
      "comers and DDR-deficient populations respectively(subsets of the ITT population). A\n",
      "secondary analysis of rPFS based on investigator assessment will also be performed.\n",
      "rPFS is defined as the time from the date of randomization to first objective evidence of\n",
      "radiographic progression as assessed in soft tissue per RECIST1.1 or in bone (upon\n",
      "subsequent confirmation) per PCWG3 guidelines, or deathdue to any cause, whichever\n",
      "occurs first,and will be summarized in months using the following calculation:\n",
      "rPFS (months) = [date of event/censoring –randomization date +1]/30.4375.\n",
      "The documentationrequiredfor the determination of radiographic progressionis shown in\n",
      "Table 5.\n",
      "Table 5. Criteria for Evidence of Radiographic Progression\n",
      "Date Criteria for Progression Criteria for Confirmation Criteria for\n",
      "Progression of Progression Documentation of Disease\n",
      "Detected (Requirement and Timing) Progression on\n",
      "(Visit) [1] Confirmatory Scan\n",
      "Week9 Bone lesions: 2or more new Timing: at least 6weeks Persistence of at least 2\n",
      "lesions compared to baseline after progression identified lesions seen at week 9\n",
      "bone scan by PCWG3 or at Week17 Visit [2] AND 2 or more new bone\n",
      "lesions on bone scan\n",
      "(compared to Week9 scan)Table 5. Criteria for Evidence of Radiographic Progression\n",
      "Date Criteria for Progression Criteria for Confirmation Criteria for\n",
      "Progression of Progression Documentation of Disease\n",
      "Detected (Requirement and Timing) Progression on\n",
      "(Visit) [1] Confirmatory Scan\n",
      "Soft tissue lesions: No confirmatory scan Not applicable\n",
      "Progressive disease on CT or required for soft tissue\n",
      "MRI by RECIST1.1 disease progression\n",
      "Week17 or Bone lesions: 2 or more new Timing: at least 6weeks Persistent of at least 2 of\n",
      "later lesions on bone scan after progression identified the lesions identified as\n",
      "compared to Week9 bone Required for bone lesions new compared to week 9\n",
      "scan observed on bone scan [2]\n",
      "Soft tissue lesions: No confirmatory scan Not applicable\n",
      "Progressive disease on CT or required for soft tissue\n",
      "MRI by RECIST1.1 disease progression\n",
      "[1] Progression detected by bone scan at an unscheduled visit prior to week 13 will requireconfirmation at\n",
      "least 6 weeks later following the confirmation criteria outlined in the table for week 9. All other\n",
      "unscheduled assessments will follow the confirmation criteria for week 17.\n",
      "[2] Confirmation must occur at the next available scan.\n",
      "rPFS will be censored in the following scenarios:\n",
      "1) The patient will be censoredon the date of the last adequate tumor assessment on or\n",
      "before the data cutoff dateif the patient does not have radiographic progression and\n",
      "does not die.\n",
      "2) The patient will becensored on the date of last adequate tumor assessment prior to\n",
      "the start of new antineoplastic therapy, if thepatient starts a new antineoplastic\n",
      "therapy prior to radiographic progressionor death.\n",
      "3) The patient will be censored onrandomizationdate, if the patient does not have\n",
      "baseline or postbaselinetumor assessments.\n",
      "4) The patient will becensoredon the date of the last adequate tumor assessment\n",
      "without evidence of disease progression prior to missed tumor assessments, if the\n",
      "patient misses 2 or more scheduled tumor assessments immediately prior to\n",
      "radiographic progression or death.\n",
      "For the purpose of rPFS censoring, apatient will be censored on the date of the last\n",
      "adequate tumor assessment prior to the start of new antineoplastic therapy if the patient\n",
      "starts a new antineoplastic therapy prior to radiographic progression or death. If a patient\n",
      "has a curative radiotherapy where the treatment intent is specified as ‘primary treatment’\n",
      "or surgery where the treatment intent is specified as ‘curative in intent’ and the surgery\n",
      "outcome is either ‘resected’ or ‘partially resected’ prior to radiographic progression or\n",
      "death, the patient will also be censored on the date of the last adequate tumor assessment\n",
      "before the radiotherapy or surgery.Two or more missed assessments is defined as follows:\n",
      " If the last adequate tumor assessment prior to the event occurs on or before 70\n",
      "days from randomization, more than 119 days from that assessment (two 8-week\n",
      "assessments plus a 7-day assessment window)to the event;\n",
      " If the last adequate tumor assessment prior to the event occurs after 70 days AND\n",
      "on or before 126days from randomization, more than 147days from that\n",
      "assessment (an8-week assessment plus a 12-week assessment plus a 7-day\n",
      "assessment window)to the event;\n",
      " If the last adequate tumor assessment prior to the event occurs after 126days from\n",
      "randomization, more than 175 days from that assessment (two 12-week\n",
      "assessments plus a 7-day assessment window)to the event.\n",
      "If a patient meets more than onecensoring criteria described above, the patient’s rPFS value\n",
      "will be censored atthe earliest censoring date.\n",
      "The stratified analysis will be based on the following randomization stratification factors:\n",
      "Previous treatment with any NHT or taxane-based chemotherapy for CSPC (yes vs. no);\n",
      "DDR mutational status (deficient vs. non-deficient/unknown).\n",
      "The primary stratified analysis will be based on the stratification information recorded in\n",
      "IWRS. A secondary stratified analysis based on DDR mutational status derived from clinical\n",
      "database will also be performed. Especially because DDR status in IWRS cannot separate\n",
      "non-deficient and unknown status, derived DDR status from clinical database will be used to\n",
      "identify the non-deficient subpopulation.\n",
      "Prior to Protocol Amendment 6, DDR mutational status for randomization/stratification was\n",
      "obtained from tumor tissue (archival or fresh biopsies)or historical test results (prior tumor\n",
      "tissue analysis using FoundationOne test). Starting with Protocol Amendment 6, DDR\n",
      "mutational status for randomization stratification was derived from either tumor tissue\n",
      "(archival slides or fresh biopsies or historical test results)or peripheral blood (liquid biopsy)\n",
      "prior to randomization. If prospective results from bloodand tumor tissue samples are both\n",
      "available, apositive result from eitherwill be considered prospectively DDR-deficient for\n",
      "randomizationstratification. Retrospectively analyzed screening plasmasamples with results\n",
      "known after randomizationand retrospectively analyzed saliva results will also be\n",
      "incorporated for patients with an unknown DDR status in exploratory analyses. For details\n",
      "see Section 5.2.7.\n",
      "Kaplan-Meier curves will be used to estimate the time-to-event distributions. The\n",
      "50th percentile of Kaplan -Meier estimates will be used to estimate the median duration of\n",
      "each endpoint. A 2-sided 95%CI based on the Brookmeyer-Crowley method will be\n",
      "provided for this estimate. In addition, the event-free rate and 95% CI at 12 months, 24\n",
      "months, and 36 months for each treatment arm will be presented.The stratified hazard ratio (talazoparib in combination with enzalutamide/control) and the\n",
      "associated 95% CI will be estimated using a Cox proportional hazards model. Ties will be\n",
      "handled using the Breslowmethod. Both one-sided and two-sided p-values will be\n",
      "providedin summary tables.\n",
      "Frequency (number and percentage) of patients with each event type (progression\n",
      "[including types of progression –i.e. bone progression, soft tissue progression, bone and\n",
      "soft tissue progression] or death) and censoring reasons will be presented by treatment arm\n",
      "along with the overall event and censoringrates.\n",
      "Reasons for censoring will be summarized according to the categories inTable 6. If a\n",
      "patient meets multiple definitions for censoringat the same visit,the list will be used to\n",
      "define the hierarchy.\n",
      "Table 6. Censoring Reasons and Hierarchy for rPFS\n",
      "Hierarchy Condition Censoring Reason\n",
      "1 No adequate baseline assessment No adequate baseline assessment\n",
      "2 Start of new antineoplastictherapy or select Start of new antineoplastictherapy\n",
      "radiotherapy/surgery before event.\n",
      "3 Event immediately after missing at least two Event after missing assessments\n",
      "consecutive assessments\n",
      "4 No event and withdrawal of consent date ≥ Withdrawal of consent\n",
      "randomization dateOR End of study (EOS) = patient\n",
      "refused further follow-up\n",
      "5 No event and lost to follow-up in any disposition page Lost to follow-up\n",
      "6 No event and EOS present OR disposition page for No adequate postbaselinetumor\n",
      "any EPOCH after screening says patient will not assessment\n",
      "continue into any subsequent phase of the study and\n",
      "no adequate postbaselinetumorassessment\n",
      "7 No event and none of the conditions in the prior Ongoing without an event\n",
      "hierarchy are met\n",
      "Median follow-up time will be estimated according to the Kaplan-Meier estimate of potential\n",
      "follow-up by the reverse Kaplan-Meier method.\n",
      "An overview forest plot of rPFS based on BICR assessment bythe following subgroups will\n",
      "be presented. A similar forest plot based on investigator assessment will also be provided.\n",
      " Age (<70/≥70)\n",
      " Geographic region(North America, European Union [EU]/Great Britain [GBR], Asia,\n",
      "rest of world [ROW])\n",
      " EasternCooperative OncologyGroup (ECOG) performance status at baseline (0, 1)\n",
      " Total Gleason Score at Diagnosis (<8/≥8) Type of progression at study entry (PSA only, radiographic progression with or\n",
      "without PSA progression)\n",
      " Baseline PSA (< vs. ≥ overall median)\n",
      " Site of metastasis at study entry(bone only, soft tissue only, both bone and soft tissue,\n",
      "none)\n",
      " DDR status by IWRS (DDR-deficient, non-deficient/unknown)\n",
      " Prior Taxane or NHT by IWRS (yes/no)\n",
      "6.2.1.1. SensitivityAnalyses\n",
      "The following sensitivity analyses will be performed separately for the all-comers and\n",
      "DDR-deficient populations to explore the robustness ofeach primaryanalysis result.\n",
      "Some of these sensitivity analyses will be presented in the CSR, while the remaining will\n",
      "be presented in other summary documents, for example, Summary of Clinical Efficacy and\n",
      "Summary of Clinical Safety.\n",
      "The sensitivity analyses will be performed following the methods described forthe\n",
      "primary analysis with the modifications below:\n",
      " RadiographicPFS counting all progression and deaths as events regardless of\n",
      "missing assessments or timing of the event (i.e. not censoring due to thestart of a new\n",
      "antineoplastictherapy prior to event or due to missed assessments)based on BICR\n",
      "andinvestigator assessments.\n",
      " RadiographicPFS counting study treatment discontinuation,start of a new\n",
      "antineoplastic therapy, andoccurrence of asymptomatic skeletal event as additional\n",
      "events based on BICR and investigator assessments. Censoring will be similar to that\n",
      "described for the primary analysis, except for the following:\n",
      "o Radiographic progression, death, discontinuation of study treatment (both\n",
      "treatment components),start of a new anti-cancer therapy, and a symptomatic\n",
      "skeletal event will all be considered as events. rPFS will be calculated as the\n",
      "time interval from the date of randomization to the date of radiographic\n",
      "progression, death, discontinuation of study treatment (both treatment\n",
      "components), start of a new anti-cancer therapy, or a symptomatic skeletal\n",
      "event, whichever occurs first.\n",
      " Radiographic PFS by assigning the dates ofcensoring and events only at scheduled\n",
      "assessment dates based on BICR and investigator assessments:\n",
      "o If aradiographic progression occurs within 7-daywindowof its scheduled\n",
      "assessment time, it will be assigned the scheduled assessment date. If a\n",
      "radiographic progression occurs outside the 7-day window and between 2assigned as the radiographic progression date (e.g., if a radiographic\n",
      "progressionoccurs between weeks 25 and 37, it will be assigned to week 37).\n",
      "o In the event of death, the event date will not be adjusted.\n",
      "DDR-deficient patients enrolled in China in Cohort 1 will be included in the analysis of\n",
      "DDR-deficient patient population. A sensitivity analysis of DDR-deficient patients by\n",
      "excluding the DDR-deficient patients enrolled in China in Cohort 1 will also be performed.\n",
      "In addition, to assess the impact ofCOVID-19, the following sensitivity analyses of rPFS\n",
      "may be performed if COVID-19 related death is reported in at least 10patients in the study:\n",
      " Radiographic PFS based on BICR assessment and censoring\n",
      " deaths due to COVID-19.\n",
      " Radiographic PFS based on investigator assessment and censoringdeaths due to\n",
      "COVID-19.\n",
      "BICR vs Investigator assessment:\n",
      "A separate summary of the BICR assessment versus investigator assessment will be provided\n",
      "for the all-comers population and for the DDR-deficient population. These will include\n",
      "numbers of concordant and discordant assessments as well as the number of cases where a\n",
      "PFS event was assessed at different timepoints by the BICR and investigator.\n",
      "The following categories will be summarized by treatment arm for each population:\n",
      " Agreement on time and occurrence of rPFS event (within 28 days) (a1),\n",
      " Agreement on rPFS event but investigator event occurred later (by >28days) (a2),\n",
      " Agreement on rPFS event but investigator event occurred earlier (by >28days) (a3),\n",
      " Investigator assessment of rPFS event, patient censored in the BICR analysis (b),\n",
      " Patient censored in the investigator assessment analysis of rPFS, BICR assessment of\n",
      "rPFS event (c), and\n",
      " Agreement on non-occurrence of rPFS event (d).\n",
      "A +/-28day window will be used to assess the agreement on timing and occurrence of an\n",
      "rPFS event.\n",
      "Total Event Discrepancy Rate (b+c)/N, Early Discrepancy Rate (a3+b)/(a+b), Late\n",
      "Discrepancy Rate (a2+c)/(a2+a3+b+c); and Overall Discrepancy Rate (a2+a3+b+c)/N will be\n",
      "calculated where a=a1+a2+a3.6.2.2. Secondary Endpoints\n",
      "Each secondary endpoint will be analyzed separately for the all-comers population and for\n",
      "the DDR-deficient population.\n",
      "6.2.2.1. Overall Survival\n",
      "OS is defined as the time from randomization to the date of death due to any cause. Patients\n",
      "last known to be alive will be censored at the date of last contact.\n",
      "OS (months) = [date of deathor censoring –randomization date +1]/30.4375.\n",
      "Aone-sided stratifiedlog-rank test will be performed on OS in the all-comers population if\n",
      "the null hypothesis of rPFS in the all-comers population is rejected. Similarly, aone-sided\n",
      "stratified log-rank test of OS will be performed in the DDR-deficient population if the null\n",
      "hypothesis of rPFS in the DDR-deficient population is rejected.\n",
      "The stratified hazard ratio (talazoparib in combination with enzalutamide/control) and the\n",
      "associated 95% CI will be estimated using a Cox proportional hazards model. Ties will be\n",
      "handled using the Breslowmethod. Both one-sided and two-sided p-values will be provided\n",
      "in summary tables. Kaplan-Meier estimates will be presented by treatment arm with a\n",
      "summary of associated statistics including the median OS with two-sided 95% CIs. In\n",
      "addition, the survival rate and 95% CI at 12months, 24months, 36months, and 48 months\n",
      "for each treatment arm will be presented as well.\n",
      "Reasons for censoring will be summarized according to the categories inTable 7. Ifa\n",
      "patient meets multiple definitions for censoring,the list will be used to define the\n",
      "hierarchy.\n",
      "Table 7. Censoring Reasons and Hierarchy for OS\n",
      "Hierarchy Condition Censoring Reason\n",
      "1 No event and withdrawal of consent date ≥ Withdrawal of consent\n",
      "randomization dateOR EOS= Subject refused further\n",
      "follow-up\n",
      "2 No event and lost to follow-up in any disposition page Lost to follow-up\n",
      "3 No event and none of the conditions in the prior Alive\n",
      "hierarchy are met\n",
      "Frequency (number and percentage) of patients with anevent and censoring reasons will\n",
      "be presented by treatment arm as follows:\n",
      " Death\n",
      "o Death due to COVID-19\n",
      " Withdrawal of consent\n",
      " Lost to follow-up Ongoing and no death.\n",
      "To assess the impact of COVID-19, the following sensitivity analyses of OS may be\n",
      "performed by applying the additional censoring rules if COVID-19 related death is reported\n",
      "in at least 10patietsin the study:\n",
      " Censoringdeaths due to COVID-19.\n",
      "6.2.2.2. Objective Response per RECIST 1.1\n",
      "ORR is defined as the proportion of patients with measurable soft tissue disease at baseline\n",
      "with a best overall confirmedsoft tissue response of CR or PR according to RECIST 1.1.\n",
      "Soft tissue responses must be confirmed by a follow-up radiographic assessment at least 4\n",
      "weeks later with no evidence of confirmed bone disease progression on repeat bone scan at\n",
      "least 6 weeks later per PCWG3 criteria. Patients without documented CR or PR will be\n",
      "considered non-responders.\n",
      "Prior to determining the best overall soft tissue response,the date of confirmed bone\n",
      "progression (if applicable) will be determined. If confirmed bone progression is documented\n",
      "and the soft tissue response at the visit where the bone progression criteria are first met is not\n",
      "PD, the derived soft tissue timepoint response incorporating bone assessments will be PD.\n",
      "This derived timepoint response will be used to determining the best overall response (BOR).\n",
      "An example is provided inTable 8.\n",
      "Table 8. Incorporation of Bone Progression into Best Overall Response\n",
      "Overall Soft\n",
      "Example Soft Tissue Tissue\n",
      "Number Timepoint Response Bone Assessment Response\n",
      "Considering\n",
      "Bone\n",
      "Progression\n",
      "(derived)\n",
      "1 Week9 CR Progression PD\n",
      "criteria met (PD)\n",
      "Week 17 CR Progression PD\n",
      "criteria\n",
      "confirmed\n",
      "2 Week 9 CR Progression CR\n",
      "criteria met\n",
      "(Non-PD)\n",
      "Week 17 CR Progression CR\n",
      "criteria NOT\n",
      "confirmed\n",
      "3 Week 9 SD Non PD SD\n",
      "Week 17 PR Progression PDTable 8. Incorporation of Bone Progression into Best Overall Response\n",
      "Overall Soft\n",
      "Example Soft Tissue Tissue\n",
      "Number Timepoint Response Bone Assessment Response\n",
      "Considering\n",
      "Bone\n",
      "Progression\n",
      "(derived)\n",
      "Week 25 PR Progression PD\n",
      "criteria\n",
      "confirmed\n",
      "Best overall response willbe assessed on patients with measurable disease based on reported\n",
      "overall responses at different evaluation timepoints from the date of randomization until\n",
      "documented disease progression (in soft tissue per RECIST 1.1 or in bone per PCWG3\n",
      "guidelines) or start of new antineoplastictherapyor curative radiotherapy where the\n",
      "treatment intent is specified as ‘primary treatment’ or surgery where the treatment intent is\n",
      "specified as ‘curative in intent’ andthe surgery outcome is either ‘resected’ or ‘partially\n",
      "resected’, according to the following rules:\n",
      " CR = at least two determinations of CR at least 4 weeks apart and documented before\n",
      "progression and start of new antineoplastictherapy\n",
      " PR = at least two determinations of PR or better (and not qualifying for a CR) at least\n",
      "4 weeks apart and before progression and start of new antineoplastic\n",
      " SD (for patients with at least one measurable lesion at baseline)= at least one SD\n",
      "assessment (or better and not qualifying for CR or PR) ≥ 8weeks after date of\n",
      "randomizationand before progression and the start of new antineoplastictherapy\n",
      " PD = progression ≤ 16weeks after date of randomizationand not qualifying for CR,\n",
      "PR or SD\n",
      " Not Evaluable (NE) = all other cases.\n",
      "For investigator assessments, global deterioration of health statuswill not be considered as\n",
      "documented disease progression.\n",
      "For patients with measurable soft tissue disease at baseline, objective response rate (ORR)\n",
      "will be summarizedfor the two treatment arms. The primary evaluation of ORR will be\n",
      "based on BICR overall tumor assessment. A secondary evaluation of ORR will be based on\n",
      "the investigator assessments using derived response based on RECIST 1.1.\n",
      "The frequency (number and proportion) of patients with best overall response of CR, PR, SD,\n",
      "Progressive Disease (PD), and NE (not-evaluable) will be tabulated.\n",
      "Patients with best overall responseof NE will be summarized by reason for having NE status. No adequate baseline assessment\n",
      " Early death (defined as death prior to 8 weeks after date or randomization)\n",
      " No postbaseline assessments due to COVID-19, i.e. participants miss tumor\n",
      "assessment visits due to COVID-19 pandemic\n",
      " No postbaselineassessments due to other reasons\n",
      " All postbaselineassessments have overall response NE\n",
      " New antineoplastictherapy started before first postbaselineassessment\n",
      " SD of insufficient duration (< 8 weeks after date of randomization)\n",
      " PD too late (>16weeks after date of randomization)\n",
      "Special and rare cases where the best overall responseis NE due to both early SD and late\n",
      "PD will be classified as ‘SD of insufficient duration’.\n",
      "ORR by treatment arm will be calculated along with the two-sided 95% CIusing a Cochran–\n",
      "Mantel–Haenszel test. The difference in response rates between treatment arms along with\n",
      "bothone-sided and two-sided p-values for thedifference will be provided.\n",
      "In addition, for each DDR mutation, ORR by treatment arm may also be explored.\n",
      "6.2.2.3. Duration of Soft Tissue Response\n",
      "For patients with measurable soft tissue disease at baselinewho have an objective response\n",
      "per RECIST 1.1, duration of soft tissue response(DoR) is defined as the time from the date\n",
      "of the first soft tissue response to the first documented objective evidence of progression (in\n",
      "soft tissue per RECIST 1.1 or in bone per PCWG3 guidelines) or start of new antineoplastic\n",
      "therapy. Those patients who did not have a soft tissue response will be excluded from the\n",
      "analysis. The censoring rules for duration of soft tissue response are as described for rPFS in\n",
      "Section 6.2.1.\n",
      "DoR (months) = [date of event or censoring–first date of CR/PR +1]/30.4375.\n",
      "Kaplan-Meier estimates (product-limit estimates) will be presented by treatment arm together\n",
      "with a summary of associated statistics including the median DR time with two-sided 95%\n",
      "CIs. The CIs for the median will be calculated according to Brookmeyer and Crowley.\n",
      "Inferential statistics (e.g. hazard ratio and p-value) will not be provided for duration of\n",
      "response given that the analysis is performed on the responders only, not the ITT population.\n",
      "Duration of soft tissue response will be reported forboth the all-comers population and the\n",
      "DDR-deficient population.\n",
      "In addition, for each DDR mutation, DoR by treatment arm may also be explored if there are\n",
      "enough patients with the mutation.6.2.2.4. Proportion of Patients with PSA response ≥ 50%\n",
      "PSA response is defined as a decline from baseline PSA (ng/mL) by at least 50%. A PSA\n",
      "response must be confirmed by a second consecutive value at least 3 weeks later. Patients\n",
      "without a baseline and at least one post baseline PSA assessment will not be analyzed for this\n",
      "endpoint. Only assessments performed from the date of randomizationuntil confirmed PSA\n",
      "progression or start of new anticancer treatment (defined as systemic anticancer therapy [other\n",
      "than study treatment], or curative radiotherapy where the treatment intent is specified as\n",
      "‘primary treatment’, or surgery where the treatment intent is specified as ‘curative in intent’\n",
      "and the surgery outcome is either ‘resected’ or ‘partially resected’), given after the first dose\n",
      "of study treatment will be considered.\n",
      "The percentage of patients in the ITT population with maximum PSA declines of at least\n",
      "50% will be calculated along with the two-sided 95% CI. The difference in response rates\n",
      "between treatment arms along with both one-sided and two-sided p-values for the difference\n",
      "in will be providedusing a Cochran–Mantel–Haenszel test in summary tables.\n",
      "PSA (ng/mL) will also be summarized descriptively by visit.\n",
      "PSA response will be reported forboth the all-comers population and the DDR-deficient\n",
      "population.\n",
      "6.2.2.5. Time to PSA Progression\n",
      "PSA progression is defined as the timefrom the date of randomization to the date of the first\n",
      "PSA value demonstrating progression, which is subsequently confirmed. If apatient starts a\n",
      "new antineoplastic therapy prior to PSAprogression, the patient will be censored on the date\n",
      "of last PSA assessment prior to the start of a new antineoplastic therapy. Patients without\n",
      "confirmed PSA progression will be censored at the date of the last PSA assessment. Patients\n",
      "without any post baseline assessments will be censored at randomization.\n",
      "PSA Progression (months) = [date of PSA progression or censoring –randomization\n",
      "date +1]/30.4375.\n",
      "For patients with PSA declines, the PSA progression date is defined as the date that a ≥ 25%\n",
      "increase and an absolute increase of ≥ 2µg/L (2ng/mL) above the nadir is documented,\n",
      "which is confirmed by a second consecutive value obtained at least 3weeks later.\n",
      "Early rises (before week 12) shouldbe ignored in determining progression. As such, for\n",
      "patients with no PSA declines, the PSA progression date is defined as the date that a ≥ 25%\n",
      "increase and an absolute increase of ≥ 2µg/L (2ng/mL) above the baseline is documented\n",
      "after week 12, which is confirmed by a second consecutive value at least 3 weeks later.\n",
      "PSA progression will be analyzedusing a one-sided stratified log-rank test. Kaplan-Meier\n",
      "estimates will be presented by treatment arm with the median and 95% CIs.\n",
      "Frequency (number and percentage) of patients with anevent orcensoring will be\n",
      "presented by treatment arm.Time to PSA progression will be reported forboth the all-comers population and the\n",
      "DDR-deficient population.\n",
      "6.2.2.6. Time to Initiation of Cytotoxic Chemotherapy\n",
      "Time to initiation of cytotoxic chemotherapy is defined as the time from randomization to the\n",
      "first use of cytotoxic chemotherapy. Cytotoxic chemotherapy will be identified based on a\n",
      "clinical review of all follow-up cancer therapies reported on the follow-up therapy CRF page.\n",
      "This review will occur prior to data unblinding.\n",
      "Results will be reported in months ([date of event or censoring –randomization])/30.4375.\n",
      "Patients not starting any cytotoxic chemotherapywill be censored at the date of last contact.\n",
      "Time to initiation of cytotoxic chemotherapy will be analyzedusing a one-sided stratified\n",
      "log-rank test. Kaplan-Meier estimates will be presented by treatment arm with the median\n",
      "and 95% CIs.\n",
      "Frequency (number and percentage) of patients with anevent orcensoring will be presented\n",
      "by treatment arm.\n",
      "Time to initiation of cytotoxic chemotherapy will be analyzedforboth the all-comers\n",
      "population and the DDR-deficient population.\n",
      "6.2.2.7. Time to Initiation of Antineoplastic Therapy\n",
      "Time to initiation of antineoplastic therapy is defined as the time from randomization to the\n",
      "first use of antineoplastic therapy. Such therapies include cytotoxic chemotherapy, hormonal\n",
      "chemotherapy, and investigational agents for prostate cancer. They will be identified based\n",
      "on a clinical review of all follow-up cancer therapies reported on the follow-up therapy CRF\n",
      "page. This review will occur prior to data unblinding.\n",
      "Results will be reported in months ([date of event or censoring –randomization])/30.4375.\n",
      "Patients not starting any antineoplastic therapy will be censored at the date of last contact.\n",
      "Time to initiation of antineoplastic chemotherapy will be analyzedusing a one-sided\n",
      "stratified log-rank test. Kaplan-Meier estimates will be presented by treatment arm with the\n",
      "median and 95% CIs.\n",
      "The results will be reported forboth the all-comers population and the DDR-deficient\n",
      "population.\n",
      "6.2.2.8. Time to First Symptomatic Skeletal Event\n",
      "Time to the first symptomatic skeletal event is defined as the time from randomization to the\n",
      "date of the first symptomatic fracture, surgery to the bone, radiotherapy to the bone, or spinal\n",
      "cord compression as reported on the Skeletal Related Events CRF page. Patients without any\n",
      "symptomatic skeletal events will be censored at the date of the last skeletal event assessment.\n",
      "Analyses will be in months ([date of event or censoring –randomization])/30.4375.Time to the first symptomatic skeletal event will be analyzedusing a one-sided stratified log-\n",
      "rank test. Kaplan-Meier estimates will be presented by treatment arm with the median and\n",
      "95% CIs.\n",
      "The results will be reported forboth the all-comers population and the DDR-deficient\n",
      "population.\n",
      "6.2.2.9. PFS2 Based on Investigator Assessment\n",
      "PFS2 is defined as the time from randomization to investigator documented disease\n",
      "progression (PSA progression, progression on imaging, or clinical progression) on the first\n",
      "subsequent antineoplastic therapy for prostate cancer, or death from any cause, whichever\n",
      "occurs first.\n",
      "PFS2 (months) = [date of event/censoring –date of randomization +1]/30.4375\n",
      "A patient will be considered to have an event if:\n",
      " date of documented progression on the first subsequent antineoplastic therapy is\n",
      "provided on follow-up cancer therapy CRF page; or\n",
      " the patient dies.\n",
      "PFS2 will be analyzedusing a one-sided stratified log-rank test. Kaplan-Meier estimates will\n",
      "be presented by treatment arm with the median and 95% CIs. Both one-sided and two-sided\n",
      "p-values will be provided in summary tables.\n",
      "The censoring andevent date options to be considered for PFS2 along with the corresponding\n",
      "censoring reason and its hierarchy are presented inTable 9. The frequency (number and\n",
      "percentage) of patients with an event and censoring reasons will be presented by treatment\n",
      "arm.\n",
      "Table 9. Outcome, Event/Censoring Dates, and Reasons for Censoring for PFS2\n",
      "Scenario Date of event/censoring Outcome/\n",
      "Censoring reason/\n",
      "Censoring hierarchy\n",
      "No PDa and No Death Date of last adequate Censored/\n",
      "tumor assessmentb No PD by investigator/\n",
      "documenting no PD 1\n",
      "No PDa and Death Date of death Event (Death)\n",
      "PDa date > NTX1c start date Start date of NTX1c Censored/\n",
      "and no death Start of new anticancer\n",
      "treatment before PD/\n",
      "2\n",
      "PDa date > NTX1c start date Date of death Event (Death)\n",
      "and deathTable 9. Outcome, Event/Censoring Dates, and Reasons for Censoring for PFS2\n",
      "Scenario Date of event/censoring Outcome/\n",
      "Censoring reason/\n",
      "Censoring hierarchy\n",
      "PDa date ≤ NTX1c start date Documented progression Event (Date of documented\n",
      "and documented progression on NTX1 progression on NTX1)\n",
      "on NTX1\n",
      "PDa date ≤ NTX1c start date Date of death Event (Death)\n",
      "and no documented\n",
      "progression on NTX1 and\n",
      "death\n",
      "PDadate ≤ NTX1c start date Date of Last Contact Censored/\n",
      "and no documented Withdraw of consent/\n",
      "progression on NTX1 and 3\n",
      "no death and the patient\n",
      "withdrew consent for\n",
      "follow-up\n",
      "PDa date ≤ NTX1c start date Date of Last Contact Censored/\n",
      "and no documented Lost to follow-up/4\n",
      "progression on NTX1 and\n",
      "no death and the patient is\n",
      "lost to follow-up\n",
      "PDa date ≤ NTX1c start date Date of Last Contact Censored/\n",
      "and no documented Ongoing without PFS2 event/\n",
      "progression on NTX1 and 5\n",
      "no death and no other\n",
      "conditions met\n",
      "a PD is the first PD while on study treatment by investigator assessment per RECIST v1.1 or per PCWG3,\n",
      "without considering any censoring rules.\n",
      "b If there is no adequate postbaseline assessment, then the censoring date is the date of randomization. If the\n",
      "patient has initiated next-line anticancer treatment, the last adequate postbaseline assessment on or prior to\n",
      "start date of next line anticancer treatment will be considered.\n",
      "c NTX1 is the first new anticancer regimen\n",
      "The PFS2results will be reported forboth the all-comers population and the DDR-deficient\n",
      "population.\n",
      "6.2.2.10. Time to Opiate use for Prostate Cancer Pain\n",
      "Time to opiate use for prostate cancer pain is defined as the time from date of randomization\n",
      "to the date of the first or new opiate medications for prostate cancer painstarted after\n",
      "randomization and will be based on the start date of medications reported on the concomitant\n",
      "medication page of the CRF reported with a category of ‘Opioids’. Patients without any\n",
      "opiate use will be censored at the last dose of study treatment.Time to opiate use for prostate cancer painwill be analyzedusing a one-sided stratified log-\n",
      "rank test. Kaplan-Meier estimates will be presented by treatment arm with the median and\n",
      "95% CIs.\n",
      "The results will be reported forboth the all-comers population and the DDR-deficient\n",
      "population.\n",
      "6.2.3. PRO Endpoints\n",
      "All of the PRO endpoints described below will be analyzed using the PRO analysis set.\n",
      "PRO endpoints will be analyzedforboth the all-comers population and the DDR-deficient\n",
      "population.\n",
      "6.2.3.1. Time to Event Endpoints\n",
      "Time to Deterioration in Patient-reported Pain Symptoms per BPI-SF\n",
      "Patient-reported pain symptoms (per the Pain Log – BPI-SF Question 3) will be completed\n",
      "for 7 consecutive days beforeeachstudy visit. In addition, the BPI-SF will be completed\n",
      "during each study visit.Four or more completed BPI-SF Question 3at each visit period(i.e.\n",
      "collectively7 consecutive days prior to each study visit and during study visit)are required\n",
      "for thepain score for each time periodto be considered evaluable. Pain score averages\n",
      "during each visit period will be calculated and will be used for the analysis of time to\n",
      "deterioration in patient-reported pain symptoms.\n",
      "Analgesic use (per Analgesic log) is recorded for seven consecutive days prior to each study\n",
      "visit and during each study visit. The worst World Health Organization (WHO)analgesic\n",
      "usage score for each visit period (seven consecutive days prior to each study visit and during\n",
      "study visit) will be used. Analgesic use is scored according to WHO criteria: zero for no use,\n",
      "one for use of non-opiate analgesics (e.g., non-steroidal anti-inflammatory drugs,\n",
      "acetaminophen, antidepressants, and agents targeting neuropathic pain), two for use of weak\n",
      "opiates for moderate pain (e.g., codeine and tramadol), and three for strong opiates for severe\n",
      "pain (e.g., morphine and fentanyl).\n",
      "Time to deterioration in patient-reported pain symptoms per BPI-SF is assessed using the\n",
      "average pain score from the BPI-SF question 3: “Please rate your pain by marking the box\n",
      "beside the number that best describes your pain at its worst in the last 24 hours.” Time to this\n",
      "event is defined as the time from randomization to onset of pain progression, where pain\n",
      "progression is defined as a ≥2 point increase from baseline in the question 3 scorefor two\n",
      "consecutive visit periods at least 4 weeks apart without a decrease in WHO analgesic usage\n",
      "score. If there is a decrease in WHO analgesic usage score, then it will not be consideredas\n",
      "pain progression even if there is a ≥2 point increase from baseline in the question 3 score.\n",
      "Patients without observed pain progression at the time of analysis will be censored at the date\n",
      "of last BPI-SF assessment.\n",
      "Kaplan-Meier estimates will be presented together with a summary of associated statisticsFrequency (number and percentage) of patients with an event or censoring will be presented.\n",
      "Time to Definitive Deterioration in Patient-reported Global Health Status/QoL per\n",
      "EORTC QLQ-C30\n",
      "Time to definitive deterioration in patient-reported global health status/QoL per EORTC\n",
      "QLQ-C30is defined as the time fromrandomization to the firstdefinitive deterioration\n",
      "defined as a ≥ 10-point decrease from baseline and no subsequent observations of a < 10-point\n",
      "decrease from baseline. Patients without a definitive deterioration at the time of analysis will\n",
      "be censored at the date of last EORTC QLQ-C30assessment.\n",
      "Kaplan-Meier estimates will be presented together with a summary of associated statistics\n",
      "including the median and quartiles with two-sided 95% CIs.\n",
      "Frequency (number and percentage) of patients with an event or censoring will be presented.\n",
      "Time to Definitive Deterioration in Patient-reported Disease-specific Urinary\n",
      "Symptoms per EORTC QLQ-PR25\n",
      "Time to definitive deterioration in patient-reported disease-specific urinary symptoms per\n",
      "EORTC QLQ-PR25 is defined as the time fromrandomization to the firstdefinitive\n",
      "deterioration defined as a ≥ 10-point increase from baseline and no subsequent observations of\n",
      "a < 10point increase from baseline. Patients without a definitive deterioration at the time of\n",
      "analysis will be censored at thedate of last EORTC QLQ-PR25 assessment.\n",
      "Kaplan-Meier estimates will be presented together with a summary of associated statistics\n",
      "including the median and quartiles with two-sided 95% CIs.\n",
      "Frequency (number and percentage) of patients with an event or censoring will be presented.\n",
      "6.2.3.2. DescriptiveSummaries and Change from Baseline\n",
      "BPI-SF\n",
      "Descriptive summaries for BPI-SFby visit will be provided. These include:\n",
      " For each visit period (collectively for study visit and the 7 consecutive days prior to\n",
      "each study visit), number and percentage of patients who completed all the BPSI-SF\n",
      "Question 3 out of a total of 8), ≥4 of the BPI-SF Question 3, and those who did not\n",
      "complete any BPI-SF Question 3 will be summarized\n",
      " Descriptive summary of the average score at each visit period for BPI-SF\n",
      "Question3\n",
      "o Each pain intensity is a whole number (0 through 10) and will be summarized as\n",
      "a continuous variable\n",
      "o Missing values (<4 of8 possible assessments per visit period) are not included\n",
      "in the summariesDescriptive statistics for change from baseline in patient-reported pain symptoms per BPI-\n",
      "SF (questions 3) will be summarized for each visit period. A graphical display of means\n",
      "over time as well as mean changes from baseline over time will also be provided.\n",
      "A longitudinal mixed effect model will also be used to summarize the change from\n",
      "baseline pain symptoms score (BPI-SF Question 3) across all visit periods. Unless\n",
      "otherwise specified, all scheduled assessments will be used in the analyses, regardless of\n",
      "adherence to study treatment.\n",
      "EQ-5D-5L Health Index\n",
      "Analysis of the EQ-5D health index will consist of descriptive statistics on means and\n",
      "changes from baseline, overall change from baselineusing a longitudinal mixed effects\n",
      "model,and graphical displays of means and changes from baseline over time. In addition,\n",
      "there will be a health status profile analysis consisting of adisplay of the number and\n",
      "percentage of patients in each of the 5response levels for each ofthe 5 dimensions at each\n",
      "visit.\n",
      "EQ-5D General Health Status (EQ-5D VAS)\n",
      "Analysis of EQ-5D VAS will consist of descriptive statistics on means and changes from\n",
      "baseline, overall change from baselineusing a longitudinal mixed effects model, and\n",
      "graphical displays of means and changes from baseline over time.\n",
      "QLQ-C30\n",
      "Analysis of the QLQ-C30will consist of descriptive statistics for each scale on means and\n",
      "changes from baseline, overall change from baselineusing a longitudinal mixed effects\n",
      "model,time to definitive deterioration,and graphical displays of means and changes from\n",
      "baseline over time.\n",
      "QLQ-PR25\n",
      "Analysis of the QLQ-PR25 will consist of descriptive statistics for each scale on means\n",
      "andchanges from baseline, overall change from baselineusing a longitudinal mixed\n",
      "effectsmodel,time to definitive deterioration, and graphical displays of means and\n",
      "changes from baseline over time.\n",
      "6.2.4. PK\n",
      "In Part 2, analyses of PK concentrations will include sampling at predoseand 2 hours post-\n",
      "dose at Weeks 3, 5 and 9, and pre-dose at Weeks 13 and 17.\n",
      "The PK analyses forPart 2 of the studywill be similar to those for Part 1 of the study. For\n",
      "details see Section 6.1.2. Separate summaries of dose-normalized C by scheduled visit\n",
      "trough\n",
      "for patients in Part 2 may also be generated.6.2.5. Other Endpoints\n",
      "6.2.5.1. CTC Conversion Rates\n",
      "CTC endpoints will be analyzedseparately forboth the all-comers population and the DDR-\n",
      "deficient population.\n",
      "For CTC counts, a summary of the mean (standard deviation), median, and range of baseline\n",
      "and postbaselinevalues will be provided for patients in theCTC evaluable set. In addition,\n",
      "the number and percentage of patients with CTC count ≥ 5 vs. < 5 and CTC count > 0 vs. =0\n",
      "per 7.5 mL will be presented as well.\n",
      "For the analysis of CTC count conversion from 5 or more CTC per 7.5 mL at baseline to < 5\n",
      "CTC per 7.5 mL post baseline, those patients with a CTC count < 5 per 7.5 mL at baseline\n",
      "will be excluded for this conversion endpoint. The proportion of patients with a conversion\n",
      "will be calculated along with the two-sided 95% CIusing the Clopper-Pearson method.\n",
      "For the analysis of CTC count conversion from detectable at baseline to 0 postbaseline, those\n",
      "patients with a CTC count of 0 per 7.5 mL of blood at baseline will be excluded for this\n",
      "conversion endpoint. The proportion of patients with such a conversionwill be calculated\n",
      "along with the two-sided 95% CIusing the Clopper-Pearson method.\n",
      "For the analysis of the proportion of patients with baseline CTCs <5 who show increased\n",
      "CTCs postbaseline, those patients with a CTC count of ≥ 5 per 7.5 mL of blood at baseline\n",
      "will be excluded from the analysis. The proportion of patients with such a conversion will be\n",
      "calculated along with the two-sided 95% CIusing the Clopper-Pearson method.\n",
      "The results will be analyzed forboth the all-comers population and the DDR-deficient\n",
      "population.\n",
      "6.2.5.2. Molecular Profiling\n",
      "A separate analysis plan will be written to describe analyses of molecular profiling of tumor\n",
      "tissue remaining after genomic testing.\n",
      "6.2.5.3. Concordance of DDR deficiency results\n",
      "The concordance of DDR deficiency results (DDR-deficient/non-deficient/unknown) will be\n",
      "exploredfor the following assay methods:\n",
      " Prospective tissue-based tests vs. retrospectively analyzed screening blood-based tests\n",
      " Prospective blood-based tests vs. retrospectively analyzed screening blood-based tests\n",
      "6.3. Subgroup Analyses\n",
      "Subgroup analyses will be performed if there is a sufficient sample size. The determination\n",
      "of whether or not there is a sufficient samplesize will be defined after enrollment is completethere are ≥ 20 patients within the defined subset and analyses of time to event endpoints will\n",
      "only be performed if there are at least 10 events on each treatment arm within the subgroup.\n",
      "Deviations from these analyses will be described in the clinical study report.\n",
      "Some of the subgroup analyses will be presented in the CSR, while the remaining will be\n",
      "presented in other summary documents, for example, Summary of Clinical Efficacy and\n",
      "Summary of Clinical Safety.\n",
      "Besides the subgroup analyses presented in the overview forest plots described in\n",
      "Section6.2.1, the following additional subgroup analyses will be performed for rPFS by\n",
      "BICR where the subgroups are subsets of the all-comers population:\n",
      " DDR mutational status derived using prospective/retrospective data (subgroup\n",
      "definitions 2-6in Section 5.2.7).\n",
      " Renal impairment (moderate, mild,normal)\n",
      " Race (Asian, White, African American, other)\n",
      " Prior NHT (yes, no)\n",
      " Prior docetaxel (yes, no)\n",
      " Baseline bone protecting agent (yes, no)\n",
      " Baseline LDH value (< vs. ≥ median)\n",
      " Baseline hemoglobin value (< vs. ≥ median)\n",
      " Baseline ALP value (< vs. ≥ median)\n",
      " Baseline CTC Count (<5, ≥ 5)\n",
      " Baseline CTC Count (0, >0)\n",
      "Similarsubgroup analyses will be performed for Cohort 2.\n",
      "A subgroup analysis for OS will be performed at the time of the final OS analysis using the\n",
      "same subgroups specified above for rPFS.\n",
      "Subgroup analyses of other efficacy parameters and subgroups analyses for Part 1 data are\n",
      "not planned.\n",
      "Key safety outputs for Part 2 will be provided to explore the following subgroups:\n",
      " Renal impairment (moderate vs.mild vs. normal),\n",
      " Age (<70vs. ≥ 70),\n",
      " Asian vs. non-Asian.Normal, mild, and moderate renal impairment are defined based on baseline eGFR of ≥90\n",
      "mL/min/1.73m2, 60-89 mL/min/1.73m2, and30-59mL/min/1.73m2 respectively, where\n",
      "eGFR willbe captured on the CRFs.\n",
      "Key safety outputs for Part 1 will be provided by startingdose. Additionally adverse events\n",
      "listings will consider the dose at the time of the start of the event.\n",
      "6.4. Baseline and Other Summaries\n",
      "Unless otherwise specified,the following summaries will be provided separately for the\n",
      "safety analysis set of Part 1 and for the ITT all-comers and DDR-deficient populations in Part\n",
      "2. For Part 1, select data may be listed instead of summarized.\n",
      "6.4.1. Baseline Summaries\n",
      "Thefollowingdemographic andbaselinedisease characteristicswill besummarized:\n",
      " Age(continuous and by groups: <65; 65-<75; >=75)\n",
      " Race\n",
      " Asian vs. non-Asian\n",
      " Weight\n",
      " Body Mass Index (BMI)\n",
      " Geographic region(NorthAmerica,Europe, Asia, Rest of World)\n",
      " Renal impairment at baseline (Normal, Mild, Moderate),\n",
      "o normal, mild, and moderate are defined based on baseline baseline eGFR of\n",
      "≥90 mL/min/1.73m2, 60-89 mL/min/1.73m2, and 30-59mL/min/1.73m2,\n",
      "respectively,\n",
      " Histopathological classification\n",
      " Baseline serum PSA (ng/mL)\n",
      " Baseline useof aboneprotecting agent (yes, no)\n",
      " Gleason score(low [2-4], medium [5-7], high [8-10])\n",
      " Gleason score (<=6, 3+4=7, 4+3=7, 8, 9-10, not reported)\n",
      " ECOGperformance status\n",
      " TNM stageat diagnosis\n",
      " TNM stage at study entry\n",
      " Disease localization at screening:\n",
      "o Bone only\n",
      "o Soft tissue only\n",
      "o Both bone and soft tissue\n",
      "o None Distribution of disease at screening:\n",
      "o Bone (includes bone with soft tissue component)\n",
      "o Lymph Node\n",
      "o Visceral Disease (lung or liver)\n",
      "o Visceral disease (lung)\n",
      "o Visceral disease (liver)\n",
      "o Other Soft Tissue\n",
      " Number of bone metastases at screening: n (%)\n",
      "o 0\n",
      "o 1-4\n",
      "o 5-9\n",
      "o 10-20\n",
      "o >20\n",
      " Type of progression at study entry:\n",
      "o PSA progression only\n",
      "o Bone progression only\n",
      "o Soft tissue progression only\n",
      "o PSA+ bone or soft tissue\n",
      "o Bone+ PSA or soft tissue\n",
      "o PSA+bone+soft tissue\n",
      " Baselinepain score by BP-SF (0-1; 2-3; >3),\n",
      " Baseline CTC count\n",
      "o Continuous summary\n",
      "o Categorical summary (≥ 5 CTC per 7.5 mL of blood, <5 CTC per 7.5 mL of\n",
      "blood)\n",
      "o Categorical summary (>0 CTC per 7.5 mL of blood, 0 CTC per 7.5 mL of\n",
      "blood)\n",
      " Time from primary diagnosis to randomization in months (date of randomization –\n",
      "date of diagnosis)/30.4375\n",
      " Derived DDR mutational status (positive, negative, unknown) with specific mutations\n",
      "prior to randomization\n",
      " DDR mutational status (positive, negative, unknown) with specific mutations based on\n",
      "blood samples only\n",
      " DDR mutational status (positive, negative, unknown) with specific mutationsbased on\n",
      "tumor tissue samples onlyThe number of patients in the following categories at the time of randomization will be\n",
      "summarized:\n",
      " Prior NHT orTaxane and DDR-deficient\n",
      " Prior NHT or Taxane and non DDR-deficient/unknown\n",
      " No Prior NHT orTaxane and DDR-deficient\n",
      " No Prior NHT or Taxane and non DDR-deficient/unknown\n",
      "A listing will be provided with the strata (defined above) at the time of randomization as well\n",
      "as based on CRF data with a flag to indicate cases where there are differences between the\n",
      "derived data and the IWRS data at the time of randomization.\n",
      "6.4.2. Medical History\n",
      "Medical history will be coded using the most current version of MedDRA and summarized\n",
      "by MedDRA’s SOC and PT. Each patient will be counted only once within each PT or SOC.\n",
      "Summaries will be ordered by primary SOC and PT in descending order of frequency by the\n",
      "experimental treatment arm. Summaries will be provided for all patients in the ITT\n",
      "population.\n",
      "6.4.3. Prior AnticancerTreatments\n",
      "Prior anticancertreatments include systemic therapy, radiation, and surgery.\n",
      "The number and percentage of patients in each of the following anticancer therapy categories\n",
      "will be tabulated:\n",
      " Patients with at least one type of prior anticancer systemic treatment including\n",
      "androgen deprivation therapy;\n",
      " Patients with at least one prior anticancer surgery;\n",
      " Patients with at least one prior anticancer radiotherapywith “primary treatment”and\n",
      "“salvage” intent;\n",
      " Patients with any prior androgen deprivation therapy.\n",
      "Prior anticancer drug therapy will be summarized as follows based on the number and\n",
      "percentage of patients:\n",
      "o Number of prior anticancer therapy regimens (including androgen deprivation\n",
      "therapy): None/ 1 / 2 / ≥3.\n",
      "The prior anticancerdrugs will be coded in the WHO Drug coding dictionary and will be\n",
      "summarized usingthe number and percentage of patients by preferred term. A patient will be\n",
      "counted only once fora given preferred term, even if he/she received the same medication atcombination with enzalutamidearm. In case of equal frequency, alphabetical order will be\n",
      "used.\n",
      "A summary of the number of patients with the followingprior cancersurgeries will be\n",
      "provided:\n",
      " Prostatectomy,\n",
      " TURP,\n",
      " Prostate Biopsy,\n",
      " Bilateral Orchiectomy,\n",
      " Pelvic Node Dissection,\n",
      " Ureteral Stent,\n",
      " Nephrostomy.\n",
      "Specific details on all other surgeries and radiotherapy(primary treatment and salvage)will\n",
      "be provided in data listings.\n",
      "6.4.4. Study Conduct and Patient Disposition\n",
      "Discontinuations from study treatment due to adverse events will be identified as either\n",
      "related or not related to study treatment. If causality is missing the event will be considered\n",
      "related to treatment. If multiple events lead to study treatment discontinuation and at least\n",
      "one was considered related, discontinuation will be reported as related to study treatment.\n",
      "COVID-19 Related Disposition\n",
      "Alisting of all patientsaffectedbyCOVID-19will be created. The listing will present subject\n",
      "number identifier byinvestigational site, and a description of COVID-19-related events\n",
      "including:\n",
      " All protocol deviations\n",
      " Related AEsif available\n",
      " Deaths\n",
      "6.4.5. Protocol Deviations\n",
      "Important protocol deviations will be compiled prior to database release and will be\n",
      "summarized by category (n(%)) using the safety population for Part 1 andthe ITT population\n",
      "forPart 2.Categories will be assigned by the study team.\n",
      "In addition, all protocol deviations related to COVID-19 will be presented in a separate\n",
      "listing.6.4.6. Study Treatment Exposure\n",
      "Exposure summaries will be presented using the safety analysis set for each part.\n",
      "Part 1 patients hada starting talazoparib dose of either 1 mg/day or 0.5 mg/dayin\n",
      "combination withenzalutamide 160 mg/day,depending on timing of enrollment. The Part\n",
      "1 data will be presented separately by the starting talazoparib dose.\n",
      "For part 2, thedailydose of talazoparibis 0.5 mg/daygivenorallyin combination with\n",
      "enzalutamide 160 mg/dayat approximatelythesametimeeach day for patients with\n",
      "normal/mild renal impairment. Thestartingtalazoparib dosewill be 0.35mg/dayin\n",
      "combination withenzalutamide 160 mg/dayforpatients with moderaterenal impairment\n",
      "(eGFR 30-59mL/min/1.73m2).\n",
      "Separate summaries will be provided for talazoparib and enzalutamide and will include the\n",
      "following:\n",
      " Treatment duration (months): Foreachpatient,treatmentdurationis definedas\n",
      "(date of last dose–dateof first dose +1) / 30.4375. Treatment duration will be\n",
      "summarizedboth as a continuous measureandacategorical measure(≤ 3 months,\n",
      "3 to <6 months, 6 to <12 months, ≥ 12 months).\n",
      " Average dailydose(mg/day): Theaveragedailydoseis definedas the\n",
      "cumulative dosedividedbythe actual number of days on the treatment.\n",
      " Dose intensity(mg/week): Doseintensity is definedas the cumulativedose\n",
      "dividedbythe treatment duration.\n",
      " Relative dose intensity (%): Relative dose intensity is defined as the ratio of the\n",
      "actual dose intensity to the planned dose intensity expressed in %. The planned\n",
      "dose intensity will be 3.5 mg (0.5 mg per day for 7 days) for patients without\n",
      "moderate renal impairment and 2.45 mg (0.35 mg per day for 7 days) for patients\n",
      "with moderate renal impairment.\n",
      "RDI (%) = 100x[dose intensity (mg/week)]/[planned dose intensity(mg/week)].\n",
      "A dose reduction is defined as a non-zero dose that is less than the prior dose.The number\n",
      "andpercentage of patients with at least one dose reductionas well as a breakdown of dose\n",
      "reductions (1 / 2 / 3) will be summarized by treatment arm.\n",
      "Reasons for dose reductions will also be summarized. There could be more than one reason\n",
      "if multiple dose reductions occur forthe same patient,though each reason will be counted\n",
      "only once for each patient. Percentages will be calculated based on the total number of\n",
      "patients in safety analysis set.\n",
      "An dosing interruption is defined a 0mg dose administered. (Note: A dosinginterruption is\n",
      "not considered a dose reduction). The number and percentage of patients with dosing\n",
      "interruptions and the corresponding reasons will be summarized by treatment arm. There\n",
      "could be more than one reasonif multiple dosinginterruption occur forthe same patient,though each reason will be counted only once for each patient. Percentages will be\n",
      "calculated based on the total number of patients in safety analysis set.\n",
      "Time to first interruption (weeks) and time to first reduction (weeks), measured from the\n",
      "date of first dose of study treatment, will be summarized for patients who had at least one\n",
      "interruption or reduction respectively.\n",
      "A summary of duration (days) of dosinginterruptions due to any AEs and for anemia only\n",
      "for each dosinginterruption will be provided,where ‘n’ is the number of dosing\n",
      "interruptions. Apatient can contribute multiple observations, one for each interruption.\n",
      "A summary of the total duration (days) of dosinginterruptions due to AEs for each\n",
      "patient will also be provided.\n",
      "6.4.7. Concomitant Medications\n",
      "Concomitant medications refer to all medications thatstarted or were ongoing at the time of\n",
      "randomization , started after randomization and continued during the on-treatment period for\n",
      "up to 28 days after the last dose of all the study treatments as well as those started during the\n",
      "on-treatment period. Concomitant medications will be coded in the WHO Drug coding\n",
      "dictionary and will be tabulated by Anatomical Therapeutic Chemical (ATC) Classification\n",
      "level 2 and preferred term in descending order of frequencyfor the talazoparib in combination\n",
      "with enzalutamidearm. In case of equal frequency regarding drug class (respectively drug\n",
      "name), alphabetical order will be used. A patient will be counted only once fora given drug\n",
      "name, even if he/she received the same medication multiple times.\n",
      "Concomitant non-drug treatments refer to non-drug treatments (radiation and surgery)\n",
      "administered during the on-treatment period. Non-drug treatments will be coded in\n",
      "MedDRA and will be summarized by MedDRA SOC and PT in descending order of\n",
      "frequencyon the talazoparib in combination with enzalutamidearm. Patients will be counted\n",
      "only once per PT even if he/she received the same treatment multiple times.\n",
      "Concomitant medications and non-drug treatments will be summarized by treatment arm for\n",
      "the Part 1 and Part 2 safety populations. Concomitant medications in will be listed for Part 1\n",
      "and Part 2.\n",
      "6.4.8. Subsequent AnticancerTherapies/Procedures\n",
      "Subsequent systemic anticancertherapies are defined as therapies collectedon the ‘Follow-\n",
      "up Cancer Therapy’ CRF page. Subsequent anticancer procedures include procedures\n",
      "collected on‘Follow-up Radiation Therapy’marked as curativeor salvage, and ‘Follow-up\n",
      "Surgery’ CRF pages where the date is on or after the date of first dose of study treatment.\n",
      "The number and percentage of patients within each category (medication therapy, radiation\n",
      "therapy, and surgeries) will be provided by treatment arm for thePart 2 ITT Population.\n",
      "Subsequent anticancertherapies and procedures will be listed for Part 1 and Part 2.\n",
      "Medications will be coded using the WHO Drug coding dictionary and will be tabulated by\n",
      "preferred term in descending order of frequency.6.5. Safety Summaries and Analyses\n",
      "Unless otherwise specified, summaries of AEs and other safety parameters will provided\n",
      "separately for Part 1 and Part 2 and will be based on the safety population. For Part 1 the\n",
      "data will be analyzed by the starting dose of talazoparib. For Part 2 as it is anticipated that\n",
      "follow-up for the primary endpoint in the DDR-deficient population will be ongoing (i.e.\n",
      "treatment assignment will still be blinded) at the time of the final analysis of rPFS in the all-\n",
      "comers population, summaries will initially be performed only for the all-comers population.\n",
      "At the time of the final rPFS analysis in the DDR-deficient population safety data will be\n",
      "summarized for the combined populations of all-comers and DDR-deficient patients in Part\n",
      "2.\n",
      "6.5.1. Adverse Events\n",
      "All analyses will be based on treatment-emergent events unless otherwise specified. AEs not\n",
      "considered treatment-emergent will be flagged in data listings.\n",
      "For Part 1 and Part 2 separately, ahigh-level summary of adverse events will include the\n",
      "number and percent of patients with:\n",
      " Any AE;\n",
      " Serious AE;\n",
      " CTCAE Grade 3-4 AEs;\n",
      " Grade 5 AEs;\n",
      " AEs leading to dose reductions of talazoparib/placebo;\n",
      " AEs leading to dose reductions of enzalutamide;\n",
      " AEs leading to dose reductions of both talazoparib/placebo and enzalutamide;\n",
      " AEs leading to dosinginterruptions of talazoparib/placebo;\n",
      " AEs leading to dosinginterruptions of enzalutamide;\n",
      " AEs leading to dosing interruptions of both talazoparib/placebo and enzalutamide;\n",
      " AEs leading to permanent discontinuationof talazoparib/placebo;\n",
      " AEs leading to permanent discontinuationof enzalutamide;\n",
      " AEs leading to permanent discontinuation of both talazoparib/placebo and\n",
      "enzalutamide.\n",
      "Seriousness, toxicity grade, action taken (interruption, reduction, and withdraw) are as\n",
      "reported by the investigator on the adverse event CRF.\n",
      "Summaries SOC and PT by treatment arm in decreasing frequency will be provided for:\n",
      " Treatment-Emergent AEs (All Causality); Treatment-Emergent AEs by Maximum CTCAEGrade (All Causality);\n",
      " Treatment-emergent COVID-19 related AEs (all causality);\n",
      " Treatment-Emergent AEs (Treatment Related);\n",
      " Treatmen -Emergent AEs by Maximum CTCAE Grade (Treatment Related);\n",
      " Serious Treatment-Emergent AEs (All Causality);\n",
      " Serious Treatment-Emergent AEs (Treatment Related);\n",
      "An AEwill be considered treatment related if the investigator considered the event related to\n",
      "one or both of study drugs given in combination.\n",
      "The following summaries of AEs will be provided by decreasing frequency of PT\n",
      "(summaries will not include SOC) in the talazoparib plus enzalutamidearm for Part 2 only:\n",
      " Treatment-Emergent AEs (All Causality) in either treatment arm;\n",
      " Treatment-Emergent AEs (All Causality) by Preferred Term and Maximum CTCAE\n",
      "Grade;\n",
      " Treatment-Emergent AEs Leading to Dosing Interruptions of Talazoparib(All\n",
      "Causality);\n",
      " Treatment-Emergent AEs Leading to Dosing Interruptions of Enzalutamide (All\n",
      "Causality);\n",
      " Treatment-Emergent AEs Leading to Dosing Interruptions of BothTalazoparib and\n",
      "Enzalutamide (All Causality);\n",
      " Treatment Emergent AEs Leading to Dose Reductions of Talazoparib(All Causality);\n",
      " Treatment Emergent AEsLeading to Dose Reductions of Enzalutamide (All\n",
      "Causality);\n",
      " Treatment Emergent AEsLeading to Dose Reductions of Both Talazoparib and\n",
      "Enzalutamide (All Causality);\n",
      " Treatment Emergent AEs Leading to Permanent Withdraw of Talazoparib (All\n",
      "Causality);\n",
      " Treatment Emergent AEs Leading to Permanent Withdraw of Enzalutamide(All\n",
      "Causality);\n",
      " Treatment Emergent AEs Leading to Permanent Withdraw of Both Talazopariband\n",
      "Enzalutamide(All Causality);\n",
      " Treatment Emergent AEs between DDR-deficient patients and non-deficient patients\n",
      "(All Causality);\n",
      " Treamtment emergent AE between normal/mild vesusmoderate renal impareiment\n",
      "(All Causality) Serious Treatment Emergent AEs (Treatment related).\n",
      "Each patient will be counted only once within each SOC and PT.\n",
      "If a patient has events with missing and non-missing toxicity grades, the maximum non-\n",
      "missing grade will be displayed. Missing grade will only be displayed in the event that only\n",
      "one AEhas been reported for a patient and the grade is missing.\n",
      "Summaries of time to first Grade 3 or 4 event and time to first SAE will also be providedfor\n",
      "the safety populations in Part 2. Patients without an event will be censored as follows:\n",
      " if the patient has discontinued from study treatment the patient will be censored 28\n",
      "days afterthe last dose of studytreatment,or before systemic anticancer therapy,\n",
      "whicheveroccurs first, and\n",
      " if the patient is still on study treatment at the time of analysis the patient will be\n",
      "censored at the last date of contact.\n",
      "6.5.2. Adverse Events of Special Interest\n",
      "See section 3.4.1for a list of AEs of Special Interest.\n",
      "For Talazoparib AESIs, separate summaries for each AESI will be provided by maximum\n",
      "toxicity and will include an ‘any event’ row along with a row for each contributing PT in\n",
      "descending order of frequency.\n",
      "Given the observed incidence of hematologic toxicities associated with the use of\n",
      "talazoparib, a summary of hematologic AEs will be provided toshow the incidence of the\n",
      "following cluster terms:\n",
      " ANEMIA: anaemia, decreased hemoglobin, decreased hematocrit, red blood cell\n",
      "count decreased\n",
      " NEUTROPENIA: neutropenia and decreased neutrophil count\n",
      " THROMBOCYTOPENIA: thrombocytopenia and platelet count decreased\n",
      " LEUKOPENIA: leukopenia or white blood cell count decreased\n",
      " LYMPHOPENIA: lymphopenia or lymphocyte count decreased\n",
      "AESIs for enzalutamide will be summazried by medical event only,not by individual\n",
      "contributing PTs if applicable..\n",
      "6.5.3. Deaths\n",
      "The frequency (number and percentage) of patients in the safety populationwho died anddeath, will be tabulated based on information from the ‘Notice of Death’ and ‘Survival\n",
      "Follow-Up’ CRFs.\n",
      "Date and cause of death will be provided in individual patient data listings with selected\n",
      "dosing information (study treatment received, date of first / last administration, dose, etc.).\n",
      "In addition, if there are ≥ 10deaths due to COVID-19, a separate death summary will be\n",
      "createdfor COVID-19 related deaths.\n",
      "6.5.4. Laboratory Data\n",
      "Laboratory results will be converted to International System of Units (Système International\n",
      "d'unités, SI) units for reporting.\n",
      "Quantitative data will be summarized using descriptive statistics (mean, standard deviation,\n",
      "median, quartiles, minimum, and maximum) of actual values and change from baseline for\n",
      "each visit over time (i.e. unscheduled assessments will be excluded). The total number of\n",
      "patients for change from baseline will include all patients who have botha baseline and a\n",
      "value at the postbaseline visit.\n",
      "Baseline will be defined as the last assessment performed on or prior to date of the first dose\n",
      "of study treatment (or prior to randomization for randomized patients). If there are multiple\n",
      "assessments that meet the baseline definition on the same day without the ability to determine\n",
      "which was truly last, then the worst grade will be assigned as the baseline grade.\n",
      "Results collected as strict inequalities (e.g., >10, <10) will be converted to numeric values\n",
      "subtracting a factor of 0.001. Expressions of the form” ≥” or “≤” will be converted to the end\n",
      "point. These numeric values will be evaluated for clinically significant abnormalities, but\n",
      "will not be included in calculations of summary statistics.\n",
      "Additionally, laboratory results will be programmatically classified accordingto NCI-\n",
      "CTCAE version 4.03. Non-numerical qualifiers will not be taken into consideration in the\n",
      "derivation of grade (e.g. hypokalemia Grade 1 and Grade 2 are only distinguished by a non-\n",
      "numerical qualifier and therefore Grade 2 will not be derived). In summary statistics the\n",
      "number and percentage of patients corresponding to grades that only include non-quantitative\n",
      "criteria will be displayed as a blank or NA (not assessed) rather than 0. If there is any\n",
      "overlap between grade criteria (e.g. CTCAE gradingcriteria for Creatinine Increased –a\n",
      "value can fall into one range based on comparison to upper limit of normal (ULN) and\n",
      "another range based on comparison to baseline), the highest (worst) grade would be assigned\n",
      "to that record. Grade 5 is defined in the CTCAE criteria guidance as an event with an\n",
      "outcome of death. Since laboratory data does not collect an outcome, Grade 5 is not used\n",
      "when programmatically grading laboratory data.\n",
      "Grade 0 or Outside Toxicity Reference (OTR) is not defined specifically byin the CTCAE\n",
      "guidance. However, programmatically this is used as a category to represent those patients\n",
      "who did not meet any of the Grades 1 to 4 criteria. If the laboratory value is evaluable for\n",
      "CTCAE criteria grading (numeric value is present, valid units and ranges are present asthe Grade 1-4 criteria for a given laboratorytest, then the value is assigned as Grade 0 or\n",
      "OTR.\n",
      "Abnormalities will be described using the worst grade by scheduled timepoint and overall.\n",
      "Worst grade by scheduled timepoint will be determined using only local laboratory results.\n",
      "Worst overall grade will be determined using both central and local laboratory results from\n",
      "scheduled and unscheduled visits. Several laboratory tests have bi-directional grading\n",
      "criteria defined so that both low (hypo) and high (hyper) values can be graded separately.\n",
      "Each criterion will be summarized separately. In the cases where a value is graded as a\n",
      "Grade 1, 2, 3, or 4 for one of the directions, that value will also be assigned as a Grade 0 for\n",
      "the opposite direction for that test. For example, a value meeting the criteria for Grade 3\n",
      "Hypercalcemia will be classified as a Grade 0 Hypocalcemia. For CTCAE terms that can be\n",
      "derived using one of several laboratory tests, the maximum postbaselinegrade for a given\n",
      "patient and CTCAE term will be the maximum across all possible laboratory tests.\n",
      "Additional laboratory results that are not part of NCI-CTCAE will be presented according to\n",
      "the following categories by scheduled timepoint as well as overall: below normal limit,\n",
      "within normal limits, and above normal limits. In the unlikely event that for a given patient,\n",
      "clinically significant abnormalities are noted in both directions (e.g., > ULNand< Lower\n",
      "Limit of Normal (LLN)), then both abnormalities are counted.Summaries at scheduled\n",
      "timepoints will consider only central laboratory data; however summaries overall will\n",
      "consider both central and local laboratory data.\n",
      "Liver function tests: Alanine aminotransferase (ALT), aspartate aminotransferase (AST),\n",
      "Alkaline Phosphatase (ALP),and total bilirubin (TBILI) are used to assess possible drug\n",
      "induced liver toxicity. The ratios of test result over the ULNwill be calculated and classified\n",
      "for these three parameters during the on-treatment period.\n",
      "Summaries of liver function tests will include the following categories. The number and\n",
      "percentage of patients with each of the following during the on-treatment period will be\n",
      "summarized by treatment arm:\n",
      " ALT ≥ 3×ULN, ALT ≥ 5xULN, ALT ≥ 10×ULN, ALT ≥ 20×ULN\n",
      " AST ≥ 3×ULN, AST ≥ 5xULN, AST ≥ 10×ULN, AST ≥ 20×ULN\n",
      " (ALT or AST) ≥ 3×ULN, (ALT or AST) ≥ 5×ULN, (ALT or AST) ≥ 10×ULN, (ALT\n",
      "or AST) ≥ 20×ULN\n",
      " TBILI ≥ 2×ULN\n",
      " Concurrent ALT ≥ 3×ULN and TBILI ≥ 2×ULN\n",
      " Concurrent AST ≥ 3×ULN and TBILI ≥ 2×ULN\n",
      " Concurrent (ALT or AST) ≥ 3×ULN and TBILI ≥ 2×ULN Concurrent (ALT or AST) ≥ 3×ULN and TBILI ≥ 2×ULN and ALP ≤ 2×ULN or\n",
      "missing\n",
      "Concurrent measurements are those occurring on the same date.\n",
      "Categories will be cumulative, i.e., a patient with an elevation of AST ≥10×ULN will also\n",
      "appear in the categories ≥5×ULN and ≥3×ULN. Liver function elevation and possible Hy’s\n",
      "Law cases will be summarized using frequency counts and percentages.\n",
      "An evaluation of Drug-Induced Serious Hepatotoxicity (eDISH) plot will also be created,\n",
      "with different symbols for different treatment arms, by graphically displaying\n",
      " peak serum ALT(/ULN) vs peak total bilirubin (/ULN) including reference lines at\n",
      "ALT=3×ULN and total bilirubin=2×ULN.\n",
      " peak serum AST(/ULN) vs peak total bilirubin (/ULN) including reference lines at\n",
      "AST=3×ULN and total bilirubin=2×ULN.\n",
      "In addition, a listing of all TBILI, ALT, AST and ALP values for patients with a postbaseline\n",
      "TBILI ≥ 2×ULN, ALT≥ 3×ULN or AST ≥ 3×ULN will be provided.\n",
      "6.5.5. Vital Signs\n",
      "Systolicanddiastolic blood pressure (mmHg),heart rate (bpm), and temperature (Celsius)\n",
      "will besummarizedat baseline andat all subsequent scheduledtimepoints. Changes from\n",
      "baseline valuewill bepresentedfor all scheduledtime points. All recorded vital signdata\n",
      "will belistedfor Parts 1 and 2.\n",
      "Thenumberandpercentage ofpatients with thefollowingvital signchanges will be\n",
      "presented.The definitions of potentiallyclinicallysignificant abnormalitiesareshown in\n",
      "Table 10.\n",
      "Table 10. PotentiallyClinicallySignificantAbnormalitiesinVitalSigns\n",
      "Parameter CriteriaforPotentiallyClinicallySignificantAbnormalities\n",
      "Systolicbloodpressure Absoluteresult> 180 mmHg andincrease from baseline ≥40 mmHg\n",
      "Absoluteresult< 90 mmHg and decrease from baseline >30 mmHg\n",
      "Diastolic bloodpressure Absoluteresult> 110 mmHg andincrease from baseline ≥30 mmHg\n",
      "Absoluteresult< 50 mmHg and decrease from baseline >20 mmHg\n",
      "≥ 20 mm HG increase from baseline\n",
      "Heart Rate Absolute result > 120 bpm and increase from baseline > 30 bpm\n",
      "Absolute result < 50 bpm and decrease from baseline >20 bpmTable 10. PotentiallyClinicallySignificantAbnormalitiesinVitalSigns\n",
      "Parameter CriteriaforPotentiallyClinicallySignificantAbnormalities\n",
      "Weight >10% decrease from baseline\n",
      "7. \n"
     ]
    }
   ],
   "source": [
    "start_keyword = 'ANALYSES AND SUMMARIES'\n",
    "end_keyword = section_end_converted.strip()\n",
    "\n",
    "# Extract the section from the PDF\n",
    "extracted_text = extract_text_from_pdf(pdf_file, start_page, end_page)\n",
    "\n",
    "# print(extracted_text)\n",
    "\n",
    "start_index = extracted_text.find('ANALYSES AND SUMMARIES')\n",
    "end_index = extracted_text.find(section_end_converted.strip())\n",
    "extracted_sec = extracted_text[start_index:end_index]\n",
    "print(extracted_sec)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "4. ANALYSIS SETS (POPULATIONS FOR ANALYSIS)\n",
      "Data from Part 1 and Part 2 will be summarized separately.\n",
      "4.1. Part 1 Analysis Sets/Populations\n",
      "Analysis Set Population Applicable Analysis\n",
      "Safety Population All patients who receivedat least one • Safety analyses\n",
      "dose of study treatment (talazoparib or • Select baseline\n",
      "enzalutamide). characteristics summaries\n",
      "Pharmacokinetic All patients who received at least one\n",
      "Population dose of study treatment in Part 1 and • PK analyses\n",
      "provided an evaluable PK sample.\n",
      "CTC Evaluable All patients from the Safety Analysis\n",
      "Population Set Part 1 with a baseline CTCs • CTC analyses\n",
      "assessment and at least 1 postbaseline\n",
      "CTCs assessment.\n",
      "4.2. Part 2 Analysis Sets/Populations\n",
      "All-comers Population:Analyses on the all-comers populationwill include patients\n",
      "unselected for DDR status enrolled in Cohort 1.\n",
      "DDR-deficientpopulation: Analysis on the DDR-deficient population will includepatients\n",
      "with DDR deficiencies enrolled in Cohorts 1 and 2.\n",
      "The following populations will be used in the data analyses.\n",
      "Analysis Set Population Applicable AnalysisIntent-to-Treat All patients randomizedto • Efficacyanalyses\n",
      "Population double-blind study treatment in Part 2 • Select baseline\n",
      "regardless of whether or not treatment characteristics summaries\n",
      "was administered.\n",
      "Safety Population All patients who receivedat least one • Safety analyses\n",
      "dose of study treatment • Select baseline\n",
      "(talazoparib/placeboor enzalutamide) characteristics summaries\n",
      "in Part 2 and is based on the actual\n",
      "treatment received.\n",
      "Patient-Reported A subset of ITT patients in Part2 who\n",
      "Outcome completed the baseline and at least • PROanalyses\n",
      "Population one postbaseline PRO assessment\n",
      "prior to the end of study.\n",
      "Pharmacokinetic All patients who received at least one\n",
      "Population dose of study treatment in Part 2and • PK analyses\n",
      "provided an evaluable PK sample.\n",
      "CTC Evaluable All patients from the Safety Analysis\n",
      "Population Set Part 2with a baseline CTCs • CTC analyses\n",
      "assessment and at least 1 postbaseline\n",
      "CTCs assessment.\n",
      "5. GENERAL METHODOLOGY AND CONVENTIONS\n",
      "The primary objective of Part 1 was to determine the startingdose of talazoparib when given\n",
      "in combination with enzalutamide during Part 2. Theinitial analysis to evaluate the safety\n",
      "and PK of talazoparib in combination with enzalutamide will beperformed after at least 12\n",
      "patients receivethe studytreatment for at least 4weeks in Part 1 (or sooner if warranted) to\n",
      "determine the appropriate dose level for the combination therapy.\n",
      "The sample size of at least 12 for Part 1 is based on feasibility considerations and is expected\n",
      "to be adequate for determining the starting dose.\n",
      "5.1. Hypotheses and Decision Rules (Part 2)\n",
      "The following statistical hypotheses will be tested to address the primary objectives:\n",
      "H : HR ≥1 vs. H : HR <1\n",
      "01 rPFS 11 rPFS\n",
      "H : HR ≥1 vs. H : HR <1\n",
      "02 rPFS+ 12 rPFS+\n",
      "where HR and HR are the hazard ratios (talazoparib in combination with\n",
      "rPFS rPFS+\n",
      "enzalutamide vs. placebo in combination with enzalutamide) of rPFS based on BICR\n",
      "assessment in theall-comers populationand in the DDR-deficient population,respectively\n"
     ]
    }
   ],
   "source": [
    "#extracting analysis sets\n",
    "analysis_start_keyword = 'ANALYSIS SETS'\n",
    "analysis_end_keyword = analysis_section_end_converted.strip()\n",
    "\n",
    "analysis_extracted_text = extract_text_from_pdf(pdf_file, analysis_start_page, analysis_end_page)\n",
    "    \n",
    "analysis_start_index = analysis_extracted_text.find('ANALYSIS SETS')\n",
    "analysis_end_index = analysis_extracted_text.find(analysis_section_end_converted.strip())\n",
    "\n",
    "analysis_extracted_section=analysis_extracted_text[analysis_start_index -3:analysis_end_index]\n",
    "print(analysis_extracted_section)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: tabula-py in c:\\users\\srivaa86\\appdata\\local\\packages\\pythonsoftwarefoundation.python.3.11_qbz5n2kfra8p0\\localcache\\local-packages\\python311\\site-packages (2.8.1)\n",
      "Requirement already satisfied: pandas>=0.25.3 in c:\\users\\srivaa86\\appdata\\local\\packages\\pythonsoftwarefoundation.python.3.11_qbz5n2kfra8p0\\localcache\\local-packages\\python311\\site-packages (from tabula-py) (2.1.0)\n",
      "Requirement already satisfied: numpy in c:\\users\\srivaa86\\appdata\\local\\packages\\pythonsoftwarefoundation.python.3.11_qbz5n2kfra8p0\\localcache\\local-packages\\python311\\site-packages (from tabula-py) (1.25.2)\n",
      "Requirement already satisfied: distro in c:\\users\\srivaa86\\appdata\\local\\packages\\pythonsoftwarefoundation.python.3.11_qbz5n2kfra8p0\\localcache\\local-packages\\python311\\site-packages (from tabula-py) (1.8.0)\n",
      "Requirement already satisfied: jpype1 in c:\\users\\srivaa86\\appdata\\local\\packages\\pythonsoftwarefoundation.python.3.11_qbz5n2kfra8p0\\localcache\\local-packages\\python311\\site-packages (from tabula-py) (1.4.1)\n",
      "Requirement already satisfied: python-dateutil>=2.8.2 in c:\\users\\srivaa86\\appdata\\local\\packages\\pythonsoftwarefoundation.python.3.11_qbz5n2kfra8p0\\localcache\\local-packages\\python311\\site-packages (from pandas>=0.25.3->tabula-py) (2.8.2)\n",
      "Requirement already satisfied: pytz>=2020.1 in c:\\users\\srivaa86\\appdata\\local\\packages\\pythonsoftwarefoundation.python.3.11_qbz5n2kfra8p0\\localcache\\local-packages\\python311\\site-packages (from pandas>=0.25.3->tabula-py) (2023.3.post1)\n",
      "Requirement already satisfied: tzdata>=2022.1 in c:\\users\\srivaa86\\appdata\\local\\packages\\pythonsoftwarefoundation.python.3.11_qbz5n2kfra8p0\\localcache\\local-packages\\python311\\site-packages (from pandas>=0.25.3->tabula-py) (2023.3)\n",
      "Requirement already satisfied: packaging in c:\\users\\srivaa86\\appdata\\local\\packages\\pythonsoftwarefoundation.python.3.11_qbz5n2kfra8p0\\localcache\\local-packages\\python311\\site-packages (from jpype1->tabula-py) (23.1)\n",
      "Requirement already satisfied: six>=1.5 in c:\\users\\srivaa86\\appdata\\local\\packages\\pythonsoftwarefoundation.python.3.11_qbz5n2kfra8p0\\localcache\\local-packages\\python311\\site-packages (from python-dateutil>=2.8.2->pandas>=0.25.3->tabula-py) (1.16.0)\n"
     ]
    }
   ],
   "source": [
    "#new codes to extract tables from the analysis sets section\n",
    "!pip install tabula-py"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "import tabula"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                                                Value\n",
      "0                                6.1. Part 1 Analyses\n",
      "1                             6.1.1. Primary Endpoint\n",
      "2                          6.1.2.1. PK Concentrations\n",
      "3                              6.1.2.2. PK Parameters\n",
      "4                        6.1.3. Exploratory Endpoints\n",
      "5                                6.2. Part 2 Analyses\n",
      "6                       6.2.1. Primary Endpoint--rPFS\n",
      "7                        6.2.1.1. SensitivityAnalyses\n",
      "8                           6.2.2.1. Overall Survival\n",
      "9          6.2.2.2. Objective Response per RECIST 1.1\n",
      "10          6.2.2.3. Duration of Soft Tissue Response\n",
      "11                   6.2.2.5. Time to PSA Progression\n",
      "12  6.2.2.6. Time to Initiation of Cytotoxic Chemo...\n",
      "13  6.2.2.7. Time to Initiation of Antineoplastic ...\n",
      "14  6.2.2.8. Time to First Symptomatic Skeletal Event\n",
      "15     6.2.2.9. PFS2 Based on Investigator Assessment\n",
      "16  6.2.2.10. Time to Opiate use for Prostate Canc...\n",
      "17                               6.2.3. PRO Endpoints\n",
      "18                   6.2.3.1. Time to Event Endpoints\n",
      "19  6.2.3.2. DescriptiveSummaries and Change from ...\n",
      "20                                          6.2.4. PK\n",
      "21                      6.2.5.1. CTC Conversion Rates\n",
      "22                       6.2.5.2. Molecular Profiling\n",
      "23     6.2.5.3. Concordance of DDR deficiency results\n",
      "24                             6.3. Subgroup Analyses\n",
      "25                  6.4. Baseline and Other Summaries\n",
      "26                          6.4.1. Baseline Summaries\n",
      "27                             6.4.2. Medical History\n",
      "28                  6.4.3. Prior AnticancerTreatments\n",
      "29       6.4.4. Study Conduct and Patient Disposition\n",
      "30                         6.4.5. Protocol Deviations\n",
      "31                     6.4.7. Concomitant Medications\n",
      "32   6.4.8. Subsequent AnticancerTherapies/Procedures\n",
      "33                              6.5.1. Adverse Events\n",
      "34          6.5.2. Adverse Events of Special Interest\n",
      "35                                      6.5.3. Deaths\n",
      "36                             6.5.4. Laboratory Data\n",
      "37                                 6.5.5. Vital Signs\n"
     ]
    }
   ],
   "source": [
    "pattern = r'^\\d\\.\\d\\.'\n",
    "lines = extracted_sec.splitlines()\n",
    "data = {'Key': [], 'Value': []}\n",
    "\n",
    "for line in lines:\n",
    "    match = re.findall(pattern, line)\n",
    "    if match:\n",
    "        data['Key'].append(match)\n",
    "        data['Value'].append(line)\n",
    "        \n",
    "df = pd.DataFrame.from_dict(data)\n",
    "df.drop('Key',axis=1,inplace=True)\n",
    "print(df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['6.1. Part 1 Analyses', '6.1.1. Primary Endpoint', '6.1.2.1. PK Concentrations', '6.1.2.2. PK Parameters', '6.1.3. Exploratory Endpoints', '6.2. Part 2 Analyses', '6.2.1. Primary Endpoint--rPFS', '6.2.1.1. SensitivityAnalyses', '6.2.2.1. Overall Survival', '6.2.2.2. Objective Response per RECIST 1.1', '6.2.2.3. Duration of Soft Tissue Response', '6.2.2.5. Time to PSA Progression', '6.2.2.6. Time to Initiation of Cytotoxic Chemotherapy', '6.2.2.7. Time to Initiation of Antineoplastic Therapy', '6.2.2.8. Time to First Symptomatic Skeletal Event', '6.2.2.9. PFS2 Based on Investigator Assessment', '6.2.2.10. Time to Opiate use for Prostate Cancer Pain', '6.2.3. PRO Endpoints', '6.2.3.1. Time to Event Endpoints', '6.2.3.2. DescriptiveSummaries and Change from Baseline', '6.2.4. PK', '6.2.5.1. CTC Conversion Rates', '6.2.5.2. Molecular Profiling', '6.2.5.3. Concordance of DDR deficiency results', '6.3. Subgroup Analyses', '6.4. Baseline and Other Summaries', '6.4.1. Baseline Summaries', '6.4.2. Medical History', '6.4.3. Prior AnticancerTreatments', '6.4.4. Study Conduct and Patient Disposition', '6.4.5. Protocol Deviations', '6.4.7. Concomitant Medications', '6.4.8. Subsequent AnticancerTherapies/Procedures', '6.5.1. Adverse Events', '6.5.2. Adverse Events of Special Interest', '6.5.3. Deaths', '6.5.4. Laboratory Data', '6.5.5. Vital Signs']\n"
     ]
    }
   ],
   "source": [
    "#converting df into a list\n",
    "sec_head = df['Value'].tolist()\n",
    "print(sec_head)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "domain_dict={'Subject-Level Analysis Dataset': 'ADSL','Baseline summaries' : 'ADSL','Physical examination':'ADPE', 'Alopecia Areata Symptom Impact Scale': 'ADAA','Subject Disposition':'ADDS','Demographics':'ADSL','AEs':'ADAE','SAEs':'ADSAE','MAEs':'ADAE', 'Bath Ankylosing Spondylitis Dis Activity': 'ADAB','Vital signs':'ADVS', \"Physician's Global Assess of Dermatology\": 'ADAD', 'Analysis Adverse Events': 'ADAE', 'Infusion-Rel Reactions and Immune-Rel AE': 'ADAEI', 'Ankylosing Spondylitis Work Instability': 'ADAI', 'Ankylosing Spondylitis Health Resource': 'ADAK', 'Disease Activity Markers': 'ADAM', 'Tanner Stage of Sexual Development': 'ADAN', 'Alopecia Areata Patient Priority Outcome': 'ADAP', 'Ankylosing Spondylitis Quality of Life': 'ADAQ', 'Severity of Alopecia Tool': 'ADAS', 'Akathisia Determination Scale': 'ADAW', 'BDI-II incl baseline cutoff categories': 'ADB2', 'Bone Body Composition': 'ADMKBB', 'NCI CTC Adverse Event (PRO-CTCAE)': 'ADBC', 'Baseline Disease Sites': 'ADBD', 'Bone Age X-Ray Assessment': 'ADBX', 'Functional Assessment of Cancer Therapy': 'ADCA', \"Children's Dermatology Life Quality Indx\": 'ADCC', 'Reactogenicity Unplanned Assessment': 'ADCECJ', 'Hemophilia Bleed Event': 'ADCEHE', 'Signs and Symptoms of Disease': 'ADSO', 'Reactogenicity Summary Diary Data': 'ADCEVD', 'Global Impression of Change': 'ADGC', 'Childhood Health Assessment': 'ADCH', 'Global Impression of Change - Modified': 'ADCI', 'Concomitant Medications Analysis Dataset': 'ADCM', 'Ulcerative Colitis History': 'ADCMUC', 'Concord Discord (RECIST) - Inv': 'ADCONC', 'Concord Discord (RECIST) - Inv Deriv': 'ADCONCD', 'Concord Discord (PCWG3) - Inv': 'ADCONCP', 'Child Health Questionnaire 50 Item': 'ADCQ', 'Columbia Sev Suicidality Rating Scale': 'ADCS', 'Cycles': 'ADCY', 'Scoring Atopic Dermatitis': 'ADDA', 'Event Date (PCWG3) - BICR': 'ADDATEPB', 'Event Date (RECIST) -Inv': 'ADDATES', 'Event Date (RECIST) - BICR': 'ADDATESB', 'Event Date (RECIST) - Inv Derived': 'ADDATESD', 'Event Date (irRECIST) - Inv': 'ADDATESI', 'Event Date (PCWG3) - Inv': 'ADDATESP', 'Disability Assessment for Dementia Scale': 'ADDB', 'Medical Device Complaints': 'ADDE', 'Dermatitis Family Impact Questionnaire': 'ADDJ', 'Derived Response - Inv': 'ADDRS', 'Disposition Analysis Dataset': 'ADDS', 'NASH Alcohol Use Disorder ID Test': 'ADDT', 'ARGUS Case Level Death': 'ADDTHC', 'ARGUS Event Level Death': 'ADDTHE', 'Protocol Deviations Analysis Dataset': 'ADDV', 'Dual X-Ray Absorptiometry': 'ADDX', 'EuroQol 5 Dim Health State Questionnaire': 'ADE5', 'Eczema Area and Severity Index': 'ADEA', 'Quantitative Ultrasound - Elastography': 'ADEB', 'SLEDAI 2K': 'ADED', 'ECG Analysis Dataset': 'ADEG','Electrocardiogram' : 'ADEG', 'Eyelash Assessment': 'ADEL', 'Entheses Assessment': 'ADEN', 'EOG Performance Status': 'ADEO', 'EU Org for Research and Treat. of Cancer': 'ADER', 'Epworth Sleepiness Scale': 'ADES', 'Exposure Analysis Dataset': 'ADEX','Treatment Exposure' : 'ADEX','Study Treatment Exposure':'ADEX', 'Eyebrow Assessment': 'ADEY', 'Reactogenicity Daily Diary Data': 'ADFACEVD', 'Fracture Assessment': 'ADFX', 'Global Impression of Severity': 'ADGE', 'Global Assess of Fn for Schizophrenia': 'ADGF', 'Patient Global Impression of Severity': 'ADGG', 'Magnetic Resonance Imaging': 'ADMR', 'Obstetrical History (GYN)': 'ADGY', 'Health Assessment Questionnaire': 'ADHA', 'Health Care Utilization': 'ADHC', 'Hauser Diary Endpoints': 'ADHD', 'Concomitant Medications':'ADCM', 'Hemophilia Joint Health Score': 'ADHJ', 'Hospital Anxiety and Depression Scale': 'ADHL', 'Hemophilia Activities List': 'ADHM', 'Hemophilia History': 'ADHP', 'Hemophilia Quality of Life': 'ADHQ', 'Alopecia Areata History': 'ADHX', 'Inflammatory Bowel Disease Questionnaire': 'ADIB', 'Incl/Excl Crit Not Met Analysis Dataset': 'ADIE', 'Brief Fatigue Inventory': 'ADIF', 'Clin. Global Impression-Alopecia Areata': 'ADIG', 'Infant Dermatitis Quality of Life Index': 'ADIL', 'Immunogenicity Sample Analysis Dataset': 'ADISDA', 'Juvenile Joint Tenderness and Swelling': 'ADJA', 'Joint and Musculoskeletal Assessment': 'ADJM', 'Joint Pain Assessment': 'ADJP', 'Ankylosing Spondylitis Swollen Joint Cnt': 'ADJS', 'Joint Tenderness and Assessment': 'ADJT', 'Kansas City Cardiomyopathy Questionnaire': 'ADKC', 'Kellgren Lawrence Grading System': 'ADKL', 'Laboratory Analysis Dataset': 'ADLB', 'Leeds Enthesitis Index': 'ADLD', 'Lower Extremity Activity Scale': 'ADLE', 'Dermatology Life Quality Index': 'ADLI', 'Low Back Pain Stratification': 'ADLP', 'MD Anderson': 'ADMA', 'Brief Pain Inventory': 'ADMB', \"Unified Parkinson's Disease Rating Scale\": 'ADMD', 'Maastricht AS Entheses': 'ADME', 'Medical History Analysis Dataset': 'ADMH', 'Mobility Measurement': 'ADMM', 'Musculoskeletal History': 'ADMS', 'Muscle Strength Assessments': 'ADMU', 'North Star Ambulatory Assessment': 'ADNA', 'Neurological Examination': 'ADNE', 'Numeric Pain Scale Rating': 'ADNR', 'Neuropathy Impairment Score': 'ADNS', 'NASH Symptom Diary': 'ADNU', 'NASH Check': 'ADNZ', 'Medical Outcomes Study': 'ADOM', 'Obstetric Examination': 'ADON', 'AE': 'ADAE','SAE':'ADSAE','WOMAC': 'ADOO', 'Opioid-Related Symptom Distress Scale': 'ADOR', '8-Point Ordinal Scale': 'ADP8', 'Pediatric ACR Response and Disease Flare': 'ADPA', 'PK Concentration': 'ADPC', 'PK Concentration (Second level)': 'ADPC2', 'Pharmacodynamics Analysis Dataset': 'ADPD', 'Physical Examination Analysis Dataset': 'ADPE', \"Parkinson's Disease Fatigue Scale\": 'ADPF', 'Patient Health Questionnaire (PHQ)': 'ADPH', 'Patient Global Impression of Change': 'ADPI', 'Patient-Oriented Eczema Measure (POEM)': 'ADPM', 'PainDETECT Questionnaire (PDEQ)': 'ADPN', 'PK Parameters Analysis Dataset': 'ADPP', 'Secondary PK Parameters': 'ADPP2', \"Parkinson's Disease Questionnaire\": 'ADPQ', 'Procedures Analysis Dataset': 'ADPR', 'Psoriasis Area and Severity Index (PASI)': 'ADPS', 'Prostate Specific Antigen': 'ADPSA', 'Parental Assessment of Disease (PDIS)': 'ADPT', 'Pruritus and Symptom Assessment for AD': 'ADPU', '5-D Pruritus Scale (P5D)': 'ADPV', \"Physician's Withdrawal Checklist (PWC)\": 'ADPW', 'Pregnancy Outcome Questionnaire': 'ADPY', 'Quebec Task Force Classification': 'ADQF', \"IC Disorder in Parkinson's Disease Scale\": 'ADQI', 'Short-Form MCGILL Pain Questionnaire-2': 'ADQSFM', 'Fatigue Severity Scale': 'ADQSFS', 'Roland-Morris Disability Questionnaire': 'ADRD', 'Modified Schobers Test': 'ADRF', 'Range of Motion Assessment': 'ADRM', 'Routine Assessment of Patient Data': 'ADRO', 'Reprod System Findings Analysis Dataset': 'ADRP', 'Response (RECIST) - Inv Derived': 'ADRSD', 'Response (RECIST) - BICR': 'ADRSB', 'Response (irRECIST) - Inv': 'ADRSI', 'Response (PCWG3) - Inv': 'ADRSP', 'Response (PCWG3) - BICR': 'ADRSPB', 'PT-Reported Trt Impact Assess-Modified': 'ADRT', 'Self-Administered PT Satisfaction Scale': 'ADSA', 'Serious Adverse Events Analysis Dataset': 'ADSAE', 'ARGUS Case Level SAE': 'ADSAEC', 'ARGUS Event Level SAE': 'ADSAEE', 'Study Body Site': 'ADSB', 'Sexual Function Questionnaire (SF-28)': 'ADSC', 'Body Surface Area for Dermatitis': 'ADSD', 'PT Global Assessment of Disease Activity': 'ADSG', 'Skeletal Events': 'ADSKL', 'Shoulder Pain and Disability Index': 'ADSP', 'Short-Form 36 Health Survey Quest': 'ADSQ', 'Follow-up Contact': 'ADSSFC', 'Survey of Autonomic Symptoms': 'ADST', 'Substance Use Analysis Dataset': 'ADSU', 'Simpson Angus Rating Scale (version 2)': 'ADSW', 'Transfusion (Blood Fluids) Details': 'ADTB', 'Tuberculosis Challenge and Reaction': 'ADTC', 'Tumor Measurement (RECIST) - Inv': 'ADTR', 'Tumor Measurement (RECIST) - BICR': 'ADTRB', 'Tumor Measurement (PCWG3) - Inv': 'ADTRP', 'Tumor Measurement (PCWG3) - BICR': 'ADTRPB', 'Trt Satisfaction Quest Medicine v.II': 'ADTS', 'Taste Questionnaire (TQ)': 'ADTT', 'Time-to-Event (RECIST) - Inv': 'ADTTE', 'Time-to-Event (RECIST) - BICR': 'ADTTEB', 'Time-to-Event (RECIST) - Inv Derived': 'ADTTED', 'Time-to-Event (irRECIST) - Inv': 'ADTTEI', 'Time-to-Event (Other Oncology Endpoints)': 'ADTTEOP', 'Time-to-Event (PCWG3) - Inv': 'ADTTEP', 'Time-to-Event (PCWG3) - BICR': 'ADTTEPB', 'Time-to-Event (PSA)': 'ADTTESP', 'Mini Mental Status Examination': 'ADU2', 'UC Endoscopic Index of Severity': 'ADUE', 'Pedia Ulcerative Colitis Activity Index': 'ADUI', 'Alopecia Areata Resource Utilization': 'ADUR', 'Immunogenicity Analysis Dataset': 'ADVA', 'NASH Promis - Fatigue': 'ADVF', 'Visual Analogue Scale': 'ADVL', 'Vital Signs Analysis Dataset': 'ADVS', 'Vaccine Administration': 'ADVX', 'Walking Distance Assessment': 'ADWK', 'WOMAC Phys Funct and Stiffness Subscale': 'ADWN', 'Work Prod and Activity Impairment Quest': 'ADWP'}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "metadata": {},
   "outputs": [],
   "source": [
    "#function to remove the numbers and special characters from the headers\n",
    "# def remove_dig_char(strings):\n",
    "#     pattern = r'[^a-zA-Z\\s]'\n",
    "#     header = []\n",
    "#     for string in strings:\n",
    "#         new_string = re.sub(pattern, '', string)\n",
    "#         header.append(new_string)\n",
    "#     return header\n",
    "\n",
    "# header = remove_dig_char(sec_head)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Anaconda3\\lib\\site-packages\\fuzzywuzzy\\fuzz.py:11: UserWarning: Using slow pure-python SequenceMatcher. Install python-Levenshtein to remove this warning\n",
      "  warnings.warn('Using slow pure-python SequenceMatcher. Install python-Levenshtein to remove this warning')\n"
     ]
    }
   ],
   "source": [
    "#creating a dictionary with mapped headers and domains\n",
    "from fuzzywuzzy import fuzz\n",
    "unique=[]\n",
    "created_dict={}\n",
    "for key in sec_head:\n",
    "    y=[]\n",
    "    for i in domain_dict:\n",
    "        \n",
    "        if fuzz.token_set_ratio(i.lower(),key.lower()) > 70:\n",
    "#             print(key,domain_dict[i])\n",
    "            if key not in unique:\n",
    "                y=[domain_dict[i]]\n",
    "                unique.append(key)\n",
    "            else:\n",
    "                y.append(domain_dict[i])\n",
    "              \n",
    "        if y!=[]:        \n",
    "            created_dict[key]=y  \n",
    "            "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "#function to retain only the unique domain types\n",
    "def extract_unique_values(dictionary):\n",
    "    unique_values = {}\n",
    "    for key, values in dictionary.items():\n",
    "        unique_values[key] = list(set(values))\n",
    "    return unique_values\n",
    "\n",
    "unique_values = extract_unique_values(created_dict)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "domain_type = {}\n",
    "for key, values in unique_values.items():\n",
    "    domain_type[key] = values"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'6.1.2.1. PK Concentrations': ['ADPC'],\n",
       " '6.1.2.2. PK Parameters': ['ADPP2', 'ADPP'],\n",
       " '6.2.2.2. Objective Response per RECIST 1.1': ['ADRSB', 'ADRSD'],\n",
       " '6.2.2.5. Time to PSA Progression': ['ADTTESP'],\n",
       " '6.2.2.8. Time to First Symptomatic Skeletal Event': ['ADTTESP', 'ADTTEP'],\n",
       " '6.2.2.9. PFS2 Based on Investigator Assessment': ['ADEY', 'ADEL'],\n",
       " '6.2.3.1. Time to Event Endpoints': ['ADTTEOP', 'ADTTESP', 'ADTTEP'],\n",
       " '6.4. Baseline and Other Summaries': ['ADSL'],\n",
       " '6.4.1. Baseline Summaries': ['ADSL'],\n",
       " '6.4.2. Medical History': ['ADMH'],\n",
       " '6.4.4. Study Conduct and Patient Disposition': ['ADDS'],\n",
       " '6.4.5. Protocol Deviations': ['ADDV'],\n",
       " '6.4.7. Concomitant Medications': ['ADCM'],\n",
       " '6.5.1. Adverse Events': ['ADAE', 'ADSAE'],\n",
       " '6.5.2. Adverse Events of Special Interest': ['ADAE'],\n",
       " '6.5.5. Vital Signs': ['ADVS']}"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "domain_type #final output"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Anaconda3\\lib\\site-packages\\ipykernel_launcher.py:18: FutureWarning: The default value of regex will change from True to False in a future version.\n"
     ]
    }
   ],
   "source": [
    "a_df = pd.DataFrame(columns=['Key', 'Value'], dtype=object)\n",
    "analysis_pattern = r'^\\d\\.\\d\\.'\n",
    "analysis_lines = analysis_extracted_section.splitlines()\n",
    "\n",
    "for aline in analysis_lines:\n",
    "    analysis_matches = re.findall(analysis_pattern, aline)\n",
    "    if analysis_matches != []:\n",
    "        a_match = re.findall(r'Population', aline)\n",
    "        if a_match != []:\n",
    "            a_data = {'Key': analysis_matches, 'Value': aline}\n",
    "            a_df = a_df.append(a_data, ignore_index=True)\n",
    "        as_match = re.findall(r'Analysis Set', aline)\n",
    "        if as_match != []:\n",
    "            a_data = {'Key': analysis_matches, 'Value': aline}\n",
    "            a_df = a_df.append(a_data, ignore_index=True)\n",
    "\n",
    "a_df.drop('Key', axis=1, inplace=True)\n",
    "a_df['Value'] = a_df['Value'].str.replace(r'\\d\\.\\d\\.\\d\\. ', '')\n",
    "\n",
    "# Convert the 'Value' column to a list\n",
    "population_list = a_df['Value'].tolist()\n",
    "unique_populations = list(set(population_list))\n",
    "\n",
    "# print(unique_populations)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [],
   "source": [
    "def extract_tables_from_pdf(pdf_file, keyword):\n",
    "    tables = []\n",
    "    with pdfplumber.open(pdf_file) as pdf:\n",
    "        for i, page in enumerate(pdf.pages):\n",
    "            text = page.extract_text()\n",
    "            if keyword in text:\n",
    "                for table in page.extract_tables():\n",
    "                    table_df = pd.DataFrame(table[1:], columns=table[0],dtype=object)\n",
    "                    table_df.columns = table_df.columns.str.lower()\n",
    "                    if keyword.lower() in table_df.columns:\n",
    "                            # Check if the header of the table matches the keyword\n",
    "                        if len(tables) > 0 and tables[-1].columns.equals(table_df.columns):\n",
    "                                # Check if the table from the next page has the same number of columns\n",
    "                            next_page = pdf.pages[i+1].extract_tables()\n",
    "                            if len(next_page) > 0 and len(next_page[0][0]) == len(table_df.columns):\n",
    "                                next_table_df = pd.DataFrame(next_page[0][1:], columns=next_page[0][0])\n",
    "                                next_table_df = next_table_df.rename(columns=dict(zip(next_table_df.columns, tables[-1].columns)))\n",
    "                                tables[-1] = pd.concat([tables[-1], next_table_df], ignore_index=True)\n",
    "                                    # st.write(tables)\n",
    "                                    # st.write(next_table_df)\n",
    "                            else:\n",
    "                                tables.append(table_df)\n",
    "                        else:\n",
    "                            tables.append(table_df)\n",
    "                            # st.write(tables)\n",
    "    return tables\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "keyword = \"population\"\n",
    "table_dfs = extract_tables_from_pdf(pdf_file, keyword)    \n",
    "if table_dfs !=[]:\n",
    "    df_big = pd.concat(table_dfs, ignore_index=True)\n",
    "else:\n",
    "    df_big = None\n",
    "        \n",
    "keyword = \"analysis set\"\n",
    "a_table_dfs = extract_tables_from_pdf(pdf_file, keyword)\n",
    "if a_table_dfs !=[]:\n",
    "    a_df_big = pd.concat(a_table_dfs, ignore_index=True)\n",
    "else:\n",
    "    a_df_big = None\n",
    "\n",
    "keyword = \"participant analysis set\"\n",
    "a1_table_dfs = extract_tables_from_pdf(pdf_file, keyword)\n",
    "\n",
    "if a1_table_dfs !=[]:\n",
    "    a1_df_big = pd.concat(a1_table_dfs, ignore_index=True)\n",
    "else:\n",
    "    a1_df_big = None\n",
    "   "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "if df_big is not None or a_df_big is not None:\n",
    "    final_df_big=pd.concat([df_big,a_df_big],ignore_index=True)\n",
    "    word_list = []\n",
    "    final_df_big.columns = final_df_big.columns.str.lower()\n",
    "    if 'population' in final_df_big.columns:\n",
    "        for index, row in final_df_big.iterrows():\n",
    "            word_list = final_df_big['population'].str.lower().tolist()\n",
    "    if 'analysis set' in final_df_big.columns:\n",
    "        for index, row in final_df_big.iterrows():\n",
    "            word_list = final_df_big['analysis set'].str.lower().tolist()\n",
    "    if 'participant analysis set' in final_df_big.columns:\n",
    "        for index, row in final_df_big.iterrows():\n",
    "            word_list = final_df_big['participant analysis set'].str.lower().tolist()\n",
    "\n",
    "    clean_word_list = [string.replace('\\uf02d', '-') for string in word_list]\n",
    "    table_unique_populations = [string.replace('\\n', ' ') for string in clean_word_list]\n",
    "                \n",
    "#     print(table_unique_populations)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['4.1. Part 1 Analysis Sets/Populations', 'patient-reported outcome population', 'safety population', 'ctc evaluable population', '4.2. Part 2 Analysis Sets/Populations', 'pharmacokinetic population']\n"
     ]
    }
   ],
   "source": [
    "population_final=unique_populations + table_unique_populations\n",
    "unique_population_final=list(set(population_final))\n",
    "print(unique_population_final)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "def print_matching_word(text_to_test, clean_word_list1):\n",
    "\n",
    "    for word in clean_word_list1:\n",
    "\n",
    "        match = re.search(r'\\b{}\\b'.format(word.lower()), text_to_test.lower())\n",
    "\n",
    "        if match:\n",
    "\n",
    "            match_out=match.group()\n",
    "\n",
    "            print(\"Match found:\",match_out)\n",
    "\n",
    "            new_text =text_to_test.lower()\n",
    "\n",
    "            start_index = new_text.index(match_out)\n",
    "            end_index = start_index + len(match_out) - 1\n",
    "\n",
    "            print(\"Start index:\", start_index)\n",
    "            print(\"End index:\", end_index)\n",
    "            \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Match found: 4.1. part 1 analysis sets/populations\n",
      "Start index: 103\n",
      "End index: 139\n",
      "Match found: safety population\n",
      "Start index: 185\n",
      "End index: 201\n",
      "Match found: 4.2. part 2 analysis sets/populations\n",
      "Start index: 675\n",
      "End index: 711\n"
     ]
    }
   ],
   "source": [
    "print_matching_word(analysis_extracted_section, unique_population_final)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Value</th>\n",
       "      <th>Paragraph</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>6.1. Part 1 Analyses</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>6.1.1. Primary Endpoint</td>\n",
       "      <td>Target safety events specified inTable 4will ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>6.1.2.1. PK Concentrations</td>\n",
       "      <td>In Part 1, analyses of PK concentrations will...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>6.1.2.2. PK Parameters</td>\n",
       "      <td>In estimating the PK parameters, BLQ values a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>6.1.3. Exploratory Endpoints</td>\n",
       "      <td>For CTC counts, a summary of the mean (standa...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>6.2. Part 2 Analyses</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>6.2.1. Primary Endpoint--rPFS</td>\n",
       "      <td>The primary efficacy analysis will compare rP...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>6.2.1.1. SensitivityAnalyses</td>\n",
       "      <td>The following sensitivity analyses will be pe...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>6.2.2.1. Overall Survival</td>\n",
       "      <td>OS is defined as the time from randomization ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>6.2.2.2. Objective Response per RECIST 1.1</td>\n",
       "      <td>ORR is defined as the proportion of patients ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>6.2.2.3. Duration of Soft Tissue Response</td>\n",
       "      <td>For patients with measurable soft tissue dise...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>6.2.2.5. Time to PSA Progression</td>\n",
       "      <td>PSA progression is defined as the timefrom th...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>6.2.2.6. Time to Initiation of Cytotoxic Chemo...</td>\n",
       "      <td>Time to initiation of cytotoxic chemotherapy ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>6.2.2.7. Time to Initiation of Antineoplastic ...</td>\n",
       "      <td>Time to initiation of antineoplastic therapy ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>6.2.2.8. Time to First Symptomatic Skeletal Event</td>\n",
       "      <td>Time to the first symptomatic skeletal event ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>6.2.2.9. PFS2 Based on Investigator Assessment</td>\n",
       "      <td>PFS2 is defined as the time from randomizatio...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>6.2.2.10. Time to Opiate use for Prostate Canc...</td>\n",
       "      <td>Time to opiate use for prostate cancer pain i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>6.2.3. PRO Endpoints</td>\n",
       "      <td>All of the PRO endpoints described below will...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>6.2.3.1. Time to Event Endpoints</td>\n",
       "      <td>Time to Deterioration in Patient-reported Pai...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>6.2.3.2. DescriptiveSummaries and Change from ...</td>\n",
       "      <td>BPI-SF Descriptive summaries for BPI-SFby vis...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>6.2.4. PK</td>\n",
       "      <td>In Part 2, analyses of PK concentrations will...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>6.2.5.1. CTC Conversion Rates</td>\n",
       "      <td>CTC endpoints will be analyzedseparately forb...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>6.2.5.2. Molecular Profiling</td>\n",
       "      <td>A separate analysis plan will be written to d...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>6.2.5.3. Concordance of DDR deficiency results</td>\n",
       "      <td>The concordance of DDR deficiency results (DD...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>6.3. Subgroup Analyses</td>\n",
       "      <td>Subgroup analyses will be performed if there ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>6.4. Baseline and Other Summaries</td>\n",
       "      <td>Unless otherwise specified,the following summ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>6.4.1. Baseline Summaries</td>\n",
       "      <td>Thefollowingdemographic andbaselinedisease ch...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>6.4.2. Medical History</td>\n",
       "      <td>Medical history will be coded using the most ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>6.4.3. Prior AnticancerTreatments</td>\n",
       "      <td>Prior anticancertreatments include systemic t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>6.4.4. Study Conduct and Patient Disposition</td>\n",
       "      <td>Discontinuations from study treatment due to ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>6.4.5. Protocol Deviations</td>\n",
       "      <td>Important protocol deviations will be compile...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>6.4.7. Concomitant Medications</td>\n",
       "      <td>Concomitant medications refer to all medicati...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>6.4.8. Subsequent AnticancerTherapies/Procedures</td>\n",
       "      <td>Subsequent systemic anticancertherapies are d...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>6.5.1. Adverse Events</td>\n",
       "      <td>All analyses will be based on treatment-emerg...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>6.5.2. Adverse Events of Special Interest</td>\n",
       "      <td>See section 3.4.1for a list of AEs of Special...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>6.5.3. Deaths</td>\n",
       "      <td>The frequency (number and percentage) of pati...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>6.5.4. Laboratory Data</td>\n",
       "      <td>Laboratory results will be converted to Inter...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>6.5.5. Vital Signs</td>\n",
       "      <td>Systolicanddiastolic blood pressure (mmHg),he...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                Value  \\\n",
       "0                                6.1. Part 1 Analyses   \n",
       "1                             6.1.1. Primary Endpoint   \n",
       "2                          6.1.2.1. PK Concentrations   \n",
       "3                              6.1.2.2. PK Parameters   \n",
       "4                        6.1.3. Exploratory Endpoints   \n",
       "5                                6.2. Part 2 Analyses   \n",
       "6                       6.2.1. Primary Endpoint--rPFS   \n",
       "7                        6.2.1.1. SensitivityAnalyses   \n",
       "8                           6.2.2.1. Overall Survival   \n",
       "9          6.2.2.2. Objective Response per RECIST 1.1   \n",
       "10          6.2.2.3. Duration of Soft Tissue Response   \n",
       "11                   6.2.2.5. Time to PSA Progression   \n",
       "12  6.2.2.6. Time to Initiation of Cytotoxic Chemo...   \n",
       "13  6.2.2.7. Time to Initiation of Antineoplastic ...   \n",
       "14  6.2.2.8. Time to First Symptomatic Skeletal Event   \n",
       "15     6.2.2.9. PFS2 Based on Investigator Assessment   \n",
       "16  6.2.2.10. Time to Opiate use for Prostate Canc...   \n",
       "17                               6.2.3. PRO Endpoints   \n",
       "18                   6.2.3.1. Time to Event Endpoints   \n",
       "19  6.2.3.2. DescriptiveSummaries and Change from ...   \n",
       "20                                          6.2.4. PK   \n",
       "21                      6.2.5.1. CTC Conversion Rates   \n",
       "22                       6.2.5.2. Molecular Profiling   \n",
       "23     6.2.5.3. Concordance of DDR deficiency results   \n",
       "24                             6.3. Subgroup Analyses   \n",
       "25                  6.4. Baseline and Other Summaries   \n",
       "26                          6.4.1. Baseline Summaries   \n",
       "27                             6.4.2. Medical History   \n",
       "28                  6.4.3. Prior AnticancerTreatments   \n",
       "29       6.4.4. Study Conduct and Patient Disposition   \n",
       "30                         6.4.5. Protocol Deviations   \n",
       "31                     6.4.7. Concomitant Medications   \n",
       "32   6.4.8. Subsequent AnticancerTherapies/Procedures   \n",
       "33                              6.5.1. Adverse Events   \n",
       "34          6.5.2. Adverse Events of Special Interest   \n",
       "35                                      6.5.3. Deaths   \n",
       "36                             6.5.4. Laboratory Data   \n",
       "37                                 6.5.5. Vital Signs   \n",
       "\n",
       "                                            Paragraph  \n",
       "0                                                      \n",
       "1    Target safety events specified inTable 4will ...  \n",
       "2    In Part 1, analyses of PK concentrations will...  \n",
       "3    In estimating the PK parameters, BLQ values a...  \n",
       "4    For CTC counts, a summary of the mean (standa...  \n",
       "5                                                      \n",
       "6    The primary efficacy analysis will compare rP...  \n",
       "7    The following sensitivity analyses will be pe...  \n",
       "8    OS is defined as the time from randomization ...  \n",
       "9    ORR is defined as the proportion of patients ...  \n",
       "10   For patients with measurable soft tissue dise...  \n",
       "11   PSA progression is defined as the timefrom th...  \n",
       "12   Time to initiation of cytotoxic chemotherapy ...  \n",
       "13   Time to initiation of antineoplastic therapy ...  \n",
       "14   Time to the first symptomatic skeletal event ...  \n",
       "15   PFS2 is defined as the time from randomizatio...  \n",
       "16   Time to opiate use for prostate cancer pain i...  \n",
       "17   All of the PRO endpoints described below will...  \n",
       "18   Time to Deterioration in Patient-reported Pai...  \n",
       "19   BPI-SF Descriptive summaries for BPI-SFby vis...  \n",
       "20   In Part 2, analyses of PK concentrations will...  \n",
       "21   CTC endpoints will be analyzedseparately forb...  \n",
       "22   A separate analysis plan will be written to d...  \n",
       "23   The concordance of DDR deficiency results (DD...  \n",
       "24   Subgroup analyses will be performed if there ...  \n",
       "25   Unless otherwise specified,the following summ...  \n",
       "26   Thefollowingdemographic andbaselinedisease ch...  \n",
       "27   Medical history will be coded using the most ...  \n",
       "28   Prior anticancertreatments include systemic t...  \n",
       "29   Discontinuations from study treatment due to ...  \n",
       "30   Important protocol deviations will be compile...  \n",
       "31   Concomitant medications refer to all medicati...  \n",
       "32   Subsequent systemic anticancertherapies are d...  \n",
       "33   All analyses will be based on treatment-emerg...  \n",
       "34   See section 3.4.1for a list of AEs of Special...  \n",
       "35   The frequency (number and percentage) of pati...  \n",
       "36   Laboratory results will be converted to Inter...  \n",
       "37   Systolicanddiastolic blood pressure (mmHg),he...  "
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#creating dataframe for domain tagging\n",
    "pattern = r'^\\d+\\.'\n",
    "\n",
    "lines = extracted_sec.splitlines()\n",
    "df = pd.DataFrame(columns=['Key','Value','Paragraph'])\n",
    "paragraph=\"\"\n",
    "\n",
    "for i, line in enumerate(lines):\n",
    "    matches = re.findall(pattern, line)\n",
    "    if matches:\n",
    "        if paragraph:\n",
    "            next_paragraph = \"\"\n",
    "            for j in range(i+1, len(lines)):\n",
    "                if lines[j].strip():\n",
    "                    next_paragraph = lines[j].strip()\n",
    "                    break\n",
    "            wrapped_lines = textwrap.wrap(paragraph.rstrip('\\r\\n'), width=70)\n",
    "            if len(wrapped_lines) > 1:\n",
    "                wrapped_lines = wrapped_lines[:-1]\n",
    "            paragraph = \"\\n\".join(wrapped_lines)\n",
    "            data = {'Key': matches, 'Value': line, 'Paragraph': paragraph + \" \" + next_paragraph}\n",
    "            df = df.append(data, ignore_index=True)\n",
    "            paragraph = \"\"\n",
    "        else:\n",
    "            data = {'Key': matches, 'Value': line, 'Paragraph': \" \"}\n",
    "            df = df.append(data, ignore_index=True)\n",
    "    else:\n",
    "        paragraph += \" \" + line.strip()\n",
    "        pattern = r'^\\d\\.\\d\\.'\n",
    "if paragraph:\n",
    "    wrapped_lines = textwrap.wrap(paragraph.rstrip('\\r\\n'), width=70)\n",
    "    if len(wrapped_lines) > 1:\n",
    "        wrapped_lines = wrapped_lines[:-1]\n",
    "    paragraph = \"\\n\".join(wrapped_lines)\n",
    "    data = {'Paragraph': paragraph}\n",
    "    df = df.append(data, ignore_index=True)\n",
    "\n",
    "df.drop('Key', axis=1,inplace=True)\n",
    "df['Paragraph'] = df['Paragraph'].shift(-1)\n",
    "df = df[:-1]\n",
    "\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "6.1. Part 1 Analyses\n",
      "  \n",
      "\n",
      "6.1.1. Primary Endpoint\n",
      "  Target safety events specified inTable 4will be evaluated in the Part\n",
      "1 safety analysisset. Table 4. Target Safety Events: Part 1 (Open-\n",
      "Label Treatment) Hematologic Toxicity Any of the following considered\n",
      "possibly or probably related to talazoparib:  Grade 4 anemia  Grade\n",
      "4 thrombocytopenia  Grade 4 neutropenia (ANC <500/µL or <0.5 × 109/L)\n",
      " Grade 3 thrombocytopenia associated with clinically significant\n",
      "bleeding  Grade 3 neutropenia or Grade 3 thrombocytopenia if daily\n",
      "dosing is interrupted for 7days  Febrile neutropenia, defined as ANC\n",
      "<1000/µLwith a single temperature of >38.3C (>101F) or a temperature\n",
      "of >38C (100.4F) sustained over a 1-hour period  Neutropenic\n",
      "infection (ANC <1000/µL or <1.0 × 109/L) Nonhematologic Toxicity Any\n",
      "Grade 3 adverse eventconsidered possibly or probably related to\n",
      "talazoparib excluding the following:  Grade 3 laboratory\n",
      "abnormalities not considered clinically significant  Grade 3 adverse\n",
      "event not considered clinically significant  Grade 3 nausea or\n",
      "vomiting that responds to medical intervention within 72hours  Grade\n",
      "3 diarrhea that can be medically managed to Grade 2 within 72hours \n",
      "Grade 3 fatigue that improves to Grade 2 within 7 days Liver\n",
      "Toxicity Any of the following considered possibly or probably related\n",
      "to talazoparib:  ALT or AST >3× ULNif baseline ALT or AST 3×ULN \n",
      "ALT or AST >5×ULN (a lower threshold should be considered if the ALT\n",
      "or AST abnormalities are accompanied by symptoms and signs of\n",
      "hepatitis ) AND 2-fold increases above baseline  ALT or AST 3×ULN\n",
      "and total bilirubin ≥2×ULN  Total bilirubin >5×ULN Toxicities will be\n",
      "classified by severity according to the National Cancer Institute\n",
      "Common Terminology Criteria for Adverse Events, version 4. As the\n",
      "targeted safety events defined above include some subjective criteria\n",
      "or multiple criteria occurring simultaneously, an assessment of\n",
      "whether or not event met the criteria of being target safety events\n",
      "requiring a reduction in the starting dose for Part 2 will be made\n",
      "based on a review of individual patient data, summaries of all AEs,and\n",
      "exposure.6.1.2. Secondary Endpoints [Pharmacokinetics] A record-level\n",
      "dataset Pharmacokinetic Analysis Set -Talazoparib will includeall\n",
      "talazoparib PK concentrations that meet thecriteria below:  PK\n",
      "samples collected at Week1  PK samples collected at Weeks 5, 9, 13,\n",
      "and 17 at the same dose level without any dose modification for at\n",
      "least 14 days. Another record-level dataset Pharmacokinetic Analysis\n",
      "Set -Enzalutamidewill includeall enzalutamideconcentrationsthat meet\n",
      "the criteria below:  PK samples collected at Week 1  PK samples\n",
      "collected at Weeks 5, 9, 13, and 17 for patients who did not\n",
      "experience any dose reductions or interruptions of enzalutamide.\n",
      "Pharmacokinetic Analysis Set –Talazopariband Pharmacokinetic Analysis\n",
      "Set – Enzalutamide will be used for PK parameter derivation and In Part 1, analyses of PK concentrations will include sampling at predose, 1, 2, 4, 6 and 24\n",
      "\n",
      "6.1.2.1. PK Concentrations\n",
      "  In Part 1, analyses of PK concentrations will include sampling at\n",
      "predose, 1, 2, 4, 6 and 24 hours postdoseat Day 1 (week 1) and week 9.\n",
      "Additionally, blood samples for PK are collected at predoseand 2 hours\n",
      "postdoseat week 5 and predose at weeks 13 and 17. All planned\n",
      "individual patients’plasma concentration data will be\n",
      "listed(Pharmacokinetic Population). PK samples obtained beyond 10% of\n",
      "the planned time will be included in the listings and could be\n",
      "included in the calculation of PK parameters (based on discretion of\n",
      "the pharmacokineticist), however, will be removed from figures and\n",
      "tables reporting mean concentrations per planned sampling times.\n",
      "PredosePKsample collection should occur prior to administration of the\n",
      "investigational product on that day, otherwise will be excluded. In\n",
      "all data presentations (except listings), values below the limit of\n",
      "the assay quantification (BLQ) will be set to zero. In listings BLQ\n",
      "values will be reported as “<LLQ”, where LLQ will be replaced with the\n",
      "value for the lower limit of quantification. Summarystatisticswill\n",
      "beprovidedforplasmaconcentrations of talazopariband enzalutamide and\n",
      "its N-desmethyl metabolite at scheduled visits by time point (using\n",
      "the PK Analysis Sets for talazoparib or enzalutamide, see\n",
      "Section6.1.2). Plasma concentration values below the limit of\n",
      "quantitation will be treated as zero in the descriptive statistics\n",
      "calculations. Zero concentrations will be considered as missing in\n",
      "geometric mean calculations. Spaghetti plots of individual\n",
      "concentrations against actual time postdose (separate plots for each In estimating the PK parameters, BLQ values at the beginning of the profile will be set toare embedded between BLQs, or quantifiable values occurring after two or more BLQs, may\n",
      "\n",
      "6.1.2.2. PK Parameters\n",
      "  In estimating the PK parameters, BLQ values at the beginning of the\n",
      "profile will be set toare embedded between BLQs, or quantifiable\n",
      "values occurring after two or more BLQs, may be set to missing at the\n",
      "discretion of the pharmacokineticist. Actual sampling times, rather\n",
      "than scheduled sampling times, will be used in all computations\n",
      "involving sampling times. If the actual time or dose time is missing,\n",
      "the scheduled time may be substituted in order to calculate the PK\n",
      "parameter. As appropriate, additional PK parameters may be calculated\n",
      "and reported. The following PK parameters of talazoparib and\n",
      "enzalutamide and its Ndesmethyl metabolite will be summarized usingthe\n",
      "Pharmacokinetic Population (specifically using the record-level sets\n",
      "called PK analysis set –Talazoparib and PK analysis set –enzalutamide)\n",
      "as appropriate: C ,C , T , AUC ,and CL /F will be summarized by dose\n",
      "and study visit. max trough max  ss Dose-normalized AUC , C , and C\n",
      "will be summarized by study visit.  max trough The above mentioned PK\n",
      "parameters (T excluded) will be summarized by arithmetic max mean,\n",
      "standard deviation and CV, geometric mean, geometric CV, minimum,\n",
      "median, maximum value and the number of evaluable parameters. The PK\n",
      "characteristics of T will max be described utilizing the number of\n",
      "observations, minimum, maximum and median. Geometric CV% is defined as\n",
      "sqrt(exp(variance of log transformed data)-1)*100 In addition, box and\n",
      "whisker plots for individual patient parameters AUC , C , and C  max\n",
      "trough by dose and scheduled visit as well as for dose-normalized AUC\n",
      ", C , and C by  max trough scheduled visit maybe be presented and\n",
      "overlaid with geometric means. For all presentations, PK data from\n",
      "Part 1 and Part 2 will be pooled. However, separate summaries of PK\n",
      "parameters including AUC , C , and C by dose level and scheduled  max\n",
      "trough visit in addition to summaries of dose-normalized AUC , C , and\n",
      "C by scheduled visit  max trough will be generated for patients in For CTC counts, a summary of the mean (standard deviation), median, and range of\n",
      "\n",
      "6.1.3. Exploratory Endpoints\n",
      "  For CTC counts, a summary of the mean (standard deviation), median,\n",
      "and range of baseline and postbaselinevalues will be provided for\n",
      "patients in Part 1 CTC evaluable population. In addition, the number\n",
      "and percentage of patients with CTC count ≥ 5vs. <5 and CTC count\n",
      ">0vs. =0 per 7.5 mL will be presented as well. The analysis of CTC\n",
      "count conversion from 5 or more CTC per 7.5 mL at baseline to < 5 CTC\n",
      "per 7.5 mL post baselinewill excludepatients with a CTC count < 5 per\n",
      "7.5 mL at baseline. The proportion of patients withsuch a conversion\n",
      "will be calculated along with the two-sided 95% CI using Clopper-\n",
      "Pearson method (exact methodfor a binomial proportion). The analysis\n",
      "of CTC count conversion from detectable at baseline to 0\n",
      "postbaselinewill exclude patients with a CTC count of 0 per 7.5 mL of\n",
      "blood at baseline. The proportion of patients with sucha\n",
      "conversionwill be calculated along with the two-sided 95% CIusing\n",
      "Clopper-Pearson method.The analysis of the proportion of patients with\n",
      "baseline CTCs <5 who show increased CTCs postbaselinewill\n",
      "excludepatients with a CTC count of ≥ 5 per 7.5 mL of blood at\n",
      "baseline. The proportion of patients with such a conversion will be\n",
      "calculated along with the two-sided 95% CI using the Clopper-Pearson\n",
      "method. A separate analysis plan will be provided to describe analyses\n",
      "of molecular profiling of tumor tissue remaining after genomic testing\n",
      "for eligibility and of saliva and ctDNA. Although not specifically\n",
      "listed as exploratory objectives,analyses of efficacy including rPFS,\n",
      "ORR in patient with soft tissue measurable disease at baseline, PSA\n",
      "response, and time to PSA progression may be evaluated during the\n",
      "course of the study and will be reported at the time of the final\n",
      "analysis of rPFS in all-comers, if not sooner. Derivations will follow\n",
      "the same rules outlined in section 6.2for Part 2. Summaries will be\n",
      "descriptive and not inferential. Specifically summaries of time to\n",
      "event endpoints will be limitedto medians and rates at specific\n",
      "timepoints of interest. Summaries of response rates will include\n",
      "number and percentage. Summaries will be provided regardless of\n",
      "mutation status or starting dose. Mutation status (where available) 6.2.1. Primary Endpoint--rPFS\n",
      "\n",
      "6.2. Part 2 Analyses\n",
      "  \n",
      "\n",
      "6.2.1. Primary Endpoint--rPFS\n",
      "  The primary efficacy analysis will compare rPFS based on BICR between\n",
      "talazoparib in combination with enzalutamide vs. talazoparib-matching\n",
      "placebo in combination with enzalutamide, and will be performed using\n",
      "anone-sided stratified log-rank test forthe all- comers and DDR-\n",
      "deficient populations respectively(subsets of the ITT population). A\n",
      "secondary analysis of rPFS based on investigator assessment will also\n",
      "be performed. rPFS is defined as the time from the date of\n",
      "randomization to first objective evidence of radiographic progression\n",
      "as assessed in soft tissue per RECIST1.1 or in bone (upon subsequent\n",
      "confirmation) per PCWG3 guidelines, or deathdue to any cause,\n",
      "whichever occurs first,and will be summarized in months using the\n",
      "following calculation: rPFS (months) = [date of event/censoring\n",
      "–randomization date +1]/30.4375. The documentationrequiredfor the\n",
      "determination of radiographic progressionis shown in Table 5. Table 5.\n",
      "Criteria for Evidence of Radiographic Progression Date Criteria for\n",
      "Progression Criteria for Confirmation Criteria for Progression of\n",
      "Progression Documentation of Disease Detected (Requirement and Timing)\n",
      "Progression on (Visit) [1] Confirmatory Scan Week9 Bone lesions: 2or\n",
      "more new Timing: at least 6weeks Persistence of at least 2 lesions\n",
      "compared to baseline after progression identified lesions seen at week\n",
      "9 bone scan by PCWG3 or at Week17 Visit [2] AND 2 or more new bone\n",
      "lesions on bone scan (compared to Week9 scan)Table 5. Criteria for\n",
      "Evidence of Radiographic Progression Date Criteria for Progression\n",
      "Criteria for Confirmation Criteria for Progression of Progression\n",
      "Documentation of Disease Detected (Requirement and Timing) Progression\n",
      "on (Visit) [1] Confirmatory Scan Soft tissue lesions: No confirmatory\n",
      "scan Not applicable Progressive disease on CT or required for soft\n",
      "tissue MRI by RECIST1.1 disease progression Week17 or Bone lesions: 2\n",
      "or more new Timing: at least 6weeks Persistent of at least 2 of later\n",
      "lesions on bone scan after progression identified the lesions\n",
      "identified as compared to Week9 bone Required for bone lesions new\n",
      "compared to week 9 scan observed on bone scan [2] Soft tissue lesions:\n",
      "No confirmatory scan Not applicable Progressive disease on CT or\n",
      "required for soft tissue MRI by RECIST1.1 disease progression [1]\n",
      "Progression detected by bone scan at an unscheduled visit prior to\n",
      "week 13 will requireconfirmation at least 6 weeks later following the\n",
      "confirmation criteria outlined in the table for week 9. All other\n",
      "unscheduled assessments will follow the confirmation criteria for week\n",
      "17. [2] Confirmation must occur at the next available scan. rPFS will\n",
      "be censored in the following scenarios: 1) The patient will be\n",
      "censoredon the date of the last adequate tumor assessment on or before\n",
      "the data cutoff dateif the patient does not have radiographic\n",
      "progression and does not die. 2) The patient will becensored on the\n",
      "date of last adequate tumor assessment prior to the start of new\n",
      "antineoplastic therapy, if thepatient starts a new antineoplastic\n",
      "therapy prior to radiographic progressionor death. 3) The patient will\n",
      "be censored onrandomizationdate, if the patient does not have baseline\n",
      "or postbaselinetumor assessments. 4) The patient will becensoredon the\n",
      "date of the last adequate tumor assessment without evidence of disease\n",
      "progression prior to missed tumor assessments, if the patient misses 2\n",
      "or more scheduled tumor assessments immediately prior to radiographic\n",
      "progression or death. For the purpose of rPFS censoring, apatient will\n",
      "be censored on the date of the last adequate tumor assessment prior to\n",
      "the start of new antineoplastic therapy if the patient starts a new\n",
      "antineoplastic therapy prior to radiographic progression or death. If\n",
      "a patient has a curative radiotherapy where the treatment intent is\n",
      "specified as ‘primary treatment’ or surgery where the treatment intent\n",
      "is specified as ‘curative in intent’ and the surgery outcome is either\n",
      "‘resected’ or ‘partially resected’ prior to radiographic progression\n",
      "or death, the patient will also be censored on the date of the last\n",
      "adequate tumor assessment before the radiotherapy or surgery.Two or\n",
      "more missed assessments is defined as follows:  If the last adequate\n",
      "tumor assessment prior to the event occurs on or before 70 days from\n",
      "randomization, more than 119 days from that assessment (two 8-week\n",
      "assessments plus a 7-day assessment window)to the event;  If the last\n",
      "adequate tumor assessment prior to the event occurs after 70 days AND\n",
      "on or before 126days from randomization, more than 147days from that\n",
      "assessment (an8-week assessment plus a 12-week assessment plus a 7-day\n",
      "assessment window)to the event;  If the last adequate tumor\n",
      "assessment prior to the event occurs after 126days from randomization,\n",
      "more than 175 days from that assessment (two 12-week assessments plus\n",
      "a 7-day assessment window)to the event. If a patient meets more than\n",
      "onecensoring criteria described above, the patient’s rPFS value will\n",
      "be censored atthe earliest censoring date. The stratified analysis\n",
      "will be based on the following randomization stratification factors:\n",
      "Previous treatment with any NHT or taxane-based chemotherapy for CSPC\n",
      "(yes vs. no); DDR mutational status (deficient vs. non-\n",
      "deficient/unknown). The primary stratified analysis will be based on\n",
      "the stratification information recorded in IWRS. A secondary\n",
      "stratified analysis based on DDR mutational status derived from\n",
      "clinical database will also be performed. Especially because DDR\n",
      "status in IWRS cannot separate non-deficient and unknown status,\n",
      "derived DDR status from clinical database will be used to identify the\n",
      "non-deficient subpopulation. Prior to Protocol Amendment 6, DDR\n",
      "mutational status for randomization/stratification was obtained from\n",
      "tumor tissue (archival or fresh biopsies)or historical test results\n",
      "(prior tumor tissue analysis using FoundationOne test). Starting with\n",
      "Protocol Amendment 6, DDR mutational status for randomization\n",
      "stratification was derived from either tumor tissue (archival slides\n",
      "or fresh biopsies or historical test results)or peripheral blood\n",
      "(liquid biopsy) prior to randomization. If prospective results from\n",
      "bloodand tumor tissue samples are both available, apositive result\n",
      "from eitherwill be considered prospectively DDR-deficient for\n",
      "randomizationstratification. Retrospectively analyzed screening\n",
      "plasmasamples with results known after randomizationand\n",
      "retrospectively analyzed saliva results will also be incorporated for\n",
      "patients with an unknown DDR status in exploratory analyses. For\n",
      "details see Section 5.2.7. Kaplan-Meier curves will be used to\n",
      "estimate the time-to-event distributions. The 50th percentile of\n",
      "Kaplan -Meier estimates will be used to estimate the median duration\n",
      "of each endpoint. A 2-sided 95%CI based on the Brookmeyer-Crowley\n",
      "method will be provided for this estimate. In addition, the event-free\n",
      "rate and 95% CI at 12 months, 24 months, and 36 months for each\n",
      "treatment arm will be presented.The stratified hazard ratio\n",
      "(talazoparib in combination with enzalutamide/control) and the\n",
      "associated 95% CI will be estimated using a Cox proportional hazards\n",
      "model. Ties will be handled using the Breslowmethod. Both one-sided\n",
      "and two-sided p-values will be providedin summary tables. Frequency\n",
      "(number and percentage) of patients with each event type (progression\n",
      "[including types of progression –i.e. bone progression, soft tissue\n",
      "progression, bone and soft tissue progression] or death) and censoring\n",
      "reasons will be presented by treatment arm along with the overall\n",
      "event and censoringrates. Reasons for censoring will be summarized\n",
      "according to the categories inTable 6. If a patient meets multiple\n",
      "definitions for censoringat the same visit,the list will be used to\n",
      "define the hierarchy. Table 6. Censoring Reasons and Hierarchy for\n",
      "rPFS Hierarchy Condition Censoring Reason 1 No adequate baseline\n",
      "assessment No adequate baseline assessment 2 Start of new\n",
      "antineoplastictherapy or select Start of new antineoplastictherapy\n",
      "radiotherapy/surgery before event. 3 Event immediately after missing\n",
      "at least two Event after missing assessments consecutive assessments 4\n",
      "No event and withdrawal of consent date ≥ Withdrawal of consent\n",
      "randomization dateOR End of study (EOS) = patient refused further\n",
      "follow-up 5 No event and lost to follow-up in any disposition page\n",
      "Lost to follow-up 6 No event and EOS present OR disposition page for\n",
      "No adequate postbaselinetumor any EPOCH after screening says patient\n",
      "will not assessment continue into any subsequent phase of the study\n",
      "and no adequate postbaselinetumorassessment 7 No event and none of the\n",
      "conditions in the prior Ongoing without an event hierarchy are met\n",
      "Median follow-up time will be estimated according to the Kaplan-Meier\n",
      "estimate of potential follow-up by the reverse Kaplan-Meier method. An\n",
      "overview forest plot of rPFS based on BICR assessment bythe following\n",
      "subgroups will be presented. A similar forest plot based on\n",
      "investigator assessment will also be provided.  Age (<70/≥70) \n",
      "Geographic region(North America, European Union [EU]/Great Britain\n",
      "[GBR], Asia, rest of world [ROW])  EasternCooperative OncologyGroup\n",
      "(ECOG) performance status at baseline (0, 1)  Total Gleason Score at\n",
      "Diagnosis (<8/≥8) Type of progression at study entry (PSA only,\n",
      "radiographic progression with or without PSA progression)  Baseline\n",
      "PSA (< vs. ≥ overall median)  Site of metastasis at study entry(bone\n",
      "only, soft tissue only, both bone and soft tissue, none)  DDR status\n",
      "by IWRS (DDR-deficient, non-deficient/unknown)  Prior Taxane or NHT The following sensitivity analyses will be performed separately for the all-comers and\n",
      "\n",
      "6.2.1.1. SensitivityAnalyses\n",
      "  The following sensitivity analyses will be performed separately for\n",
      "the all-comers and DDR-deficient populations to explore the robustness\n",
      "ofeach primaryanalysis result. Some of these sensitivity analyses will\n",
      "be presented in the CSR, while the remaining will be presented in\n",
      "other summary documents, for example, Summary of Clinical Efficacy and\n",
      "Summary of Clinical Safety. The sensitivity analyses will be performed\n",
      "following the methods described forthe primary analysis with the\n",
      "modifications below:  RadiographicPFS counting all progression and\n",
      "deaths as events regardless of missing assessments or timing of the\n",
      "event (i.e. not censoring due to thestart of a new\n",
      "antineoplastictherapy prior to event or due to missed\n",
      "assessments)based on BICR andinvestigator assessments. \n",
      "RadiographicPFS counting study treatment discontinuation,start of a\n",
      "new antineoplastic therapy, andoccurrence of asymptomatic skeletal\n",
      "event as additional events based on BICR and investigator assessments.\n",
      "Censoring will be similar to that described for the primary analysis,\n",
      "except for the following: o Radiographic progression, death,\n",
      "discontinuation of study treatment (both treatment components),start\n",
      "of a new anti-cancer therapy, and a symptomatic skeletal event will\n",
      "all be considered as events. rPFS will be calculated as the time\n",
      "interval from the date of randomization to the date of radiographic\n",
      "progression, death, discontinuation of study treatment (both treatment\n",
      "components), start of a new anti-cancer therapy, or a symptomatic\n",
      "skeletal event, whichever occurs first.  Radiographic PFS by\n",
      "assigning the dates ofcensoring and events only at scheduled\n",
      "assessment dates based on BICR and investigator assessments: o If\n",
      "aradiographic progression occurs within 7-daywindowof its scheduled\n",
      "assessment time, it will be assigned the scheduled assessment date. If\n",
      "a radiographic progression occurs outside the 7-day window and between\n",
      "2assigned as the radiographic progression date (e.g., if a\n",
      "radiographic progressionoccurs between weeks 25 and 37, it will be\n",
      "assigned to week 37). o In the event of death, the event date will not\n",
      "be adjusted. DDR-deficient patients enrolled in China in Cohort 1 will\n",
      "be included in the analysis of DDR-deficient patient population. A\n",
      "sensitivity analysis of DDR-deficient patients by excluding the DDR-\n",
      "deficient patients enrolled in China in Cohort 1 will also be\n",
      "performed. In addition, to assess the impact ofCOVID-19, the following\n",
      "sensitivity analyses of rPFS may be performed if COVID-19 related\n",
      "death is reported in at least 10patients in the study:  Radiographic\n",
      "PFS based on BICR assessment and censoring  deaths due to COVID-19. \n",
      "Radiographic PFS based on investigator assessment and censoringdeaths\n",
      "due to COVID-19. BICR vs Investigator assessment: A separate summary\n",
      "of the BICR assessment versus investigator assessment will be provided\n",
      "for the all-comers population and for the DDR-deficient population.\n",
      "These will include numbers of concordant and discordant assessments as\n",
      "well as the number of cases where a PFS event was assessed at\n",
      "different timepoints by the BICR and investigator. The following\n",
      "categories will be summarized by treatment arm for each population: \n",
      "Agreement on time and occurrence of rPFS event (within 28 days) (a1),\n",
      " Agreement on rPFS event but investigator event occurred later (by\n",
      ">28days) (a2),  Agreement on rPFS event but investigator event\n",
      "occurred earlier (by >28days) (a3),  Investigator assessment of rPFS\n",
      "event, patient censored in the BICR analysis (b),  Patient censored\n",
      "in the investigator assessment analysis of rPFS, BICR assessment of\n",
      "rPFS event (c), and  Agreement on non-occurrence of rPFS event (d). A\n",
      "+/-28day window will be used to assess the agreement on timing and\n",
      "occurrence of an rPFS event. Total Event Discrepancy Rate (b+c)/N,\n",
      "Early Discrepancy Rate (a3+b)/(a+b), Late Discrepancy Rate\n",
      "(a2+c)/(a2+a3+b+c); and Overall Discrepancy Rate (a2+a3+b+c)/N will be\n",
      "calculated where a=a1+a2+a3.6.2.2. Secondary Endpoints Each secondary\n",
      "endpoint will be analyzed separately for the all-comers population and OS is defined as the time from randomization to the date of death due to any cause. Patients\n",
      "\n",
      "6.2.2.1. Overall Survival\n",
      "  OS is defined as the time from randomization to the date of death due\n",
      "to any cause. Patients last known to be alive will be censored at the\n",
      "date of last contact. OS (months) = [date of deathor censoring\n",
      "–randomization date +1]/30.4375. Aone-sided stratifiedlog-rank test\n",
      "will be performed on OS in the all-comers population if the null\n",
      "hypothesis of rPFS in the all-comers population is rejected.\n",
      "Similarly, aone-sided stratified log-rank test of OS will be performed\n",
      "in the DDR-deficient population if the null hypothesis of rPFS in the\n",
      "DDR-deficient population is rejected. The stratified hazard ratio\n",
      "(talazoparib in combination with enzalutamide/control) and the\n",
      "associated 95% CI will be estimated using a Cox proportional hazards\n",
      "model. Ties will be handled using the Breslowmethod. Both one-sided\n",
      "and two-sided p-values will be provided in summary tables. Kaplan-\n",
      "Meier estimates will be presented by treatment arm with a summary of\n",
      "associated statistics including the median OS with two-sided 95% CIs.\n",
      "In addition, the survival rate and 95% CI at 12months, 24months,\n",
      "36months, and 48 months for each treatment arm will be presented as\n",
      "well. Reasons for censoring will be summarized according to the\n",
      "categories inTable 7. Ifa patient meets multiple definitions for\n",
      "censoring,the list will be used to define the hierarchy. Table 7.\n",
      "Censoring Reasons and Hierarchy for OS Hierarchy Condition Censoring\n",
      "Reason 1 No event and withdrawal of consent date ≥ Withdrawal of\n",
      "consent randomization dateOR EOS= Subject refused further follow-up 2\n",
      "No event and lost to follow-up in any disposition page Lost to follow-\n",
      "up 3 No event and none of the conditions in the prior Alive hierarchy\n",
      "are met Frequency (number and percentage) of patients with anevent and\n",
      "censoring reasons will be presented by treatment arm as follows: \n",
      "Death o Death due to COVID-19  Withdrawal of consent  Lost to\n",
      "follow-up Ongoing and no death. To assess the impact of COVID-19, the\n",
      "following sensitivity analyses of OS may be performed by applying the\n",
      "additional censoring rules if COVID-19 related death is reported in at ORR is defined as the proportion of patients with measurable soft tissue disease at baseline\n",
      "\n",
      "6.2.2.2. Objective Response per RECIST 1.1\n",
      "  ORR is defined as the proportion of patients with measurable soft\n",
      "tissue disease at baseline with a best overall confirmedsoft tissue\n",
      "response of CR or PR according to RECIST 1.1. Soft tissue responses\n",
      "must be confirmed by a follow-up radiographic assessment at least 4\n",
      "weeks later with no evidence of confirmed bone disease progression on\n",
      "repeat bone scan at least 6 weeks later per PCWG3 criteria. Patients\n",
      "without documented CR or PR will be considered non-responders. Prior\n",
      "to determining the best overall soft tissue response,the date of\n",
      "confirmed bone progression (if applicable) will be determined. If\n",
      "confirmed bone progression is documented and the soft tissue response\n",
      "at the visit where the bone progression criteria are first met is not\n",
      "PD, the derived soft tissue timepoint response incorporating bone\n",
      "assessments will be PD. This derived timepoint response will be used\n",
      "to determining the best overall response (BOR). An example is provided\n",
      "inTable 8. Table 8. Incorporation of Bone Progression into Best\n",
      "Overall Response Overall Soft Example Soft Tissue Tissue Number\n",
      "Timepoint Response Bone Assessment Response Considering Bone\n",
      "Progression (derived) 1 Week9 CR Progression PD criteria met (PD) Week\n",
      "17 CR Progression PD criteria confirmed 2 Week 9 CR Progression CR\n",
      "criteria met (Non-PD) Week 17 CR Progression CR criteria NOT confirmed\n",
      "3 Week 9 SD Non PD SD Week 17 PR Progression PDTable 8. Incorporation\n",
      "of Bone Progression into Best Overall Response Overall Soft Example\n",
      "Soft Tissue Tissue Number Timepoint Response Bone Assessment Response\n",
      "Considering Bone Progression (derived) Week 25 PR Progression PD\n",
      "criteria confirmed Best overall response willbe assessed on patients\n",
      "with measurable disease based on reported overall responses at\n",
      "different evaluation timepoints from the date of randomization until\n",
      "documented disease progression (in soft tissue per RECIST 1.1 or in\n",
      "bone per PCWG3 guidelines) or start of new antineoplastictherapyor\n",
      "curative radiotherapy where the treatment intent is specified as\n",
      "‘primary treatment’ or surgery where the treatment intent is specified\n",
      "as ‘curative in intent’ andthe surgery outcome is either ‘resected’ or\n",
      "‘partially resected’, according to the following rules:  CR = at\n",
      "least two determinations of CR at least 4 weeks apart and documented\n",
      "before progression and start of new antineoplastictherapy  PR = at\n",
      "least two determinations of PR or better (and not qualifying for a CR)\n",
      "at least 4 weeks apart and before progression and start of new\n",
      "antineoplastic  SD (for patients with at least one measurable lesion\n",
      "at baseline)= at least one SD assessment (or better and not qualifying\n",
      "for CR or PR) ≥ 8weeks after date of randomizationand before\n",
      "progression and the start of new antineoplastictherapy  PD =\n",
      "progression ≤ 16weeks after date of randomizationand not qualifying\n",
      "for CR, PR or SD  Not Evaluable (NE) = all other cases. For\n",
      "investigator assessments, global deterioration of health statuswill\n",
      "not be considered as documented disease progression. For patients with\n",
      "measurable soft tissue disease at baseline, objective response rate\n",
      "(ORR) will be summarizedfor the two treatment arms. The primary\n",
      "evaluation of ORR will be based on BICR overall tumor assessment. A\n",
      "secondary evaluation of ORR will be based on the investigator\n",
      "assessments using derived response based on RECIST 1.1. The frequency\n",
      "(number and proportion) of patients with best overall response of CR,\n",
      "PR, SD, Progressive Disease (PD), and NE (not-evaluable) will be\n",
      "tabulated. Patients with best overall responseof NE will be summarized\n",
      "by reason for having NE status. No adequate baseline assessment \n",
      "Early death (defined as death prior to 8 weeks after date or\n",
      "randomization)  No postbaseline assessments due to COVID-19, i.e.\n",
      "participants miss tumor assessment visits due to COVID-19 pandemic \n",
      "No postbaselineassessments due to other reasons  All\n",
      "postbaselineassessments have overall response NE  New\n",
      "antineoplastictherapy started before first postbaselineassessment  SD\n",
      "of insufficient duration (< 8 weeks after date of randomization)  PD\n",
      "too late (>16weeks after date of randomization) Special and rare cases\n",
      "where the best overall responseis NE due to both early SD and late PD\n",
      "will be classified as ‘SD of insufficient duration’. ORR by treatment\n",
      "arm will be calculated along with the two-sided 95% CIusing a Cochran–\n",
      "Mantel–Haenszel test. The difference in response rates between\n",
      "treatment arms along with bothone-sided and two-sided p-values for\n",
      "thedifference will be provided. In addition, for each DDR mutation, For patients with measurable soft tissue disease at baselinewho have an objective response\n",
      "\n",
      "6.2.2.3. Duration of Soft Tissue Response\n",
      "  For patients with measurable soft tissue disease at baselinewho have\n",
      "an objective response per RECIST 1.1, duration of soft tissue\n",
      "response(DoR) is defined as the time from the date of the first soft\n",
      "tissue response to the first documented objective evidence of\n",
      "progression (in soft tissue per RECIST 1.1 or in bone per PCWG3\n",
      "guidelines) or start of new antineoplastic therapy. Those patients who\n",
      "did not have a soft tissue response will be excluded from the\n",
      "analysis. The censoring rules for duration of soft tissue response are\n",
      "as described for rPFS in Section 6.2.1. DoR (months) = [date of event\n",
      "or censoring–first date of CR/PR +1]/30.4375. Kaplan-Meier estimates\n",
      "(product-limit estimates) will be presented by treatment arm together\n",
      "with a summary of associated statistics including the median DR time\n",
      "with two-sided 95% CIs. The CIs for the median will be calculated\n",
      "according to Brookmeyer and Crowley. Inferential statistics (e.g.\n",
      "hazard ratio and p-value) will not be provided for duration of\n",
      "response given that the analysis is performed on the responders only,\n",
      "not the ITT population. Duration of soft tissue response will be\n",
      "reported forboth the all-comers population and the DDR-deficient\n",
      "population. In addition, for each DDR mutation, DoR by treatment arm\n",
      "may also be explored if there are enough patients with the\n",
      "mutation.6.2.2.4. Proportion of Patients with PSA response ≥ 50% PSA\n",
      "response is defined as a decline from baseline PSA (ng/mL) by at least\n",
      "50%. A PSA response must be confirmed by a second consecutive value at\n",
      "least 3 weeks later. Patients without a baseline and at least one post\n",
      "baseline PSA assessment will not be analyzed for this endpoint. Only\n",
      "assessments performed from the date of randomizationuntil confirmed\n",
      "PSA progression or start of new anticancer treatment (defined as\n",
      "systemic anticancer therapy [other than study treatment], or curative\n",
      "radiotherapy where the treatment intent is specified as ‘primary\n",
      "treatment’, or surgery where the treatment intent is specified as\n",
      "‘curative in intent’ and the surgery outcome is either ‘resected’ or\n",
      "‘partially resected’), given after the first dose of study treatment\n",
      "will be considered. The percentage of patients in the ITT population\n",
      "with maximum PSA declines of at least 50% will be calculated along\n",
      "with the two-sided 95% CI. The difference in response rates between\n",
      "treatment arms along with both one-sided and two-sided p-values for\n",
      "the difference in will be providedusing a Cochran–Mantel–Haenszel test\n",
      "in summary tables. PSA (ng/mL) will also be summarized descriptively\n",
      "by visit. PSA response will be reported forboth the all-comers PSA progression is defined as the timefrom the date of randomization to the date of the first\n",
      "\n",
      "6.2.2.5. Time to PSA Progression\n",
      "  PSA progression is defined as the timefrom the date of randomization\n",
      "to the date of the first PSA value demonstrating progression, which is\n",
      "subsequently confirmed. If apatient starts a new antineoplastic\n",
      "therapy prior to PSAprogression, the patient will be censored on the\n",
      "date of last PSA assessment prior to the start of a new antineoplastic\n",
      "therapy. Patients without confirmed PSA progression will be censored\n",
      "at the date of the last PSA assessment. Patients without any post\n",
      "baseline assessments will be censored at randomization. PSA\n",
      "Progression (months) = [date of PSA progression or censoring\n",
      "–randomization date +1]/30.4375. For patients with PSA declines, the\n",
      "PSA progression date is defined as the date that a ≥ 25% increase and\n",
      "an absolute increase of ≥ 2µg/L (2ng/mL) above the nadir is\n",
      "documented, which is confirmed by a second consecutive value obtained\n",
      "at least 3weeks later. Early rises (before week 12) shouldbe ignored\n",
      "in determining progression. As such, for patients with no PSA\n",
      "declines, the PSA progression date is defined as the date that a ≥ 25%\n",
      "increase and an absolute increase of ≥ 2µg/L (2ng/mL) above the\n",
      "baseline is documented after week 12, which is confirmed by a second\n",
      "consecutive value at least 3 weeks later. PSA progression will be\n",
      "analyzedusing a one-sided stratified log-rank test. Kaplan-Meier\n",
      "estimates will be presented by treatment arm with the median and 95%\n",
      "CIs. Frequency (number and percentage) of patients with anevent\n",
      "orcensoring will be presented by treatment arm.Time to PSA progression\n",
      "will be reported forboth the all-comers population and the DDR- Time to initiation of cytotoxic chemotherapy is defined as the time from randomization to the\n",
      "\n",
      "6.2.2.6. Time to Initiation of Cytotoxic Chemotherapy\n",
      "  Time to initiation of cytotoxic chemotherapy is defined as the time\n",
      "from randomization to the first use of cytotoxic chemotherapy.\n",
      "Cytotoxic chemotherapy will be identified based on a clinical review\n",
      "of all follow-up cancer therapies reported on the follow-up therapy\n",
      "CRF page. This review will occur prior to data unblinding. Results\n",
      "will be reported in months ([date of event or censoring\n",
      "–randomization])/30.4375. Patients not starting any cytotoxic\n",
      "chemotherapywill be censored at the date of last contact. Time to\n",
      "initiation of cytotoxic chemotherapy will be analyzedusing a one-sided\n",
      "stratified log-rank test. Kaplan-Meier estimates will be presented by\n",
      "treatment arm with the median and 95% CIs. Frequency (number and\n",
      "percentage) of patients with anevent orcensoring will be presented by\n",
      "treatment arm. Time to initiation of cytotoxic chemotherapy will be\n",
      "analyzedforboth the all-comers population and the DDR-deficient Time to initiation of antineoplastic therapy is defined as the time from randomization to the\n",
      "\n",
      "6.2.2.7. Time to Initiation of Antineoplastic Therapy\n",
      "  Time to initiation of antineoplastic therapy is defined as the time\n",
      "from randomization to the first use of antineoplastic therapy. Such\n",
      "therapies include cytotoxic chemotherapy, hormonal chemotherapy, and\n",
      "investigational agents for prostate cancer. They will be identified\n",
      "based on a clinical review of all follow-up cancer therapies reported\n",
      "on the follow-up therapy CRF page. This review will occur prior to\n",
      "data unblinding. Results will be reported in months ([date of event or\n",
      "censoring –randomization])/30.4375. Patients not starting any\n",
      "antineoplastic therapy will be censored at the date of last contact.\n",
      "Time to initiation of antineoplastic chemotherapy will be\n",
      "analyzedusing a one-sided stratified log-rank test. Kaplan-Meier\n",
      "estimates will be presented by treatment arm with the median and 95%\n",
      "CIs. The results will be reported forboth the all-comers population Time to the first symptomatic skeletal event is defined as the time from randomization to the\n",
      "\n",
      "6.2.2.8. Time to First Symptomatic Skeletal Event\n",
      "  Time to the first symptomatic skeletal event is defined as the time\n",
      "from randomization to the date of the first symptomatic fracture,\n",
      "surgery to the bone, radiotherapy to the bone, or spinal cord\n",
      "compression as reported on the Skeletal Related Events CRF page.\n",
      "Patients without any symptomatic skeletal events will be censored at\n",
      "the date of the last skeletal event assessment. Analyses will be in\n",
      "months ([date of event or censoring –randomization])/30.4375.Time to\n",
      "the first symptomatic skeletal event will be analyzedusing a one-sided\n",
      "stratified log- rank test. Kaplan-Meier estimates will be presented by\n",
      "treatment arm with the median and 95% CIs. The results will be\n",
      "reported forboth the all-comers population and the DDR-deficient PFS2 is defined as the time from randomization to investigator documented disease\n",
      "\n",
      "6.2.2.9. PFS2 Based on Investigator Assessment\n",
      "  PFS2 is defined as the time from randomization to investigator\n",
      "documented disease progression (PSA progression, progression on\n",
      "imaging, or clinical progression) on the first subsequent\n",
      "antineoplastic therapy for prostate cancer, or death from any cause,\n",
      "whichever occurs first. PFS2 (months) = [date of event/censoring –date\n",
      "of randomization +1]/30.4375 A patient will be considered to have an\n",
      "event if:  date of documented progression on the first subsequent\n",
      "antineoplastic therapy is provided on follow-up cancer therapy CRF\n",
      "page; or  the patient dies. PFS2 will be analyzedusing a one-sided\n",
      "stratified log-rank test. Kaplan-Meier estimates will be presented by\n",
      "treatment arm with the median and 95% CIs. Both one-sided and two-\n",
      "sided p-values will be provided in summary tables. The censoring\n",
      "andevent date options to be considered for PFS2 along with the\n",
      "corresponding censoring reason and its hierarchy are presented inTable\n",
      "9. The frequency (number and percentage) of patients with an event and\n",
      "censoring reasons will be presented by treatment arm. Table 9.\n",
      "Outcome, Event/Censoring Dates, and Reasons for Censoring for PFS2\n",
      "Scenario Date of event/censoring Outcome/ Censoring reason/ Censoring\n",
      "hierarchy No PDa and No Death Date of last adequate Censored/ tumor\n",
      "assessmentb No PD by investigator/ documenting no PD 1 No PDa and\n",
      "Death Date of death Event (Death) PDa date > NTX1c start date Start\n",
      "date of NTX1c Censored/ and no death Start of new anticancer treatment\n",
      "before PD/ 2 PDa date > NTX1c start date Date of death Event (Death)\n",
      "and deathTable 9. Outcome, Event/Censoring Dates, and Reasons for\n",
      "Censoring for PFS2 Scenario Date of event/censoring Outcome/ Censoring\n",
      "reason/ Censoring hierarchy PDa date ≤ NTX1c start date Documented\n",
      "progression Event (Date of documented and documented progression on\n",
      "NTX1 progression on NTX1) on NTX1 PDa date ≤ NTX1c start date Date of\n",
      "death Event (Death) and no documented progression on NTX1 and death\n",
      "PDadate ≤ NTX1c start date Date of Last Contact Censored/ and no\n",
      "documented Withdraw of consent/ progression on NTX1 and 3 no death and\n",
      "the patient withdrew consent for follow-up PDa date ≤ NTX1c start date\n",
      "Date of Last Contact Censored/ and no documented Lost to follow-up/4\n",
      "progression on NTX1 and no death and the patient is lost to follow-up\n",
      "PDa date ≤ NTX1c start date Date of Last Contact Censored/ and no\n",
      "documented Ongoing without PFS2 event/ progression on NTX1 and 5 no\n",
      "death and no other conditions met a PD is the first PD while on study\n",
      "treatment by investigator assessment per RECIST v1.1 or per PCWG3,\n",
      "without considering any censoring rules. b If there is no adequate\n",
      "postbaseline assessment, then the censoring date is the date of\n",
      "randomization. If the patient has initiated next-line anticancer\n",
      "treatment, the last adequate postbaseline assessment on or prior to\n",
      "start date of next line anticancer treatment will be considered. c\n",
      "NTX1 is the first new anticancer regimen The PFS2results will be\n",
      "reported forboth the all-comers population and the DDR-deficient Time to opiate use for prostate cancer pain is defined as the time from date of randomization\n",
      "\n",
      "6.2.2.10. Time to Opiate use for Prostate Cancer Pain\n",
      "  Time to opiate use for prostate cancer pain is defined as the time\n",
      "from date of randomization to the date of the first or new opiate\n",
      "medications for prostate cancer painstarted after randomization and\n",
      "will be based on the start date of medications reported on the\n",
      "concomitant medication page of the CRF reported with a category of\n",
      "‘Opioids’. Patients without any opiate use will be censored at the\n",
      "last dose of study treatment.Time to opiate use for prostate cancer\n",
      "painwill be analyzedusing a one-sided stratified log- rank test.\n",
      "Kaplan-Meier estimates will be presented by treatment arm with the\n",
      "median and 95% CIs. The results will be reported forboth the all- All of the PRO endpoints described below will be analyzed using the PRO analysis set.\n",
      "\n",
      "6.2.3. PRO Endpoints\n",
      "  All of the PRO endpoints described below will be analyzed using the\n",
      "PRO analysis set. PRO endpoints will be analyzedforboth the all-comers Time to Deterioration in Patient-reported Pain Symptoms per BPI-SF\n",
      "\n",
      "6.2.3.1. Time to Event Endpoints\n",
      "  Time to Deterioration in Patient-reported Pain Symptoms per BPI-SF\n",
      "Patient-reported pain symptoms (per the Pain Log – BPI-SF Question 3)\n",
      "will be completed for 7 consecutive days beforeeachstudy visit. In\n",
      "addition, the BPI-SF will be completed during each study visit.Four or\n",
      "more completed BPI-SF Question 3at each visit period(i.e.\n",
      "collectively7 consecutive days prior to each study visit and during\n",
      "study visit)are required for thepain score for each time periodto be\n",
      "considered evaluable. Pain score averages during each visit period\n",
      "will be calculated and will be used for the analysis of time to\n",
      "deterioration in patient-reported pain symptoms. Analgesic use (per\n",
      "Analgesic log) is recorded for seven consecutive days prior to each\n",
      "study visit and during each study visit. The worst World Health\n",
      "Organization (WHO)analgesic usage score for each visit period (seven\n",
      "consecutive days prior to each study visit and during study visit)\n",
      "will be used. Analgesic use is scored according to WHO criteria: zero\n",
      "for no use, one for use of non-opiate analgesics (e.g., non-steroidal\n",
      "anti-inflammatory drugs, acetaminophen, antidepressants, and agents\n",
      "targeting neuropathic pain), two for use of weak opiates for moderate\n",
      "pain (e.g., codeine and tramadol), and three for strong opiates for\n",
      "severe pain (e.g., morphine and fentanyl). Time to deterioration in\n",
      "patient-reported pain symptoms per BPI-SF is assessed using the\n",
      "average pain score from the BPI-SF question 3: “Please rate your pain\n",
      "by marking the box beside the number that best describes your pain at\n",
      "its worst in the last 24 hours.” Time to this event is defined as the\n",
      "time from randomization to onset of pain progression, where pain\n",
      "progression is defined as a ≥2 point increase from baseline in the\n",
      "question 3 scorefor two consecutive visit periods at least 4 weeks\n",
      "apart without a decrease in WHO analgesic usage score. If there is a\n",
      "decrease in WHO analgesic usage score, then it will not be\n",
      "consideredas pain progression even if there is a ≥2 point increase\n",
      "from baseline in the question 3 score. Patients without observed pain\n",
      "progression at the time of analysis will be censored at the date of\n",
      "last BPI-SF assessment. Kaplan-Meier estimates will be presented\n",
      "together with a summary of associated statisticsFrequency (number and\n",
      "percentage) of patients with an event or censoring will be presented.\n",
      "Time to Definitive Deterioration in Patient-reported Global Health\n",
      "Status/QoL per EORTC QLQ-C30 Time to definitive deterioration in\n",
      "patient-reported global health status/QoL per EORTC QLQ-C30is defined\n",
      "as the time fromrandomization to the firstdefinitive deterioration\n",
      "defined as a ≥ 10-point decrease from baseline and no subsequent\n",
      "observations of a < 10-point decrease from baseline. Patients without\n",
      "a definitive deterioration at the time of analysis will be censored at\n",
      "the date of last EORTC QLQ-C30assessment. Kaplan-Meier estimates will\n",
      "be presented together with a summary of associated statistics\n",
      "including the median and quartiles with two-sided 95% CIs. Frequency\n",
      "(number and percentage) of patients with an event or censoring will be\n",
      "presented. Time to Definitive Deterioration in Patient-reported\n",
      "Disease-specific Urinary Symptoms per EORTC QLQ-PR25 Time to\n",
      "definitive deterioration in patient-reported disease-specific urinary\n",
      "symptoms per EORTC QLQ-PR25 is defined as the time fromrandomization\n",
      "to the firstdefinitive deterioration defined as a ≥ 10-point increase\n",
      "from baseline and no subsequent observations of a < 10point increase\n",
      "from baseline. Patients without a definitive deterioration at the time\n",
      "of analysis will be censored at thedate of last EORTC QLQ-PR25\n",
      "assessment. Kaplan-Meier estimates will be presented together with a\n",
      "summary of associated statistics including the median and quartiles\n",
      "with two-sided 95% CIs. Frequency (number and percentage) of patients BPI-SF\n",
      "\n",
      "6.2.3.2. DescriptiveSummaries and Change from Baseline\n",
      "  BPI-SF Descriptive summaries for BPI-SFby visit will be provided.\n",
      "These include:  For each visit period (collectively for study visit\n",
      "and the 7 consecutive days prior to each study visit), number and\n",
      "percentage of patients who completed all the BPSI-SF Question 3 out of\n",
      "a total of 8), ≥4 of the BPI-SF Question 3, and those who did not\n",
      "complete any BPI-SF Question 3 will be summarized  Descriptive\n",
      "summary of the average score at each visit period for BPI-SF Question3\n",
      "o Each pain intensity is a whole number (0 through 10) and will be\n",
      "summarized as a continuous variable o Missing values (<4 of8 possible\n",
      "assessments per visit period) are not included in the\n",
      "summariesDescriptive statistics for change from baseline in patient-\n",
      "reported pain symptoms per BPI- SF (questions 3) will be summarized\n",
      "for each visit period. A graphical display of means over time as well\n",
      "as mean changes from baseline over time will also be provided. A\n",
      "longitudinal mixed effect model will also be used to summarize the\n",
      "change from baseline pain symptoms score (BPI-SF Question 3) across\n",
      "all visit periods. Unless otherwise specified, all scheduled\n",
      "assessments will be used in the analyses, regardless of adherence to\n",
      "study treatment. EQ-5D-5L Health Index Analysis of the EQ-5D health\n",
      "index will consist of descriptive statistics on means and changes from\n",
      "baseline, overall change from baselineusing a longitudinal mixed\n",
      "effects model,and graphical displays of means and changes from\n",
      "baseline over time. In addition, there will be a health status profile\n",
      "analysis consisting of adisplay of the number and percentage of\n",
      "patients in each of the 5response levels for each ofthe 5 dimensions\n",
      "at each visit. EQ-5D General Health Status (EQ-5D VAS) Analysis of\n",
      "EQ-5D VAS will consist of descriptive statistics on means and changes\n",
      "from baseline, overall change from baselineusing a longitudinal mixed\n",
      "effects model, and graphical displays of means and changes from\n",
      "baseline over time. QLQ-C30 Analysis of the QLQ-C30will consist of\n",
      "descriptive statistics for each scale on means and changes from\n",
      "baseline, overall change from baselineusing a longitudinal mixed\n",
      "effects model,time to definitive deterioration,and graphical displays\n",
      "of means and changes from baseline over time. QLQ-PR25 Analysis of the\n",
      "QLQ-PR25 will consist of descriptive statistics for each scale on\n",
      "means andchanges from baseline, overall change from baselineusing a\n",
      "longitudinal mixed effectsmodel,time to definitive deterioration, and In Part 2, analyses of PK concentrations will include sampling at predoseand 2 hours post-\n",
      "\n",
      "6.2.4. PK\n",
      "  In Part 2, analyses of PK concentrations will include sampling at\n",
      "predoseand 2 hours post- dose at Weeks 3, 5 and 9, and pre-dose at\n",
      "Weeks 13 and 17. The PK analyses forPart 2 of the studywill be similar\n",
      "to those for Part 1 of the study. For details see Section 6.1.2.\n",
      "Separate summaries of dose-normalized C by scheduled visit trough for CTC endpoints will be analyzedseparately forboth the all-comers population and the DDR-\n",
      "\n",
      "6.2.5.1. CTC Conversion Rates\n",
      "  CTC endpoints will be analyzedseparately forboth the all-comers\n",
      "population and the DDR- deficient population. For CTC counts, a\n",
      "summary of the mean (standard deviation), median, and range of\n",
      "baseline and postbaselinevalues will be provided for patients in\n",
      "theCTC evaluable set. In addition, the number and percentage of\n",
      "patients with CTC count ≥ 5 vs. < 5 and CTC count > 0 vs. =0 per 7.5\n",
      "mL will be presented as well. For the analysis of CTC count conversion\n",
      "from 5 or more CTC per 7.5 mL at baseline to < 5 CTC per 7.5 mL post\n",
      "baseline, those patients with a CTC count < 5 per 7.5 mL at baseline\n",
      "will be excluded for this conversion endpoint. The proportion of\n",
      "patients with a conversion will be calculated along with the two-sided\n",
      "95% CIusing the Clopper-Pearson method. For the analysis of CTC count\n",
      "conversion from detectable at baseline to 0 postbaseline, those\n",
      "patients with a CTC count of 0 per 7.5 mL of blood at baseline will be\n",
      "excluded for this conversion endpoint. The proportion of patients with\n",
      "such a conversionwill be calculated along with the two-sided 95%\n",
      "CIusing the Clopper-Pearson method. For the analysis of the proportion\n",
      "of patients with baseline CTCs <5 who show increased CTCs\n",
      "postbaseline, those patients with a CTC count of ≥ 5 per 7.5 mL of\n",
      "blood at baseline will be excluded from the analysis. The proportion\n",
      "of patients with such a conversion will be calculated along with the\n",
      "two-sided 95% CIusing the Clopper-Pearson method. The results will be\n",
      "analyzed forboth the all-comers population and the DDR-deficient A separate analysis plan will be written to describe analyses of molecular profiling of tumor\n",
      "\n",
      "6.2.5.2. Molecular Profiling\n",
      "  A separate analysis plan will be written to describe analyses of The concordance of DDR deficiency results (DDR-deficient/non-deficient/unknown) will be\n",
      "\n",
      "6.2.5.3. Concordance of DDR deficiency results\n",
      "  The concordance of DDR deficiency results (DDR-deficient/non-\n",
      "deficient/unknown) will be exploredfor the following assay methods: \n",
      "Prospective tissue-based tests vs. retrospectively analyzed screening\n",
      "blood-based tests  Prospective blood-based tests vs. retrospectively Subgroup analyses will be performed if there is a sufficient sample size. The determination\n",
      "\n",
      "6.3. Subgroup Analyses\n",
      "  Subgroup analyses will be performed if there is a sufficient sample\n",
      "size. The determination of whether or not there is a sufficient\n",
      "samplesize will be defined after enrollment is completethere are ≥ 20\n",
      "patients within the defined subset and analyses of time to event\n",
      "endpoints will only be performed if there are at least 10 events on\n",
      "each treatment arm within the subgroup. Deviations from these analyses\n",
      "will be described in the clinical study report. Some of the subgroup\n",
      "analyses will be presented in the CSR, while the remaining will be\n",
      "presented in other summary documents, for example, Summary of Clinical\n",
      "Efficacy and Summary of Clinical Safety. Besides the subgroup analyses\n",
      "presented in the overview forest plots described in Section6.2.1, the\n",
      "following additional subgroup analyses will be performed for rPFS by\n",
      "BICR where the subgroups are subsets of the all-comers population: \n",
      "DDR mutational status derived using prospective/retrospective data\n",
      "(subgroup definitions 2-6in Section 5.2.7).  Renal impairment\n",
      "(moderate, mild,normal)  Race (Asian, White, African American, other)\n",
      " Prior NHT (yes, no)  Prior docetaxel (yes, no)  Baseline bone\n",
      "protecting agent (yes, no)  Baseline LDH value (< vs. ≥ median) \n",
      "Baseline hemoglobin value (< vs. ≥ median)  Baseline ALP value (< vs.\n",
      "≥ median)  Baseline CTC Count (<5, ≥ 5)  Baseline CTC Count (0, >0)\n",
      "Similarsubgroup analyses will be performed for Cohort 2. A subgroup\n",
      "analysis for OS will be performed at the time of the final OS analysis\n",
      "using the same subgroups specified above for rPFS. Subgroup analyses\n",
      "of other efficacy parameters and subgroups analyses for Part 1 data\n",
      "are not planned. Key safety outputs for Part 2 will be provided to\n",
      "explore the following subgroups:  Renal impairment (moderate vs.mild\n",
      "vs. normal),  Age (<70vs. ≥ 70),  Asian vs. non-Asian.Normal, mild,\n",
      "and moderate renal impairment are defined based on baseline eGFR of\n",
      "≥90 mL/min/1.73m2, 60-89 mL/min/1.73m2, and30-59mL/min/1.73m2\n",
      "respectively, where eGFR willbe captured on the CRFs. Key safety\n",
      "outputs for Part 1 will be provided by startingdose. Additionally\n",
      "adverse events listings will consider the dose at the time of the Unless otherwise specified,the following summaries will be provided separately for the\n",
      "\n",
      "6.4. Baseline and Other Summaries\n",
      "  Unless otherwise specified,the following summaries will be provided\n",
      "separately for the safety analysis set of Part 1 and for the ITT all-\n",
      "comers and DDR-deficient populations in Part 2. For Part 1, select Thefollowingdemographic andbaselinedisease characteristicswill besummarized:\n",
      "\n",
      "6.4.1. Baseline Summaries\n",
      "  Thefollowingdemographic andbaselinedisease characteristicswill\n",
      "besummarized:  Age(continuous and by groups: <65; 65-<75; >=75) \n",
      "Race  Asian vs. non-Asian  Weight  Body Mass Index (BMI) \n",
      "Geographic region(NorthAmerica,Europe, Asia, Rest of World)  Renal\n",
      "impairment at baseline (Normal, Mild, Moderate), o normal, mild, and\n",
      "moderate are defined based on baseline baseline eGFR of ≥90\n",
      "mL/min/1.73m2, 60-89 mL/min/1.73m2, and 30-59mL/min/1.73m2,\n",
      "respectively,  Histopathological classification  Baseline serum PSA\n",
      "(ng/mL)  Baseline useof aboneprotecting agent (yes, no)  Gleason\n",
      "score(low [2-4], medium [5-7], high [8-10])  Gleason score (<=6,\n",
      "3+4=7, 4+3=7, 8, 9-10, not reported)  ECOGperformance status  TNM\n",
      "stageat diagnosis  TNM stage at study entry  Disease localization at\n",
      "screening: o Bone only o Soft tissue only o Both bone and soft tissue\n",
      "o None Distribution of disease at screening: o Bone (includes bone\n",
      "with soft tissue component) o Lymph Node o Visceral Disease (lung or\n",
      "liver) o Visceral disease (lung) o Visceral disease (liver) o Other\n",
      "Soft Tissue  Number of bone metastases at screening: n (%) o 0 o 1-4\n",
      "o 5-9 o 10-20 o >20  Type of progression at study entry: o PSA\n",
      "progression only o Bone progression only o Soft tissue progression\n",
      "only o PSA+ bone or soft tissue o Bone+ PSA or soft tissue o\n",
      "PSA+bone+soft tissue  Baselinepain score by BP-SF (0-1; 2-3; >3), \n",
      "Baseline CTC count o Continuous summary o Categorical summary (≥ 5 CTC\n",
      "per 7.5 mL of blood, <5 CTC per 7.5 mL of blood) o Categorical summary\n",
      "(>0 CTC per 7.5 mL of blood, 0 CTC per 7.5 mL of blood)  Time from\n",
      "primary diagnosis to randomization in months (date of randomization –\n",
      "date of diagnosis)/30.4375  Derived DDR mutational status (positive,\n",
      "negative, unknown) with specific mutations prior to randomization \n",
      "DDR mutational status (positive, negative, unknown) with specific\n",
      "mutations based on blood samples only  DDR mutational status\n",
      "(positive, negative, unknown) with specific mutationsbased on tumor\n",
      "tissue samples onlyThe number of patients in the following categories\n",
      "at the time of randomization will be summarized:  Prior NHT orTaxane\n",
      "and DDR-deficient  Prior NHT or Taxane and non DDR-deficient/unknown\n",
      " No Prior NHT orTaxane and DDR-deficient  No Prior NHT or Taxane and\n",
      "non DDR-deficient/unknown A listing will be provided with the strata\n",
      "(defined above) at the time of randomization as well as based on CRF\n",
      "data with a flag to indicate cases where there are differences between Medical history will be coded using the most current version of MedDRA and summarized\n",
      "\n",
      "6.4.2. Medical History\n",
      "  Medical history will be coded using the most current version of\n",
      "MedDRA and summarized by MedDRA’s SOC and PT. Each patient will be\n",
      "counted only once within each PT or SOC. Summaries will be ordered by\n",
      "primary SOC and PT in descending order of frequency by the\n",
      "experimental treatment arm. Summaries will be provided for all Prior anticancertreatments include systemic therapy, radiation, and surgery.\n",
      "\n",
      "6.4.3. Prior AnticancerTreatments\n",
      "  Prior anticancertreatments include systemic therapy, radiation, and\n",
      "surgery. The number and percentage of patients in each of the\n",
      "following anticancer therapy categories will be tabulated:  Patients\n",
      "with at least one type of prior anticancer systemic treatment\n",
      "including androgen deprivation therapy;  Patients with at least one\n",
      "prior anticancer surgery;  Patients with at least one prior\n",
      "anticancer radiotherapywith “primary treatment”and “salvage” intent; \n",
      "Patients with any prior androgen deprivation therapy. Prior anticancer\n",
      "drug therapy will be summarized as follows based on the number and\n",
      "percentage of patients: o Number of prior anticancer therapy regimens\n",
      "(including androgen deprivation therapy): None/ 1 / 2 / ≥3. The prior\n",
      "anticancerdrugs will be coded in the WHO Drug coding dictionary and\n",
      "will be summarized usingthe number and percentage of patients by\n",
      "preferred term. A patient will be counted only once fora given\n",
      "preferred term, even if he/she received the same medication\n",
      "atcombination with enzalutamidearm. In case of equal frequency,\n",
      "alphabetical order will be used. A summary of the number of patients\n",
      "with the followingprior cancersurgeries will be provided: \n",
      "Prostatectomy,  TURP,  Prostate Biopsy,  Bilateral Orchiectomy, \n",
      "Pelvic Node Dissection,  Ureteral Stent,  Nephrostomy. Specific\n",
      "details on all other surgeries and radiotherapy(primary treatment and Discontinuations from study treatment due to adverse events will be identified as either\n",
      "\n",
      "6.4.4. Study Conduct and Patient Disposition\n",
      "  Discontinuations from study treatment due to adverse events will be\n",
      "identified as either related or not related to study treatment. If\n",
      "causality is missing the event will be considered related to\n",
      "treatment. If multiple events lead to study treatment discontinuation\n",
      "and at least one was considered related, discontinuation will be\n",
      "reported as related to study treatment. COVID-19 Related Disposition\n",
      "Alisting of all patientsaffectedbyCOVID-19will be created. The listing\n",
      "will present subject number identifier byinvestigational site, and a\n",
      "description of COVID-19-related events including:  All protocol Important protocol deviations will be compiled prior to database release and will be\n",
      "\n",
      "6.4.5. Protocol Deviations\n",
      "  Important protocol deviations will be compiled prior to database\n",
      "release and will be summarized by category (n(%)) using the safety\n",
      "population for Part 1 andthe ITT population forPart 2.Categories will\n",
      "be assigned by the study team. In addition, all protocol deviations\n",
      "related to COVID-19 will be presented in a separate listing.6.4.6.\n",
      "Study Treatment Exposure Exposure summaries will be presented using\n",
      "the safety analysis set for each part. Part 1 patients hada starting\n",
      "talazoparib dose of either 1 mg/day or 0.5 mg/dayin combination\n",
      "withenzalutamide 160 mg/day,depending on timing of enrollment. The\n",
      "Part 1 data will be presented separately by the starting talazoparib\n",
      "dose. For part 2, thedailydose of talazoparibis 0.5\n",
      "mg/daygivenorallyin combination with enzalutamide 160 mg/dayat\n",
      "approximatelythesametimeeach day for patients with normal/mild renal\n",
      "impairment. Thestartingtalazoparib dosewill be 0.35mg/dayin\n",
      "combination withenzalutamide 160 mg/dayforpatients with moderaterenal\n",
      "impairment (eGFR 30-59mL/min/1.73m2). Separate summaries will be\n",
      "provided for talazoparib and enzalutamide and will include the\n",
      "following:  Treatment duration (months):\n",
      "Foreachpatient,treatmentdurationis definedas (date of last dose–dateof\n",
      "first dose +1) / 30.4375. Treatment duration will be summarizedboth as\n",
      "a continuous measureandacategorical measure(≤ 3 months, 3 to <6\n",
      "months, 6 to <12 months, ≥ 12 months).  Average dailydose(mg/day):\n",
      "Theaveragedailydoseis definedas the cumulative dosedividedbythe actual\n",
      "number of days on the treatment.  Dose intensity(mg/week):\n",
      "Doseintensity is definedas the cumulativedose dividedbythe treatment\n",
      "duration.  Relative dose intensity (%): Relative dose intensity is\n",
      "defined as the ratio of the actual dose intensity to the planned dose\n",
      "intensity expressed in %. The planned dose intensity will be 3.5 mg\n",
      "(0.5 mg per day for 7 days) for patients without moderate renal\n",
      "impairment and 2.45 mg (0.35 mg per day for 7 days) for patients with\n",
      "moderate renal impairment. RDI (%) = 100x[dose intensity\n",
      "(mg/week)]/[planned dose intensity(mg/week)]. A dose reduction is\n",
      "defined as a non-zero dose that is less than the prior dose.The number\n",
      "andpercentage of patients with at least one dose reductionas well as a\n",
      "breakdown of dose reductions (1 / 2 / 3) will be summarized by\n",
      "treatment arm. Reasons for dose reductions will also be summarized.\n",
      "There could be more than one reason if multiple dose reductions occur\n",
      "forthe same patient,though each reason will be counted only once for\n",
      "each patient. Percentages will be calculated based on the total number\n",
      "of patients in safety analysis set. An dosing interruption is defined\n",
      "a 0mg dose administered. (Note: A dosinginterruption is not considered\n",
      "a dose reduction). The number and percentage of patients with dosing\n",
      "interruptions and the corresponding reasons will be summarized by\n",
      "treatment arm. There could be more than one reasonif multiple\n",
      "dosinginterruption occur forthe same patient,though each reason will\n",
      "be counted only once for each patient. Percentages will be calculated\n",
      "based on the total number of patients in safety analysis set. Time to\n",
      "first interruption (weeks) and time to first reduction (weeks),\n",
      "measured from the date of first dose of study treatment, will be\n",
      "summarized for patients who had at least one interruption or reduction\n",
      "respectively. A summary of duration (days) of dosinginterruptions due\n",
      "to any AEs and for anemia only for each dosinginterruption will be\n",
      "provided,where ‘n’ is the number of dosing interruptions. Apatient can\n",
      "contribute multiple observations, one for each interruption. A summary\n",
      "of the total duration (days) of dosinginterruptions due to AEs for Concomitant medications refer to all medications thatstarted or were ongoing at the time of\n",
      "\n",
      "6.4.7. Concomitant Medications\n",
      "  Concomitant medications refer to all medications thatstarted or were\n",
      "ongoing at the time of randomization , started after randomization and\n",
      "continued during the on-treatment period for up to 28 days after the\n",
      "last dose of all the study treatments as well as those started during\n",
      "the on-treatment period. Concomitant medications will be coded in the\n",
      "WHO Drug coding dictionary and will be tabulated by Anatomical\n",
      "Therapeutic Chemical (ATC) Classification level 2 and preferred term\n",
      "in descending order of frequencyfor the talazoparib in combination\n",
      "with enzalutamidearm. In case of equal frequency regarding drug class\n",
      "(respectively drug name), alphabetical order will be used. A patient\n",
      "will be counted only once fora given drug name, even if he/she\n",
      "received the same medication multiple times. Concomitant non-drug\n",
      "treatments refer to non-drug treatments (radiation and surgery)\n",
      "administered during the on-treatment period. Non-drug treatments will\n",
      "be coded in MedDRA and will be summarized by MedDRA SOC and PT in\n",
      "descending order of frequencyon the talazoparib in combination with\n",
      "enzalutamidearm. Patients will be counted only once per PT even if\n",
      "he/she received the same treatment multiple times. Concomitant\n",
      "medications and non-drug treatments will be summarized by treatment\n",
      "arm for the Part 1 and Part 2 safety populations. Concomitant Subsequent systemic anticancertherapies are defined as therapies collectedon the ‘Follow-\n",
      "\n",
      "6.4.8. Subsequent AnticancerTherapies/Procedures\n",
      "  Subsequent systemic anticancertherapies are defined as therapies\n",
      "collectedon the ‘Follow- up Cancer Therapy’ CRF page. Subsequent\n",
      "anticancer procedures include procedures collected on‘Follow-up\n",
      "Radiation Therapy’marked as curativeor salvage, and ‘Follow-up\n",
      "Surgery’ CRF pages where the date is on or after the date of first\n",
      "dose of study treatment. The number and percentage of patients within\n",
      "each category (medication therapy, radiation therapy, and surgeries)\n",
      "will be provided by treatment arm for thePart 2 ITT Population.\n",
      "Subsequent anticancertherapies and procedures will be listed for Part\n",
      "1 and Part 2. Medications will be coded using the WHO Drug coding\n",
      "dictionary and will be tabulated by preferred term in descending order\n",
      "of frequency.6.5. Safety Summaries and Analyses Unless otherwise\n",
      "specified, summaries of AEs and other safety parameters will provided\n",
      "separately for Part 1 and Part 2 and will be based on the safety\n",
      "population. For Part 1 the data will be analyzed by the starting dose\n",
      "of talazoparib. For Part 2 as it is anticipated that follow-up for the\n",
      "primary endpoint in the DDR-deficient population will be ongoing (i.e.\n",
      "treatment assignment will still be blinded) at the time of the final\n",
      "analysis of rPFS in the all- comers population, summaries will\n",
      "initially be performed only for the all-comers population. At the time\n",
      "of the final rPFS analysis in the DDR-deficient population safety data\n",
      "will be summarized for the combined populations of all-comers and DDR- All analyses will be based on treatment-emergent events unless otherwise specified. AEs not\n",
      "\n",
      "6.5.1. Adverse Events\n",
      "  All analyses will be based on treatment-emergent events unless\n",
      "otherwise specified. AEs not considered treatment-emergent will be\n",
      "flagged in data listings. For Part 1 and Part 2 separately, ahigh-\n",
      "level summary of adverse events will include the number and percent of\n",
      "patients with:  Any AE;  Serious AE;  CTCAE Grade 3-4 AEs;  Grade\n",
      "5 AEs;  AEs leading to dose reductions of talazoparib/placebo;  AEs\n",
      "leading to dose reductions of enzalutamide;  AEs leading to dose\n",
      "reductions of both talazoparib/placebo and enzalutamide;  AEs leading\n",
      "to dosinginterruptions of talazoparib/placebo;  AEs leading to\n",
      "dosinginterruptions of enzalutamide;  AEs leading to dosing\n",
      "interruptions of both talazoparib/placebo and enzalutamide;  AEs\n",
      "leading to permanent discontinuationof talazoparib/placebo;  AEs\n",
      "leading to permanent discontinuationof enzalutamide;  AEs leading to\n",
      "permanent discontinuation of both talazoparib/placebo and\n",
      "enzalutamide. Seriousness, toxicity grade, action taken (interruption,\n",
      "reduction, and withdraw) are as reported by the investigator on the\n",
      "adverse event CRF. Summaries SOC and PT by treatment arm in decreasing\n",
      "frequency will be provided for:  Treatment-Emergent AEs (All\n",
      "Causality); Treatment-Emergent AEs by Maximum CTCAEGrade (All\n",
      "Causality);  Treatment-emergent COVID-19 related AEs (all causality);\n",
      " Treatment-Emergent AEs (Treatment Related);  Treatmen -Emergent AEs\n",
      "by Maximum CTCAE Grade (Treatment Related);  Serious Treatment-\n",
      "Emergent AEs (All Causality);  Serious Treatment-Emergent AEs\n",
      "(Treatment Related); An AEwill be considered treatment related if the\n",
      "investigator considered the event related to one or both of study\n",
      "drugs given in combination. The following summaries of AEs will be\n",
      "provided by decreasing frequency of PT (summaries will not include\n",
      "SOC) in the talazoparib plus enzalutamidearm for Part 2 only: \n",
      "Treatment-Emergent AEs (All Causality) in either treatment arm; \n",
      "Treatment-Emergent AEs (All Causality) by Preferred Term and Maximum\n",
      "CTCAE Grade;  Treatment-Emergent AEs Leading to Dosing Interruptions\n",
      "of Talazoparib(All Causality);  Treatment-Emergent AEs Leading to\n",
      "Dosing Interruptions of Enzalutamide (All Causality);  Treatment-\n",
      "Emergent AEs Leading to Dosing Interruptions of BothTalazoparib and\n",
      "Enzalutamide (All Causality);  Treatment Emergent AEs Leading to Dose\n",
      "Reductions of Talazoparib(All Causality);  Treatment Emergent\n",
      "AEsLeading to Dose Reductions of Enzalutamide (All Causality); \n",
      "Treatment Emergent AEsLeading to Dose Reductions of Both Talazoparib\n",
      "and Enzalutamide (All Causality);  Treatment Emergent AEs Leading to\n",
      "Permanent Withdraw of Talazoparib (All Causality);  Treatment\n",
      "Emergent AEs Leading to Permanent Withdraw of Enzalutamide(All\n",
      "Causality);  Treatment Emergent AEs Leading to Permanent Withdraw of\n",
      "Both Talazopariband Enzalutamide(All Causality);  Treatment Emergent\n",
      "AEs between DDR-deficient patients and non-deficient patients (All\n",
      "Causality);  Treamtment emergent AE between normal/mild vesusmoderate\n",
      "renal impareiment (All Causality) Serious Treatment Emergent AEs\n",
      "(Treatment related). Each patient will be counted only once within\n",
      "each SOC and PT. If a patient has events with missing and non-missing\n",
      "toxicity grades, the maximum non- missing grade will be displayed.\n",
      "Missing grade will only be displayed in the event that only one AEhas\n",
      "been reported for a patient and the grade is missing. Summaries of\n",
      "time to first Grade 3 or 4 event and time to first SAE will also be\n",
      "providedfor the safety populations in Part 2. Patients without an\n",
      "event will be censored as follows:  if the patient has discontinued\n",
      "from study treatment the patient will be censored 28 days afterthe\n",
      "last dose of studytreatment,or before systemic anticancer therapy,\n",
      "whicheveroccurs first, and  if the patient is still on study\n",
      "treatment at the time of analysis the patient will be censored at the See section 3.4.1for a list of AEs of Special Interest.\n",
      "\n",
      "6.5.2. Adverse Events of Special Interest\n",
      "  See section 3.4.1for a list of AEs of Special Interest. For\n",
      "Talazoparib AESIs, separate summaries for each AESI will be provided\n",
      "by maximum toxicity and will include an ‘any event’ row along with a\n",
      "row for each contributing PT in descending order of frequency. Given\n",
      "the observed incidence of hematologic toxicities associated with the\n",
      "use of talazoparib, a summary of hematologic AEs will be provided\n",
      "toshow the incidence of the following cluster terms:  ANEMIA:\n",
      "anaemia, decreased hemoglobin, decreased hematocrit, red blood cell\n",
      "count decreased  NEUTROPENIA: neutropenia and decreased neutrophil\n",
      "count  THROMBOCYTOPENIA: thrombocytopenia and platelet count\n",
      "decreased  LEUKOPENIA: leukopenia or white blood cell count decreased\n",
      " LYMPHOPENIA: lymphopenia or lymphocyte count decreased AESIs for\n",
      "enzalutamide will be summazried by medical event only,not by The frequency (number and percentage) of patients in the safety populationwho died anddeath, will be tabulated based on information from the ‘Notice of Death’ and ‘Survival\n",
      "\n",
      "6.5.3. Deaths\n",
      "  The frequency (number and percentage) of patients in the safety\n",
      "populationwho died anddeath, will be tabulated based on information\n",
      "from the ‘Notice of Death’ and ‘Survival Follow-Up’ CRFs. Date and\n",
      "cause of death will be provided in individual patient data listings\n",
      "with selected dosing information (study treatment received, date of\n",
      "first / last administration, dose, etc.). In addition, if there are ≥\n",
      "10deaths due to COVID-19, a separate death summary will be createdfor Laboratory results will be converted to International System of Units (Système International\n",
      "\n",
      "6.5.4. Laboratory Data\n",
      "  Laboratory results will be converted to International System of Units\n",
      "(Système International d'unités, SI) units for reporting. Quantitative\n",
      "data will be summarized using descriptive statistics (mean, standard\n",
      "deviation, median, quartiles, minimum, and maximum) of actual values\n",
      "and change from baseline for each visit over time (i.e. unscheduled\n",
      "assessments will be excluded). The total number of patients for change\n",
      "from baseline will include all patients who have botha baseline and a\n",
      "value at the postbaseline visit. Baseline will be defined as the last\n",
      "assessment performed on or prior to date of the first dose of study\n",
      "treatment (or prior to randomization for randomized patients). If\n",
      "there are multiple assessments that meet the baseline definition on\n",
      "the same day without the ability to determine which was truly last,\n",
      "then the worst grade will be assigned as the baseline grade. Results\n",
      "collected as strict inequalities (e.g., >10, <10) will be converted to\n",
      "numeric values subtracting a factor of 0.001. Expressions of the form”\n",
      "≥” or “≤” will be converted to the end point. These numeric values\n",
      "will be evaluated for clinically significant abnormalities, but will\n",
      "not be included in calculations of summary statistics. Additionally,\n",
      "laboratory results will be programmatically classified accordingto\n",
      "NCI- CTCAE version 4.03. Non-numerical qualifiers will not be taken\n",
      "into consideration in the derivation of grade (e.g. hypokalemia Grade\n",
      "1 and Grade 2 are only distinguished by a non- numerical qualifier and\n",
      "therefore Grade 2 will not be derived). In summary statistics the\n",
      "number and percentage of patients corresponding to grades that only\n",
      "include non-quantitative criteria will be displayed as a blank or NA\n",
      "(not assessed) rather than 0. If there is any overlap between grade\n",
      "criteria (e.g. CTCAE gradingcriteria for Creatinine Increased –a value\n",
      "can fall into one range based on comparison to upper limit of normal\n",
      "(ULN) and another range based on comparison to baseline), the highest\n",
      "(worst) grade would be assigned to that record. Grade 5 is defined in\n",
      "the CTCAE criteria guidance as an event with an outcome of death.\n",
      "Since laboratory data does not collect an outcome, Grade 5 is not used\n",
      "when programmatically grading laboratory data. Grade 0 or Outside\n",
      "Toxicity Reference (OTR) is not defined specifically byin the CTCAE\n",
      "guidance. However, programmatically this is used as a category to\n",
      "represent those patients who did not meet any of the Grades 1 to 4\n",
      "criteria. If the laboratory value is evaluable for CTCAE criteria\n",
      "grading (numeric value is present, valid units and ranges are present\n",
      "asthe Grade 1-4 criteria for a given laboratorytest, then the value is\n",
      "assigned as Grade 0 or OTR. Abnormalities will be described using the\n",
      "worst grade by scheduled timepoint and overall. Worst grade by\n",
      "scheduled timepoint will be determined using only local laboratory\n",
      "results. Worst overall grade will be determined using both central and\n",
      "local laboratory results from scheduled and unscheduled visits.\n",
      "Several laboratory tests have bi-directional grading criteria defined\n",
      "so that both low (hypo) and high (hyper) values can be graded\n",
      "separately. Each criterion will be summarized separately. In the cases\n",
      "where a value is graded as a Grade 1, 2, 3, or 4 for one of the\n",
      "directions, that value will also be assigned as a Grade 0 for the\n",
      "opposite direction for that test. For example, a value meeting the\n",
      "criteria for Grade 3 Hypercalcemia will be classified as a Grade 0\n",
      "Hypocalcemia. For CTCAE terms that can be derived using one of several\n",
      "laboratory tests, the maximum postbaselinegrade for a given patient\n",
      "and CTCAE term will be the maximum across all possible laboratory\n",
      "tests. Additional laboratory results that are not part of NCI-CTCAE\n",
      "will be presented according to the following categories by scheduled\n",
      "timepoint as well as overall: below normal limit, within normal\n",
      "limits, and above normal limits. In the unlikely event that for a\n",
      "given patient, clinically significant abnormalities are noted in both\n",
      "directions (e.g., > ULNand< Lower Limit of Normal (LLN)), then both\n",
      "abnormalities are counted.Summaries at scheduled timepoints will\n",
      "consider only central laboratory data; however summaries overall will\n",
      "consider both central and local laboratory data. Liver function tests:\n",
      "Alanine aminotransferase (ALT), aspartate aminotransferase (AST),\n",
      "Alkaline Phosphatase (ALP),and total bilirubin (TBILI) are used to\n",
      "assess possible drug induced liver toxicity. The ratios of test result\n",
      "over the ULNwill be calculated and classified for these three\n",
      "parameters during the on-treatment period. Summaries of liver function\n",
      "tests will include the following categories. The number and percentage\n",
      "of patients with each of the following during the on-treatment period\n",
      "will be summarized by treatment arm:  ALT ≥ 3×ULN, ALT ≥ 5xULN, ALT ≥\n",
      "10×ULN, ALT ≥ 20×ULN  AST ≥ 3×ULN, AST ≥ 5xULN, AST ≥ 10×ULN, AST ≥\n",
      "20×ULN  (ALT or AST) ≥ 3×ULN, (ALT or AST) ≥ 5×ULN, (ALT or AST) ≥\n",
      "10×ULN, (ALT or AST) ≥ 20×ULN  TBILI ≥ 2×ULN  Concurrent ALT ≥ 3×ULN\n",
      "and TBILI ≥ 2×ULN  Concurrent AST ≥ 3×ULN and TBILI ≥ 2×ULN \n",
      "Concurrent (ALT or AST) ≥ 3×ULN and TBILI ≥ 2×ULN Concurrent (ALT or\n",
      "AST) ≥ 3×ULN and TBILI ≥ 2×ULN and ALP ≤ 2×ULN or missing Concurrent\n",
      "measurements are those occurring on the same date. Categories will be\n",
      "cumulative, i.e., a patient with an elevation of AST ≥10×ULN will also\n",
      "appear in the categories ≥5×ULN and ≥3×ULN. Liver function elevation\n",
      "and possible Hy’s Law cases will be summarized using frequency counts\n",
      "and percentages. An evaluation of Drug-Induced Serious Hepatotoxicity\n",
      "(eDISH) plot will also be created, with different symbols for\n",
      "different treatment arms, by graphically displaying  peak serum\n",
      "ALT(/ULN) vs peak total bilirubin (/ULN) including reference lines at\n",
      "ALT=3×ULN and total bilirubin=2×ULN.  peak serum AST(/ULN) vs peak\n",
      "total bilirubin (/ULN) including reference lines at AST=3×ULN and\n",
      "total bilirubin=2×ULN. In addition, a listing of all TBILI, ALT, AST\n",
      "and ALP values for patients with a postbaseline TBILI ≥ 2×ULN, ALT≥ Systolicanddiastolic blood pressure (mmHg),heart rate (bpm), and temperature (Celsius)\n",
      "\n",
      "6.5.5. Vital Signs\n",
      "  Systolicanddiastolic blood pressure (mmHg),heart rate (bpm), and\n",
      "temperature (Celsius) will besummarizedat baseline andat all\n",
      "subsequent scheduledtimepoints. Changes from baseline valuewill\n",
      "bepresentedfor all scheduledtime points. All recorded vital signdata\n",
      "will belistedfor Parts 1 and 2. Thenumberandpercentage ofpatients with\n",
      "thefollowingvital signchanges will be presented.The definitions of\n",
      "potentiallyclinicallysignificant abnormalitiesareshown in Table 10.\n",
      "Table 10. PotentiallyClinicallySignificantAbnormalitiesinVitalSigns\n",
      "Parameter CriteriaforPotentiallyClinicallySignificantAbnormalities\n",
      "Systolicbloodpressure Absoluteresult> 180 mmHg andincrease from\n",
      "baseline ≥40 mmHg Absoluteresult< 90 mmHg and decrease from baseline\n",
      ">30 mmHg Diastolic bloodpressure Absoluteresult> 110 mmHg andincrease\n",
      "from baseline ≥30 mmHg Absoluteresult< 50 mmHg and decrease from\n",
      "baseline >20 mmHg ≥ 20 mm HG increase from baseline Heart Rate\n",
      "Absolute result > 120 bpm and increase from baseline > 30 bpm Absolute\n",
      "result < 50 bpm and decrease from baseline >20 bpmTable 10.\n",
      "PotentiallyClinicallySignificantAbnormalitiesinVitalSigns Parameter\n",
      "CriteriaforPotentiallyClinicallySignificantAbnormalities Weight >10%\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "extracted_sec1 = \"\"\n",
    "\n",
    "# Iterate over rows and append the values and corresponding paragraphs to the variable\n",
    "for index, row in df.iterrows():\n",
    "    value = row['Value']\n",
    "    paragraph = row['Paragraph']\n",
    "\n",
    "    # Append value and paragraph to the variable\n",
    "    extracted_sec1 += f\"{value}\\n {paragraph}\\n\\n\"\n",
    "\n",
    "# Print the variable (optional)\n",
    "print(extracted_sec1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [],
   "source": [
    "def tag_text_with_values(dictionary, text):\n",
    "    tagged_text = text\n",
    "\n",
    "    for key, values in dictionary.items():\n",
    "        for value in values:\n",
    "            tagged_text = tagged_text.replace(value, f\"**{key}**\")\n",
    "\n",
    "    return tagged_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "6.1. Part 1 Analyses\n",
      "  \n",
      "\n",
      "6.1.1. Primary Endpoint\n",
      "  Target safety events specified inTable 4will be evaluated in the Part\n",
      "1 safety analysisset. Table 4. Target Safety Events: Part 1 (Open-\n",
      "Label Treatment) Hematologic Toxicity Any of the following considered\n",
      "possibly or probably related to talazoparib:  Grade 4 anemia  Grade\n",
      "4 thrombocytopenia  Grade 4 neutropenia (ANC <500/µL or <0.5 × 109/L)\n",
      " Grade 3 thrombocytopenia associated with clinically significant\n",
      "bleeding  Grade 3 neutropenia or Grade 3 thrombocytopenia if daily\n",
      "dosing is interrupted for 7days  Febrile neutropenia, defined as ANC\n",
      "<1000/µLwith a single temperature of >38.3C (>101F) or a temperature\n",
      "of >38C (100.4F) sustained over a 1-hour period  Neutropenic\n",
      "infection (ANC <1000/µL or <1.0 × 109/L) Nonhematologic Toxicity Any\n",
      "Grade 3 adverse eventconsidered possibly or probably related to\n",
      "talazoparib excluding the following:  Grade 3 laboratory\n",
      "abnormalities not considered clinically significant  Grade 3 adverse\n",
      "event not considered clinically significant  Grade 3 nausea or\n",
      "vomiting that responds to medical intervention within 72hours  Grade\n",
      "3 diarrhea that can be medically managed to Grade 2 within 72hours \n",
      "Grade 3 fatigue that improves to Grade 2 within 7 days Liver\n",
      "Toxicity Any of the following considered possibly or probably related\n",
      "to talazoparib:  ALT or AST >3× ULNif baseline ALT or AST 3×ULN \n",
      "ALT or AST >5×ULN (a lower threshold should be considered if the ALT\n",
      "or AST abnormalities are accompanied by symptoms and signs of\n",
      "hepatitis ) AND 2-fold increases above baseline  ALT or AST 3×ULN\n",
      "and total bilirubin ≥2×ULN  Total bilirubin >5×ULN Toxicities will be\n",
      "classified by severity according to the National Cancer Institute\n",
      "Common Terminology Criteria for Adverse Events, version 4. As the\n",
      "targeted safety events defined above include some subjective criteria\n",
      "or multiple criteria occurring simultaneously, an assessment of\n",
      "whether or not event met the criteria of being target safety events\n",
      "requiring a reduction in the starting dose for Part 2 will be made\n",
      "based on a review of individual patient data, summaries of all AEs,and\n",
      "exposure.6.1.2. Secondary Endpoints [Pharmacokinetics] A record-level\n",
      "dataset Pharmacokinetic Analysis Set -Talazoparib will includeall\n",
      "talazoparib PK concentrations that meet thecriteria below:  PK\n",
      "samples collected at Week1  PK samples collected at Weeks 5, 9, 13,\n",
      "and 17 at the same dose level without any dose modification for at\n",
      "least 14 days. Another record-level dataset Pharmacokinetic Analysis\n",
      "Set -Enzalutamidewill includeall enzalutamideconcentrationsthat meet\n",
      "the criteria below:  PK samples collected at Week 1  PK samples\n",
      "collected at Weeks 5, 9, 13, and 17 for patients who did not\n",
      "experience any dose reductions or interruptions of enzalutamide.\n",
      "Pharmacokinetic Analysis Set –Talazopariband Pharmacokinetic Analysis\n",
      "Set – Enzalutamide will be used for PK parameter derivation and In Part 1, analyses of PK concentrations will include sampling at predose, 1, 2, 4, 6 and 24\n",
      "\n",
      "6.1.2.1. PK Concentrations\n",
      "  In Part 1, analyses of PK concentrations will include sampling at\n",
      "predose, 1, 2, 4, 6 and 24 hours postdoseat Day 1 (week 1) and week 9.\n",
      "Additionally, blood samples for PK are collected at predoseand 2 hours\n",
      "postdoseat week 5 and predose at weeks 13 and 17. All planned\n",
      "individual patients’plasma concentration data will be\n",
      "listed(Pharmacokinetic Population). PK samples obtained beyond 10% of\n",
      "the planned time will be included in the listings and could be\n",
      "included in the calculation of PK parameters (based on discretion of\n",
      "the pharmacokineticist), however, will be removed from figures and\n",
      "tables reporting mean concentrations per planned sampling times.\n",
      "PredosePKsample collection should occur prior to administration of the\n",
      "investigational product on that day, otherwise will be excluded. In\n",
      "all data presentations (except listings), values below the limit of\n",
      "the assay quantification (BLQ) will be set to zero. In listings BLQ\n",
      "values will be reported as “<LLQ”, where LLQ will be replaced with the\n",
      "value for the lower limit of quantification. Summarystatisticswill\n",
      "beprovidedforplasmaconcentrations of talazopariband enzalutamide and\n",
      "its N-desmethyl metabolite at scheduled visits by time point (using\n",
      "the PK Analysis Sets for talazoparib or enzalutamide, see\n",
      "Section6.1.2). Plasma concentration values below the limit of\n",
      "quantitation will be treated as zero in the descriptive statistics\n",
      "calculations. Zero concentrations will be considered as missing in\n",
      "geometric mean calculations. Spaghetti plots of individual\n",
      "concentrations against actual time postdose (separate plots for each In estimating the PK parameters, BLQ values at the beginning of the profile will be set toare embedded between BLQs, or quantifiable values occurring after two or more BLQs, may\n",
      "\n",
      "6.1.2.2. PK Parameters\n",
      "  In estimating the PK parameters, BLQ values at the beginning of the\n",
      "profile will be set toare embedded between BLQs, or quantifiable\n",
      "values occurring after two or more BLQs, may be set to missing at the\n",
      "discretion of the pharmacokineticist. Actual sampling times, rather\n",
      "than scheduled sampling times, will be used in all computations\n",
      "involving sampling times. If the actual time or dose time is missing,\n",
      "the scheduled time may be substituted in order to calculate the PK\n",
      "parameter. As appropriate, additional PK parameters may be calculated\n",
      "and reported. The following PK parameters of talazoparib and\n",
      "enzalutamide and its Ndesmethyl metabolite will be summarized usingthe\n",
      "Pharmacokinetic Population (specifically using the record-level sets\n",
      "called PK analysis set –Talazoparib and PK analysis set –enzalutamide)\n",
      "as appropriate: C ,C , T , AUC ,and CL /F will be summarized by dose\n",
      "and study visit. max trough max  ss Dose-normalized AUC , C , and C\n",
      "will be summarized by study visit.  max trough The above mentioned PK\n",
      "parameters (T excluded) will be summarized by arithmetic max mean,\n",
      "standard deviation and CV, geometric mean, geometric CV, minimum,\n",
      "median, maximum value and the number of evaluable parameters. The PK\n",
      "characteristics of T will max be described utilizing the number of\n",
      "observations, minimum, maximum and median. Geometric CV% is defined as\n",
      "sqrt(exp(variance of log transformed data)-1)*100 In addition, box and\n",
      "whisker plots for individual patient parameters AUC , C , and C  max\n",
      "trough by dose and scheduled visit as well as for dose-normalized AUC\n",
      ", C , and C by  max trough scheduled visit maybe be presented and\n",
      "overlaid with geometric means. For all presentations, PK data from\n",
      "Part 1 and Part 2 will be pooled. However, separate summaries of PK\n",
      "parameters including AUC , C , and C by dose level and scheduled  max\n",
      "trough visit in addition to summaries of dose-normalized AUC , C , and\n",
      "C by scheduled visit  max trough will be generated for patients in For CTC counts, a summary of the mean (standard deviation), median, and range of\n",
      "\n",
      "6.1.3. Exploratory Endpoints\n",
      "  For CTC counts, a summary of the mean (standard deviation), median,\n",
      "and range of baseline and postbaselinevalues will be provided for\n",
      "patients in Part 1 CTC evaluable population. In addition, the number\n",
      "and percentage of patients with CTC count ≥ 5vs. <5 and CTC count\n",
      ">0vs. =0 per 7.5 mL will be presented as well. The analysis of CTC\n",
      "count conversion from 5 or more CTC per 7.5 mL at baseline to < 5 CTC\n",
      "per 7.5 mL post baselinewill excludepatients with a CTC count < 5 per\n",
      "7.5 mL at baseline. The proportion of patients withsuch a conversion\n",
      "will be calculated along with the two-sided 95% CI using Clopper-\n",
      "Pearson method (exact methodfor a binomial proportion). The analysis\n",
      "of CTC count conversion from detectable at baseline to 0\n",
      "postbaselinewill exclude patients with a CTC count of 0 per 7.5 mL of\n",
      "blood at baseline. The proportion of patients with sucha\n",
      "conversionwill be calculated along with the two-sided 95% CIusing\n",
      "Clopper-Pearson method.The analysis of the proportion of patients with\n",
      "baseline CTCs <5 who show increased CTCs postbaselinewill\n",
      "excludepatients with a CTC count of ≥ 5 per 7.5 mL of blood at\n",
      "baseline. The proportion of patients with such a conversion will be\n",
      "calculated along with the two-sided 95% CI using the Clopper-Pearson\n",
      "method. A separate analysis plan will be provided to describe analyses\n",
      "of molecular profiling of tumor tissue remaining after genomic testing\n",
      "for eligibility and of saliva and ctDNA. Although not specifically\n",
      "listed as exploratory objectives,analyses of efficacy including rPFS,\n",
      "ORR in patient with soft tissue measurable disease at baseline, PSA\n",
      "response, and time to PSA progression may be evaluated during the\n",
      "course of the study and will be reported at the time of the final\n",
      "analysis of rPFS in all-comers, if not sooner. Derivations will follow\n",
      "the same rules outlined in section 6.2for Part 2. Summaries will be\n",
      "descriptive and not inferential. Specifically summaries of time to\n",
      "event endpoints will be limitedto medians and rates at specific\n",
      "timepoints of interest. Summaries of response rates will include\n",
      "number and percentage. Summaries will be provided regardless of\n",
      "mutation status or starting dose. Mutation status (where available) 6.2.1. Primary Endpoint--rPFS\n",
      "\n",
      "6.2. Part 2 Analyses\n",
      "  \n",
      "\n",
      "6.2.1. Primary Endpoint--rPFS\n",
      "  The primary efficacy analysis will compare rPFS based on BICR between\n",
      "talazoparib in combination with enzalutamide vs. talazoparib-matching\n",
      "placebo in combination with enzalutamide, and will be performed using\n",
      "anone-sided stratified log-rank test forthe all- comers and DDR-\n",
      "deficient populations respectively(subsets of the ITT population). A\n",
      "secondary analysis of rPFS based on investigator assessment will also\n",
      "be performed. rPFS is defined as the time from the date of\n",
      "randomization to first objective evidence of radiographic progression\n",
      "as assessed in soft tissue per RECIST1.1 or in bone (upon subsequent\n",
      "confirmation) per PCWG3 guidelines, or deathdue to any cause,\n",
      "whichever occurs first,and will be summarized in months using the\n",
      "following calculation: rPFS (months) = [date of event/censoring\n",
      "–randomization date +1]/30.4375. The documentationrequiredfor the\n",
      "determination of radiographic progressionis shown in Table 5. Table 5.\n",
      "Criteria for Evidence of Radiographic Progression Date Criteria for\n",
      "Progression Criteria for Confirmation Criteria for Progression of\n",
      "Progression Documentation of Disease Detected (Requirement and Timing)\n",
      "Progression on (Visit) [1] Confirmatory Scan Week9 Bone lesions: 2or\n",
      "more new Timing: at least 6weeks Persistence of at least 2 lesions\n",
      "compared to baseline after progression identified lesions seen at week\n",
      "9 bone scan by PCWG3 or at Week17 Visit [2] AND 2 or more new bone\n",
      "lesions on bone scan (compared to Week9 scan)Table 5. Criteria for\n",
      "Evidence of Radiographic Progression Date Criteria for Progression\n",
      "Criteria for Confirmation Criteria for Progression of Progression\n",
      "Documentation of Disease Detected (Requirement and Timing) Progression\n",
      "on (Visit) [1] Confirmatory Scan Soft tissue lesions: No confirmatory\n",
      "scan Not applicable Progressive disease on CT or required for soft\n",
      "tissue MRI by RECIST1.1 disease progression Week17 or Bone lesions: 2\n",
      "or more new Timing: at least 6weeks Persistent of at least 2 of later\n",
      "lesions on bone scan after progression identified the lesions\n",
      "identified as compared to Week9 bone Required for bone lesions new\n",
      "compared to week 9 scan observed on bone scan [2] Soft tissue lesions:\n",
      "No confirmatory scan Not applicable Progressive disease on CT or\n",
      "required for soft tissue MRI by RECIST1.1 disease progression [1]\n",
      "Progression detected by bone scan at an unscheduled visit prior to\n",
      "week 13 will requireconfirmation at least 6 weeks later following the\n",
      "confirmation criteria outlined in the table for week 9. All other\n",
      "unscheduled assessments will follow the confirmation criteria for week\n",
      "17. [2] Confirmation must occur at the next available scan. rPFS will\n",
      "be censored in the following scenarios: 1) The patient will be\n",
      "censoredon the date of the last adequate tumor assessment on or before\n",
      "the data cutoff dateif the patient does not have radiographic\n",
      "progression and does not die. 2) The patient will becensored on the\n",
      "date of last adequate tumor assessment prior to the start of new\n",
      "antineoplastic therapy, if thepatient starts a new antineoplastic\n",
      "therapy prior to radiographic progressionor death. 3) The patient will\n",
      "be censored onrandomizationdate, if the patient does not have baseline\n",
      "or postbaselinetumor assessments. 4) The patient will becensoredon the\n",
      "date of the last adequate tumor assessment without evidence of disease\n",
      "progression prior to missed tumor assessments, if the patient misses 2\n",
      "or more scheduled tumor assessments immediately prior to radiographic\n",
      "progression or death. For the purpose of rPFS censoring, apatient will\n",
      "be censored on the date of the last adequate tumor assessment prior to\n",
      "the start of new antineoplastic therapy if the patient starts a new\n",
      "antineoplastic therapy prior to radiographic progression or death. If\n",
      "a patient has a curative radiotherapy where the treatment intent is\n",
      "specified as ‘primary treatment’ or surgery where the treatment intent\n",
      "is specified as ‘curative in intent’ and the surgery outcome is either\n",
      "‘resected’ or ‘partially resected’ prior to radiographic progression\n",
      "or death, the patient will also be censored on the date of the last\n",
      "adequate tumor assessment before the radiotherapy or surgery.Two or\n",
      "more missed assessments is defined as follows:  If the last adequate\n",
      "tumor assessment prior to the event occurs on or before 70 days from\n",
      "randomization, more than 119 days from that assessment (two 8-week\n",
      "assessments plus a 7-day assessment window)to the event;  If the last\n",
      "adequate tumor assessment prior to the event occurs after 70 days AND\n",
      "on or before 126days from randomization, more than 147days from that\n",
      "assessment (an8-week assessment plus a 12-week assessment plus a 7-day\n",
      "assessment window)to the event;  If the last adequate tumor\n",
      "assessment prior to the event occurs after 126days from randomization,\n",
      "more than 175 days from that assessment (two 12-week assessments plus\n",
      "a 7-day assessment window)to the event. If a patient meets more than\n",
      "onecensoring criteria described above, the patient’s rPFS value will\n",
      "be censored atthe earliest censoring date. The stratified analysis\n",
      "will be based on the following randomization stratification factors:\n",
      "Previous treatment with any NHT or taxane-based chemotherapy for CSPC\n",
      "(yes vs. no); DDR mutational status (deficient vs. non-\n",
      "deficient/unknown). The primary stratified analysis will be based on\n",
      "the stratification information recorded in IWRS. A secondary\n",
      "stratified analysis based on DDR mutational status derived from\n",
      "clinical database will also be performed. Especially because DDR\n",
      "status in IWRS cannot separate non-deficient and unknown status,\n",
      "derived DDR status from clinical database will be used to identify the\n",
      "non-deficient subpopulation. Prior to Protocol Amendment 6, DDR\n",
      "mutational status for randomization/stratification was obtained from\n",
      "tumor tissue (archival or fresh biopsies)or historical test results\n",
      "(prior tumor tissue analysis using FoundationOne test). Starting with\n",
      "Protocol Amendment 6, DDR mutational status for randomization\n",
      "stratification was derived from either tumor tissue (archival slides\n",
      "or fresh biopsies or historical test results)or peripheral blood\n",
      "(liquid biopsy) prior to randomization. If prospective results from\n",
      "bloodand tumor tissue samples are both available, apositive result\n",
      "from eitherwill be considered prospectively DDR-deficient for\n",
      "randomizationstratification. Retrospectively analyzed screening\n",
      "plasmasamples with results known after randomizationand\n",
      "retrospectively analyzed saliva results will also be incorporated for\n",
      "patients with an unknown DDR status in exploratory analyses. For\n",
      "details see Section 5.2.7. Kaplan-Meier curves will be used to\n",
      "estimate the time-to-event distributions. The 50th percentile of\n",
      "Kaplan -Meier estimates will be used to estimate the median duration\n",
      "of each endpoint. A 2-sided 95%CI based on the Brookmeyer-Crowley\n",
      "method will be provided for this estimate. In addition, the event-free\n",
      "rate and 95% CI at 12 months, 24 months, and 36 months for each\n",
      "treatment arm will be presented.The stratified hazard ratio\n",
      "(talazoparib in combination with enzalutamide/control) and the\n",
      "associated 95% CI will be estimated using a Cox proportional hazards\n",
      "model. Ties will be handled using the Breslowmethod. Both one-sided\n",
      "and two-sided p-values will be providedin summary tables. Frequency\n",
      "(number and percentage) of patients with each event type (progression\n",
      "[including types of progression –i.e. bone progression, soft tissue\n",
      "progression, bone and soft tissue progression] or death) and censoring\n",
      "reasons will be presented by treatment arm along with the overall\n",
      "event and censoringrates. Reasons for censoring will be summarized\n",
      "according to the categories inTable 6. If a patient meets multiple\n",
      "definitions for censoringat the same visit,the list will be used to\n",
      "define the hierarchy. Table 6. Censoring Reasons and Hierarchy for\n",
      "rPFS Hierarchy Condition Censoring Reason 1 No adequate baseline\n",
      "assessment No adequate baseline assessment 2 Start of new\n",
      "antineoplastictherapy or select Start of new antineoplastictherapy\n",
      "radiotherapy/surgery before event. 3 Event immediately after missing\n",
      "at least two Event after missing assessments consecutive assessments 4\n",
      "No event and withdrawal of consent date ≥ Withdrawal of consent\n",
      "randomization dateOR End of study (EOS) = patient refused further\n",
      "follow-up 5 No event and lost to follow-up in any disposition page\n",
      "Lost to follow-up 6 No event and EOS present OR disposition page for\n",
      "No adequate postbaselinetumor any EPOCH after screening says patient\n",
      "will not assessment continue into any subsequent phase of the study\n",
      "and no adequate postbaselinetumorassessment 7 No event and none of the\n",
      "conditions in the prior Ongoing without an event hierarchy are met\n",
      "Median follow-up time will be estimated according to the Kaplan-Meier\n",
      "estimate of potential follow-up by the reverse Kaplan-Meier method. An\n",
      "overview forest plot of rPFS based on BICR assessment bythe following\n",
      "subgroups will be presented. A similar forest plot based on\n",
      "investigator assessment will also be provided.  Age (<70/≥70) \n",
      "Geographic region(North America, European Union [EU]/Great Britain\n",
      "[GBR], Asia, rest of world [ROW])  EasternCooperative OncologyGroup\n",
      "(ECOG) performance status at baseline (0, 1)  Total Gleason Score at\n",
      "Diagnosis (<8/≥8) Type of progression at study entry (PSA only,\n",
      "radiographic progression with or without PSA progression)  Baseline\n",
      "PSA (< vs. ≥ overall median)  Site of metastasis at study entry(bone\n",
      "only, soft tissue only, both bone and soft tissue, none)  DDR status\n",
      "by IWRS (DDR-deficient, non-deficient/unknown)  Prior Taxane or NHT The following sensitivity analyses will be performed separately for the all-comers and\n",
      "\n",
      "6.2.1.1. SensitivityAnalyses\n",
      "  The following sensitivity analyses will be performed separately for\n",
      "the all-comers and DDR-deficient populations to explore the robustness\n",
      "ofeach primaryanalysis result. Some of these sensitivity analyses will\n",
      "be presented in the CSR, while the remaining will be presented in\n",
      "other summary documents, for example, Summary of Clinical Efficacy and\n",
      "Summary of Clinical Safety. The sensitivity analyses will be performed\n",
      "following the methods described forthe primary analysis with the\n",
      "modifications below:  RadiographicPFS counting all progression and\n",
      "deaths as events regardless of missing assessments or timing of the\n",
      "event (i.e. not censoring due to thestart of a new\n",
      "antineoplastictherapy prior to event or due to missed\n",
      "assessments)based on BICR andinvestigator assessments. \n",
      "RadiographicPFS counting study treatment discontinuation,start of a\n",
      "new antineoplastic therapy, andoccurrence of asymptomatic skeletal\n",
      "event as additional events based on BICR and investigator assessments.\n",
      "Censoring will be similar to that described for the primary analysis,\n",
      "except for the following: o Radiographic progression, death,\n",
      "discontinuation of study treatment (both treatment components),start\n",
      "of a new anti-cancer therapy, and a symptomatic skeletal event will\n",
      "all be considered as events. rPFS will be calculated as the time\n",
      "interval from the date of randomization to the date of radiographic\n",
      "progression, death, discontinuation of study treatment (both treatment\n",
      "components), start of a new anti-cancer therapy, or a symptomatic\n",
      "skeletal event, whichever occurs first.  Radiographic PFS by\n",
      "assigning the dates ofcensoring and events only at scheduled\n",
      "assessment dates based on BICR and investigator assessments: o If\n",
      "aradiographic progression occurs within 7-daywindowof its scheduled\n",
      "assessment time, it will be assigned the scheduled assessment date. If\n",
      "a radiographic progression occurs outside the 7-day window and between\n",
      "2assigned as the radiographic progression date (e.g., if a\n",
      "radiographic progressionoccurs between weeks 25 and 37, it will be\n",
      "assigned to week 37). o In the event of death, the event date will not\n",
      "be adjusted. DDR-deficient patients enrolled in China in Cohort 1 will\n",
      "be included in the analysis of DDR-deficient patient population. A\n",
      "sensitivity analysis of DDR-deficient patients by excluding the DDR-\n",
      "deficient patients enrolled in China in Cohort 1 will also be\n",
      "performed. In addition, to assess the impact ofCOVID-19, the following\n",
      "sensitivity analyses of rPFS may be performed if COVID-19 related\n",
      "death is reported in at least 10patients in the study:  Radiographic\n",
      "PFS based on BICR assessment and censoring  deaths due to COVID-19. \n",
      "Radiographic PFS based on investigator assessment and censoringdeaths\n",
      "due to COVID-19. BICR vs Investigator assessment: A separate summary\n",
      "of the BICR assessment versus investigator assessment will be provided\n",
      "for the all-comers population and for the DDR-deficient population.\n",
      "These will include numbers of concordant and discordant assessments as\n",
      "well as the number of cases where a PFS event was assessed at\n",
      "different timepoints by the BICR and investigator. The following\n",
      "categories will be summarized by treatment arm for each population: \n",
      "Agreement on time and occurrence of rPFS event (within 28 days) (a1),\n",
      " Agreement on rPFS event but investigator event occurred later (by\n",
      ">28days) (a2),  Agreement on rPFS event but investigator event\n",
      "occurred earlier (by >28days) (a3),  Investigator assessment of rPFS\n",
      "event, patient censored in the BICR analysis (b),  Patient censored\n",
      "in the investigator assessment analysis of rPFS, BICR assessment of\n",
      "rPFS event (c), and  Agreement on non-occurrence of rPFS event (d). A\n",
      "+/-28day window will be used to assess the agreement on timing and\n",
      "occurrence of an rPFS event. Total Event Discrepancy Rate (b+c)/N,\n",
      "Early Discrepancy Rate (a3+b)/(a+b), Late Discrepancy Rate\n",
      "(a2+c)/(a2+a3+b+c); and Overall Discrepancy Rate (a2+a3+b+c)/N will be\n",
      "calculated where a=a1+a2+a3.6.2.2. Secondary Endpoints Each secondary\n",
      "endpoint will be analyzed separately for the all-comers population and OS is defined as the time from randomization to the date of death due to any cause. Patients\n",
      "\n",
      "6.2.2.1. Overall Survival\n",
      "  OS is defined as the time from randomization to the date of death due\n",
      "to any cause. Patients last known to be alive will be censored at the\n",
      "date of last contact. OS (months) = [date of deathor censoring\n",
      "–randomization date +1]/30.4375. Aone-sided stratifiedlog-rank test\n",
      "will be performed on OS in the all-comers population if the null\n",
      "hypothesis of rPFS in the all-comers population is rejected.\n",
      "Similarly, aone-sided stratified log-rank test of OS will be performed\n",
      "in the DDR-deficient population if the null hypothesis of rPFS in the\n",
      "DDR-deficient population is rejected. The stratified hazard ratio\n",
      "(talazoparib in combination with enzalutamide/control) and the\n",
      "associated 95% CI will be estimated using a Cox proportional hazards\n",
      "model. Ties will be handled using the Breslowmethod. Both one-sided\n",
      "and two-sided p-values will be provided in summary tables. Kaplan-\n",
      "Meier estimates will be presented by treatment arm with a summary of\n",
      "associated statistics including the median OS with two-sided 95% CIs.\n",
      "In addition, the survival rate and 95% CI at 12months, 24months,\n",
      "36months, and 48 months for each treatment arm will be presented as\n",
      "well. Reasons for censoring will be summarized according to the\n",
      "categories inTable 7. Ifa patient meets multiple definitions for\n",
      "censoring,the list will be used to define the hierarchy. Table 7.\n",
      "Censoring Reasons and Hierarchy for OS Hierarchy Condition Censoring\n",
      "Reason 1 No event and withdrawal of consent date ≥ Withdrawal of\n",
      "consent randomization dateOR EOS= Subject refused further follow-up 2\n",
      "No event and lost to follow-up in any disposition page Lost to follow-\n",
      "up 3 No event and none of the conditions in the prior Alive hierarchy\n",
      "are met Frequency (number and percentage) of patients with anevent and\n",
      "censoring reasons will be presented by treatment arm as follows: \n",
      "Death o Death due to COVID-19  Withdrawal of consent  Lost to\n",
      "follow-up Ongoing and no death. To assess the impact of COVID-19, the\n",
      "following sensitivity analyses of OS may be performed by applying the\n",
      "additional censoring rules if COVID-19 related death is reported in at ORR is defined as the proportion of patients with measurable soft tissue disease at baseline\n",
      "\n",
      "6.2.2.2. Objective Response per RECIST 1.1\n",
      "  ORR is defined as the proportion of patients with measurable soft\n",
      "tissue disease at baseline with a best overall confirmedsoft tissue\n",
      "response of CR or PR according to RECIST 1.1. Soft tissue responses\n",
      "must be confirmed by a follow-up radiographic assessment at least 4\n",
      "weeks later with no evidence of confirmed bone disease progression on\n",
      "repeat bone scan at least 6 weeks later per PCWG3 criteria. Patients\n",
      "without documented CR or PR will be considered non-responders. Prior\n",
      "to determining the best overall soft tissue response,the date of\n",
      "confirmed bone progression (if applicable) will be determined. If\n",
      "confirmed bone progression is documented and the soft tissue response\n",
      "at the visit where the bone progression criteria are first met is not\n",
      "PD, the derived soft tissue timepoint response incorporating bone\n",
      "assessments will be PD. This derived timepoint response will be used\n",
      "to determining the best overall response (BOR). An example is provided\n",
      "inTable 8. Table 8. Incorporation of Bone Progression into Best\n",
      "Overall Response Overall Soft Example Soft Tissue Tissue Number\n",
      "Timepoint Response Bone Assessment Response Considering Bone\n",
      "Progression (derived) 1 Week9 CR Progression PD criteria met (PD) Week\n",
      "17 CR Progression PD criteria confirmed 2 Week 9 CR Progression CR\n",
      "criteria met (Non-PD) Week 17 CR Progression CR criteria NOT confirmed\n",
      "3 Week 9 SD Non PD SD Week 17 PR Progression PDTable 8. Incorporation\n",
      "of Bone Progression into Best Overall Response Overall Soft Example\n",
      "Soft Tissue Tissue Number Timepoint Response Bone Assessment Response\n",
      "Considering Bone Progression (derived) Week 25 PR Progression PD\n",
      "criteria confirmed Best overall response willbe assessed on patients\n",
      "with measurable disease based on reported overall responses at\n",
      "different evaluation timepoints from the date of randomization until\n",
      "documented disease progression (in soft tissue per RECIST 1.1 or in\n",
      "bone per PCWG3 guidelines) or start of new antineoplastictherapyor\n",
      "curative radiotherapy where the treatment intent is specified as\n",
      "‘primary treatment’ or surgery where the treatment intent is specified\n",
      "as ‘curative in intent’ andthe surgery outcome is either ‘resected’ or\n",
      "‘partially resected’, according to the following rules:  CR = at\n",
      "least two determinations of CR at least 4 weeks apart and documented\n",
      "before progression and start of new antineoplastictherapy  PR = at\n",
      "least two determinations of PR or better (and not qualifying for a CR)\n",
      "at least 4 weeks apart and before progression and start of new\n",
      "antineoplastic  SD (for patients with at least one measurable lesion\n",
      "at baseline)= at least one SD assessment (or better and not qualifying\n",
      "for CR or PR) ≥ 8weeks after date of randomizationand before\n",
      "progression and the start of new antineoplastictherapy  PD =\n",
      "progression ≤ 16weeks after date of randomizationand not qualifying\n",
      "for CR, PR or SD  Not Evaluable (NE) = all other cases. For\n",
      "investigator assessments, global deterioration of health statuswill\n",
      "not be considered as documented disease progression. For patients with\n",
      "measurable soft tissue disease at baseline, objective response rate\n",
      "(ORR) will be summarizedfor the two treatment arms. The primary\n",
      "evaluation of ORR will be based on BICR overall tumor assessment. A\n",
      "secondary evaluation of ORR will be based on the investigator\n",
      "assessments using derived response based on RECIST 1.1. The frequency\n",
      "(number and proportion) of patients with best overall response of CR,\n",
      "PR, SD, Progressive Disease (PD), and NE (not-evaluable) will be\n",
      "tabulated. Patients with best overall responseof NE will be summarized\n",
      "by reason for having NE status. No adequate baseline assessment \n",
      "Early death (defined as death prior to 8 weeks after date or\n",
      "randomization)  No postbaseline assessments due to COVID-19, i.e.\n",
      "participants miss tumor assessment visits due to COVID-19 pandemic \n",
      "No postbaselineassessments due to other reasons  All\n",
      "postbaselineassessments have overall response NE  New\n",
      "antineoplastictherapy started before first postbaselineassessment  SD\n",
      "of insufficient duration (< 8 weeks after date of randomization)  PD\n",
      "too late (>16weeks after date of randomization) Special and rare cases\n",
      "where the best overall responseis NE due to both early SD and late PD\n",
      "will be classified as ‘SD of insufficient duration’. ORR by treatment\n",
      "arm will be calculated along with the two-sided 95% CIusing a Cochran–\n",
      "Mantel–Haenszel test. The difference in response rates between\n",
      "treatment arms along with bothone-sided and two-sided p-values for\n",
      "thedifference will be provided. In addition, for each DDR mutation, For patients with measurable soft tissue disease at baselinewho have an objective response\n",
      "\n",
      "6.2.2.3. Duration of Soft Tissue Response\n",
      "  For patients with measurable soft tissue disease at baselinewho have\n",
      "an objective response per RECIST 1.1, duration of soft tissue\n",
      "response(DoR) is defined as the time from the date of the first soft\n",
      "tissue response to the first documented objective evidence of\n",
      "progression (in soft tissue per RECIST 1.1 or in bone per PCWG3\n",
      "guidelines) or start of new antineoplastic therapy. Those patients who\n",
      "did not have a soft tissue response will be excluded from the\n",
      "analysis. The censoring rules for duration of soft tissue response are\n",
      "as described for rPFS in Section 6.2.1. DoR (months) = [date of event\n",
      "or censoring–first date of CR/PR +1]/30.4375. Kaplan-Meier estimates\n",
      "(product-limit estimates) will be presented by treatment arm together\n",
      "with a summary of associated statistics including the median DR time\n",
      "with two-sided 95% CIs. The CIs for the median will be calculated\n",
      "according to Brookmeyer and Crowley. Inferential statistics (e.g.\n",
      "hazard ratio and p-value) will not be provided for duration of\n",
      "response given that the analysis is performed on the responders only,\n",
      "not the ITT population. Duration of soft tissue response will be\n",
      "reported forboth the all-comers population and the DDR-deficient\n",
      "population. In addition, for each DDR mutation, DoR by treatment arm\n",
      "may also be explored if there are enough patients with the\n",
      "mutation.6.2.2.4. Proportion of Patients with PSA response ≥ 50% PSA\n",
      "response is defined as a decline from baseline PSA (ng/mL) by at least\n",
      "50%. A PSA response must be confirmed by a second consecutive value at\n",
      "least 3 weeks later. Patients without a baseline and at least one post\n",
      "baseline PSA assessment will not be analyzed for this endpoint. Only\n",
      "assessments performed from the date of randomizationuntil confirmed\n",
      "PSA progression or start of new anticancer treatment (defined as\n",
      "systemic anticancer therapy [other than study treatment], or curative\n",
      "radiotherapy where the treatment intent is specified as ‘primary\n",
      "treatment’, or surgery where the treatment intent is specified as\n",
      "‘curative in intent’ and the surgery outcome is either ‘resected’ or\n",
      "‘partially resected’), given after the first dose of study treatment\n",
      "will be considered. The percentage of patients in the ITT population\n",
      "with maximum PSA declines of at least 50% will be calculated along\n",
      "with the two-sided 95% CI. The difference in response rates between\n",
      "treatment arms along with both one-sided and two-sided p-values for\n",
      "the difference in will be providedusing a Cochran–Mantel–Haenszel test\n",
      "in summary tables. PSA (ng/mL) will also be summarized descriptively\n",
      "by visit. PSA response will be reported forboth the all-comers PSA progression is defined as the timefrom the date of randomization to the date of the first\n",
      "\n",
      "6.2.2.5. Time to PSA Progression\n",
      "  PSA progression is defined as the timefrom the date of randomization\n",
      "to the date of the first PSA value demonstrating progression, which is\n",
      "subsequently confirmed. If apatient starts a new antineoplastic\n",
      "therapy prior to PSAprogression, the patient will be censored on the\n",
      "date of last PSA assessment prior to the start of a new antineoplastic\n",
      "therapy. Patients without confirmed PSA progression will be censored\n",
      "at the date of the last PSA assessment. Patients without any post\n",
      "baseline assessments will be censored at randomization. PSA\n",
      "Progression (months) = [date of PSA progression or censoring\n",
      "–randomization date +1]/30.4375. For patients with PSA declines, the\n",
      "PSA progression date is defined as the date that a ≥ 25% increase and\n",
      "an absolute increase of ≥ 2µg/L (2ng/mL) above the nadir is\n",
      "documented, which is confirmed by a second consecutive value obtained\n",
      "at least 3weeks later. Early rises (before week 12) shouldbe ignored\n",
      "in determining progression. As such, for patients with no PSA\n",
      "declines, the PSA progression date is defined as the date that a ≥ 25%\n",
      "increase and an absolute increase of ≥ 2µg/L (2ng/mL) above the\n",
      "baseline is documented after week 12, which is confirmed by a second\n",
      "consecutive value at least 3 weeks later. PSA progression will be\n",
      "analyzedusing a one-sided stratified log-rank test. Kaplan-Meier\n",
      "estimates will be presented by treatment arm with the median and 95%\n",
      "CIs. Frequency (number and percentage) of patients with anevent\n",
      "orcensoring will be presented by treatment arm.Time to PSA progression\n",
      "will be reported forboth the all-comers population and the DDR- Time to initiation of cytotoxic chemotherapy is defined as the time from randomization to the\n",
      "\n",
      "6.2.2.6. Time to Initiation of Cytotoxic Chemotherapy\n",
      "  Time to initiation of cytotoxic chemotherapy is defined as the time\n",
      "from randomization to the first use of cytotoxic chemotherapy.\n",
      "Cytotoxic chemotherapy will be identified based on a clinical review\n",
      "of all follow-up cancer therapies reported on the follow-up therapy\n",
      "CRF page. This review will occur prior to data unblinding. Results\n",
      "will be reported in months ([date of event or censoring\n",
      "–randomization])/30.4375. Patients not starting any cytotoxic\n",
      "chemotherapywill be censored at the date of last contact. Time to\n",
      "initiation of cytotoxic chemotherapy will be analyzedusing a one-sided\n",
      "stratified log-rank test. Kaplan-Meier estimates will be presented by\n",
      "treatment arm with the median and 95% CIs. Frequency (number and\n",
      "percentage) of patients with anevent orcensoring will be presented by\n",
      "treatment arm. Time to initiation of cytotoxic chemotherapy will be\n",
      "analyzedforboth the all-comers population and the DDR-deficient Time to initiation of antineoplastic therapy is defined as the time from randomization to the\n",
      "\n",
      "6.2.2.7. Time to Initiation of Antineoplastic Therapy\n",
      "  Time to initiation of antineoplastic therapy is defined as the time\n",
      "from randomization to the first use of antineoplastic therapy. Such\n",
      "therapies include cytotoxic chemotherapy, hormonal chemotherapy, and\n",
      "investigational agents for prostate cancer. They will be identified\n",
      "based on a clinical review of all follow-up cancer therapies reported\n",
      "on the follow-up therapy CRF page. This review will occur prior to\n",
      "data unblinding. Results will be reported in months ([date of event or\n",
      "censoring –randomization])/30.4375. Patients not starting any\n",
      "antineoplastic therapy will be censored at the date of last contact.\n",
      "Time to initiation of antineoplastic chemotherapy will be\n",
      "analyzedusing a one-sided stratified log-rank test. Kaplan-Meier\n",
      "estimates will be presented by treatment arm with the median and 95%\n",
      "CIs. The results will be reported forboth the all-comers population Time to the first symptomatic skeletal event is defined as the time from randomization to the\n",
      "\n",
      "6.2.2.8. Time to First Symptomatic Skeletal Event\n",
      "  Time to the first symptomatic skeletal event is defined as the time\n",
      "from randomization to the date of the first symptomatic fracture,\n",
      "surgery to the bone, radiotherapy to the bone, or spinal cord\n",
      "compression as reported on the Skeletal Related Events CRF page.\n",
      "Patients without any symptomatic skeletal events will be censored at\n",
      "the date of the last skeletal event assessment. Analyses will be in\n",
      "months ([date of event or censoring –randomization])/30.4375.Time to\n",
      "the first symptomatic skeletal event will be analyzedusing a one-sided\n",
      "stratified log- rank test. Kaplan-Meier estimates will be presented by\n",
      "treatment arm with the median and 95% CIs. The results will be\n",
      "reported forboth the all-comers population and the DDR-deficient PFS2 is defined as the time from randomization to investigator documented disease\n",
      "\n",
      "6.2.2.9. PFS2 Based on Investigator Assessment\n",
      "  PFS2 is defined as the time from randomization to investigator\n",
      "documented disease progression (PSA progression, progression on\n",
      "imaging, or clinical progression) on the first subsequent\n",
      "antineoplastic therapy for prostate cancer, or death from any cause,\n",
      "whichever occurs first. PFS2 (months) = [date of event/censoring –date\n",
      "of randomization +1]/30.4375 A patient will be considered to have an\n",
      "event if:  date of documented progression on the first subsequent\n",
      "antineoplastic therapy is provided on follow-up cancer therapy CRF\n",
      "page; or  the patient dies. PFS2 will be analyzedusing a one-sided\n",
      "stratified log-rank test. Kaplan-Meier estimates will be presented by\n",
      "treatment arm with the median and 95% CIs. Both one-sided and two-\n",
      "sided p-values will be provided in summary tables. The censoring\n",
      "andevent date options to be considered for PFS2 along with the\n",
      "corresponding censoring reason and its hierarchy are presented inTable\n",
      "9. The frequency (number and percentage) of patients with an event and\n",
      "censoring reasons will be presented by treatment arm. Table 9.\n",
      "Outcome, Event/Censoring Dates, and Reasons for Censoring for PFS2\n",
      "Scenario Date of event/censoring Outcome/ Censoring reason/ Censoring\n",
      "hierarchy No PDa and No Death Date of last adequate Censored/ tumor\n",
      "assessmentb No PD by investigator/ documenting no PD 1 No PDa and\n",
      "Death Date of death Event (Death) PDa date > NTX1c start date Start\n",
      "date of NTX1c Censored/ and no death Start of new anticancer treatment\n",
      "before PD/ 2 PDa date > NTX1c start date Date of death Event (Death)\n",
      "and deathTable 9. Outcome, Event/Censoring Dates, and Reasons for\n",
      "Censoring for PFS2 Scenario Date of event/censoring Outcome/ Censoring\n",
      "reason/ Censoring hierarchy PDa date ≤ NTX1c start date Documented\n",
      "progression Event (Date of documented and documented progression on\n",
      "NTX1 progression on NTX1) on NTX1 PDa date ≤ NTX1c start date Date of\n",
      "death Event (Death) and no documented progression on NTX1 and death\n",
      "PDadate ≤ NTX1c start date Date of Last Contact Censored/ and no\n",
      "documented Withdraw of consent/ progression on NTX1 and 3 no death and\n",
      "the patient withdrew consent for follow-up PDa date ≤ NTX1c start date\n",
      "Date of Last Contact Censored/ and no documented Lost to follow-up/4\n",
      "progression on NTX1 and no death and the patient is lost to follow-up\n",
      "PDa date ≤ NTX1c start date Date of Last Contact Censored/ and no\n",
      "documented Ongoing without PFS2 event/ progression on NTX1 and 5 no\n",
      "death and no other conditions met a PD is the first PD while on study\n",
      "treatment by investigator assessment per RECIST v1.1 or per PCWG3,\n",
      "without considering any censoring rules. b If there is no adequate\n",
      "postbaseline assessment, then the censoring date is the date of\n",
      "randomization. If the patient has initiated next-line anticancer\n",
      "treatment, the last adequate postbaseline assessment on or prior to\n",
      "start date of next line anticancer treatment will be considered. c\n",
      "NTX1 is the first new anticancer regimen The PFS2results will be\n",
      "reported forboth the all-comers population and the DDR-deficient Time to opiate use for prostate cancer pain is defined as the time from date of randomization\n",
      "\n",
      "6.2.2.10. Time to Opiate use for Prostate Cancer Pain\n",
      "  Time to opiate use for prostate cancer pain is defined as the time\n",
      "from date of randomization to the date of the first or new opiate\n",
      "medications for prostate cancer painstarted after randomization and\n",
      "will be based on the start date of medications reported on the\n",
      "concomitant medication page of the CRF reported with a category of\n",
      "‘Opioids’. Patients without any opiate use will be censored at the\n",
      "last dose of study treatment.Time to opiate use for prostate cancer\n",
      "painwill be analyzedusing a one-sided stratified log- rank test.\n",
      "Kaplan-Meier estimates will be presented by treatment arm with the\n",
      "median and 95% CIs. The results will be reported forboth the all- All of the PRO endpoints described below will be analyzed using the PRO analysis set.\n",
      "\n",
      "6.2.3. PRO Endpoints\n",
      "  All of the PRO endpoints described below will be analyzed using the\n",
      "PRO analysis set. PRO endpoints will be analyzedforboth the all-comers Time to Deterioration in Patient-reported Pain Symptoms per BPI-SF\n",
      "\n",
      "6.2.3.1. Time to Event Endpoints\n",
      "  Time to Deterioration in Patient-reported Pain Symptoms per BPI-SF\n",
      "Patient-reported pain symptoms (per the Pain Log – BPI-SF Question 3)\n",
      "will be completed for 7 consecutive days beforeeachstudy visit. In\n",
      "addition, the BPI-SF will be completed during each study visit.Four or\n",
      "more completed BPI-SF Question 3at each visit period(i.e.\n",
      "collectively7 consecutive days prior to each study visit and during\n",
      "study visit)are required for thepain score for each time periodto be\n",
      "considered evaluable. Pain score averages during each visit period\n",
      "will be calculated and will be used for the analysis of time to\n",
      "deterioration in patient-reported pain symptoms. Analgesic use (per\n",
      "Analgesic log) is recorded for seven consecutive days prior to each\n",
      "study visit and during each study visit. The worst World Health\n",
      "Organization (WHO)analgesic usage score for each visit period (seven\n",
      "consecutive days prior to each study visit and during study visit)\n",
      "will be used. Analgesic use is scored according to WHO criteria: zero\n",
      "for no use, one for use of non-opiate analgesics (e.g., non-steroidal\n",
      "anti-inflammatory drugs, acetaminophen, antidepressants, and agents\n",
      "targeting neuropathic pain), two for use of weak opiates for moderate\n",
      "pain (e.g., codeine and tramadol), and three for strong opiates for\n",
      "severe pain (e.g., morphine and fentanyl). Time to deterioration in\n",
      "patient-reported pain symptoms per BPI-SF is assessed using the\n",
      "average pain score from the BPI-SF question 3: “Please rate your pain\n",
      "by marking the box beside the number that best describes your pain at\n",
      "its worst in the last 24 hours.” Time to this event is defined as the\n",
      "time from randomization to onset of pain progression, where pain\n",
      "progression is defined as a ≥2 point increase from baseline in the\n",
      "question 3 scorefor two consecutive visit periods at least 4 weeks\n",
      "apart without a decrease in WHO analgesic usage score. If there is a\n",
      "decrease in WHO analgesic usage score, then it will not be\n",
      "consideredas pain progression even if there is a ≥2 point increase\n",
      "from baseline in the question 3 score. Patients without observed pain\n",
      "progression at the time of analysis will be censored at the date of\n",
      "last BPI-SF assessment. Kaplan-Meier estimates will be presented\n",
      "together with a summary of associated statisticsFrequency (number and\n",
      "percentage) of patients with an event or censoring will be presented.\n",
      "Time to Definitive Deterioration in Patient-reported Global Health\n",
      "Status/QoL per EORTC QLQ-C30 Time to definitive deterioration in\n",
      "patient-reported global health status/QoL per EORTC QLQ-C30is defined\n",
      "as the time fromrandomization to the firstdefinitive deterioration\n",
      "defined as a ≥ 10-point decrease from baseline and no subsequent\n",
      "observations of a < 10-point decrease from baseline. Patients without\n",
      "a definitive deterioration at the time of analysis will be censored at\n",
      "the date of last EORTC QLQ-C30assessment. Kaplan-Meier estimates will\n",
      "be presented together with a summary of associated statistics\n",
      "including the median and quartiles with two-sided 95% CIs. Frequency\n",
      "(number and percentage) of patients with an event or censoring will be\n",
      "presented. Time to Definitive Deterioration in Patient-reported\n",
      "Disease-specific Urinary Symptoms per EORTC QLQ-PR25 Time to\n",
      "definitive deterioration in patient-reported disease-specific urinary\n",
      "symptoms per EORTC QLQ-PR25 is defined as the time fromrandomization\n",
      "to the firstdefinitive deterioration defined as a ≥ 10-point increase\n",
      "from baseline and no subsequent observations of a < 10point increase\n",
      "from baseline. Patients without a definitive deterioration at the time\n",
      "of analysis will be censored at thedate of last EORTC QLQ-PR25\n",
      "assessment. Kaplan-Meier estimates will be presented together with a\n",
      "summary of associated statistics including the median and quartiles\n",
      "with two-sided 95% CIs. Frequency (number and percentage) of patients BPI-SF\n",
      "\n",
      "6.2.3.2. DescriptiveSummaries and Change from Baseline\n",
      "  BPI-SF Descriptive summaries for BPI-SFby visit will be provided.\n",
      "These include:  For each visit period (collectively for study visit\n",
      "and the 7 consecutive days prior to each study visit), number and\n",
      "percentage of patients who completed all the BPSI-SF Question 3 out of\n",
      "a total of 8), ≥4 of the BPI-SF Question 3, and those who did not\n",
      "complete any BPI-SF Question 3 will be summarized  Descriptive\n",
      "summary of the average score at each visit period for BPI-SF Question3\n",
      "o Each pain intensity is a whole number (0 through 10) and will be\n",
      "summarized as a continuous variable o Missing values (<4 of8 possible\n",
      "assessments per visit period) are not included in the\n",
      "summariesDescriptive statistics for change from baseline in patient-\n",
      "reported pain symptoms per BPI- SF (questions 3) will be summarized\n",
      "for each visit period. A graphical display of means over time as well\n",
      "as mean changes from baseline over time will also be provided. A\n",
      "longitudinal mixed effect model will also be used to summarize the\n",
      "change from baseline pain symptoms score (BPI-SF Question 3) across\n",
      "all visit periods. Unless otherwise specified, all scheduled\n",
      "assessments will be used in the analyses, regardless of adherence to\n",
      "study treatment. EQ-5D-5L Health Index Analysis of the EQ-5D health\n",
      "index will consist of descriptive statistics on means and changes from\n",
      "baseline, overall change from baselineusing a longitudinal mixed\n",
      "effects model,and graphical displays of means and changes from\n",
      "baseline over time. In addition, there will be a health status profile\n",
      "analysis consisting of adisplay of the number and percentage of\n",
      "patients in each of the 5response levels for each ofthe 5 dimensions\n",
      "at each visit. EQ-5D General Health Status (EQ-5D VAS) Analysis of\n",
      "EQ-5D VAS will consist of descriptive statistics on means and changes\n",
      "from baseline, overall change from baselineusing a longitudinal mixed\n",
      "effects model, and graphical displays of means and changes from\n",
      "baseline over time. QLQ-C30 Analysis of the QLQ-C30will consist of\n",
      "descriptive statistics for each scale on means and changes from\n",
      "baseline, overall change from baselineusing a longitudinal mixed\n",
      "effects model,time to definitive deterioration,and graphical displays\n",
      "of means and changes from baseline over time. QLQ-PR25 Analysis of the\n",
      "QLQ-PR25 will consist of descriptive statistics for each scale on\n",
      "means andchanges from baseline, overall change from baselineusing a\n",
      "longitudinal mixed effectsmodel,time to definitive deterioration, and In Part 2, analyses of PK concentrations will include sampling at predoseand 2 hours post-\n",
      "\n",
      "6.2.4. PK\n",
      "  In Part 2, analyses of PK concentrations will include sampling at\n",
      "predoseand 2 hours post- dose at Weeks 3, 5 and 9, and pre-dose at\n",
      "Weeks 13 and 17. The PK analyses forPart 2 of the studywill be similar\n",
      "to those for Part 1 of the study. For details see Section 6.1.2.\n",
      "Separate summaries of dose-normalized C by scheduled visit trough for CTC endpoints will be analyzedseparately forboth the all-comers population and the DDR-\n",
      "\n",
      "6.2.5.1. CTC Conversion Rates\n",
      "  CTC endpoints will be analyzedseparately forboth the all-comers\n",
      "population and the DDR- deficient population. For CTC counts, a\n",
      "summary of the mean (standard deviation), median, and range of\n",
      "baseline and postbaselinevalues will be provided for patients in\n",
      "theCTC evaluable set. In addition, the number and percentage of\n",
      "patients with CTC count ≥ 5 vs. < 5 and CTC count > 0 vs. =0 per 7.5\n",
      "mL will be presented as well. For the analysis of CTC count conversion\n",
      "from 5 or more CTC per 7.5 mL at baseline to < 5 CTC per 7.5 mL post\n",
      "baseline, those patients with a CTC count < 5 per 7.5 mL at baseline\n",
      "will be excluded for this conversion endpoint. The proportion of\n",
      "patients with a conversion will be calculated along with the two-sided\n",
      "95% CIusing the Clopper-Pearson method. For the analysis of CTC count\n",
      "conversion from detectable at baseline to 0 postbaseline, those\n",
      "patients with a CTC count of 0 per 7.5 mL of blood at baseline will be\n",
      "excluded for this conversion endpoint. The proportion of patients with\n",
      "such a conversionwill be calculated along with the two-sided 95%\n",
      "CIusing the Clopper-Pearson method. For the analysis of the proportion\n",
      "of patients with baseline CTCs <5 who show increased CTCs\n",
      "postbaseline, those patients with a CTC count of ≥ 5 per 7.5 mL of\n",
      "blood at baseline will be excluded from the analysis. The proportion\n",
      "of patients with such a conversion will be calculated along with the\n",
      "two-sided 95% CIusing the Clopper-Pearson method. The results will be\n",
      "analyzed forboth the all-comers population and the DDR-deficient A separate analysis plan will be written to describe analyses of molecular profiling of tumor\n",
      "\n",
      "6.2.5.2. Molecular Profiling\n",
      "  A separate analysis plan will be written to describe analyses of The concordance of DDR deficiency results (DDR-deficient/non-deficient/unknown) will be\n",
      "\n",
      "6.2.5.3. Concordance of DDR deficiency results\n",
      "  The concordance of DDR deficiency results (DDR-deficient/non-\n",
      "deficient/unknown) will be exploredfor the following assay methods: \n",
      "Prospective tissue-based tests vs. retrospectively analyzed screening\n",
      "blood-based tests  Prospective blood-based tests vs. retrospectively Subgroup analyses will be performed if there is a sufficient sample size. The determination\n",
      "\n",
      "6.3. Subgroup Analyses\n",
      "  Subgroup analyses will be performed if there is a sufficient sample\n",
      "size. The determination of whether or not there is a sufficient\n",
      "samplesize will be defined after enrollment is completethere are ≥ 20\n",
      "patients within the defined subset and analyses of time to event\n",
      "endpoints will only be performed if there are at least 10 events on\n",
      "each treatment arm within the subgroup. Deviations from these analyses\n",
      "will be described in the clinical study report. Some of the subgroup\n",
      "analyses will be presented in the CSR, while the remaining will be\n",
      "presented in other summary documents, for example, Summary of Clinical\n",
      "Efficacy and Summary of Clinical Safety. Besides the subgroup analyses\n",
      "presented in the overview forest plots described in Section6.2.1, the\n",
      "following additional subgroup analyses will be performed for rPFS by\n",
      "BICR where the subgroups are subsets of the all-comers population: \n",
      "DDR mutational status derived using prospective/retrospective data\n",
      "(subgroup definitions 2-6in Section 5.2.7).  Renal impairment\n",
      "(moderate, mild,normal)  Race (Asian, White, African American, other)\n",
      " Prior NHT (yes, no)  Prior docetaxel (yes, no)  Baseline bone\n",
      "protecting agent (yes, no)  Baseline LDH value (< vs. ≥ median) \n",
      "Baseline hemoglobin value (< vs. ≥ median)  Baseline ALP value (< vs.\n",
      "≥ median)  Baseline CTC Count (<5, ≥ 5)  Baseline CTC Count (0, >0)\n",
      "Similarsubgroup analyses will be performed for Cohort 2. A subgroup\n",
      "analysis for OS will be performed at the time of the final OS analysis\n",
      "using the same subgroups specified above for rPFS. Subgroup analyses\n",
      "of other efficacy parameters and subgroups analyses for Part 1 data\n",
      "are not planned. Key safety outputs for Part 2 will be provided to\n",
      "explore the following subgroups:  Renal impairment (moderate vs.mild\n",
      "vs. normal),  Age (<70vs. ≥ 70),  Asian vs. non-Asian.Normal, mild,\n",
      "and moderate renal impairment are defined based on baseline eGFR of\n",
      "≥90 mL/min/1.73m2, 60-89 mL/min/1.73m2, and30-59mL/min/1.73m2\n",
      "respectively, where eGFR willbe captured on the CRFs. Key safety\n",
      "outputs for Part 1 will be provided by startingdose. Additionally\n",
      "adverse events listings will consider the dose at the time of the Unless otherwise specified,the following summaries will be provided separately for the\n",
      "\n",
      "6.4. Baseline and Other Summaries\n",
      "  Unless otherwise specified,the following summaries will be provided\n",
      "separately for the safety analysis set of Part 1 and for the ITT all-\n",
      "comers and DDR-deficient populations in Part 2. For Part 1, select Thefollowingdemographic andbaselinedisease characteristicswill besummarized:\n",
      "\n",
      "6.4.1. Baseline Summaries\n",
      "  Thefollowingdemographic andbaselinedisease characteristicswill\n",
      "besummarized:  Age(continuous and by groups: <65; 65-<75; >=75) \n",
      "Race  Asian vs. non-Asian  Weight  Body Mass Index (BMI) \n",
      "Geographic region(NorthAmerica,Europe, Asia, Rest of World)  Renal\n",
      "impairment at baseline (Normal, Mild, Moderate), o normal, mild, and\n",
      "moderate are defined based on baseline baseline eGFR of ≥90\n",
      "mL/min/1.73m2, 60-89 mL/min/1.73m2, and 30-59mL/min/1.73m2,\n",
      "respectively,  Histopathological classification  Baseline serum PSA\n",
      "(ng/mL)  Baseline useof aboneprotecting agent (yes, no)  Gleason\n",
      "score(low [2-4], medium [5-7], high [8-10])  Gleason score (<=6,\n",
      "3+4=7, 4+3=7, 8, 9-10, not reported)  ECOGperformance status  TNM\n",
      "stageat diagnosis  TNM stage at study entry  Disease localization at\n",
      "screening: o Bone only o Soft tissue only o Both bone and soft tissue\n",
      "o None Distribution of disease at screening: o Bone (includes bone\n",
      "with soft tissue component) o Lymph Node o Visceral Disease (lung or\n",
      "liver) o Visceral disease (lung) o Visceral disease (liver) o Other\n",
      "Soft Tissue  Number of bone metastases at screening: n (%) o 0 o 1-4\n",
      "o 5-9 o 10-20 o >20  Type of progression at study entry: o PSA\n",
      "progression only o Bone progression only o Soft tissue progression\n",
      "only o PSA+ bone or soft tissue o Bone+ PSA or soft tissue o\n",
      "PSA+bone+soft tissue  Baselinepain score by BP-SF (0-1; 2-3; >3), \n",
      "Baseline CTC count o Continuous summary o Categorical summary (≥ 5 CTC\n",
      "per 7.5 mL of blood, <5 CTC per 7.5 mL of blood) o Categorical summary\n",
      "(>0 CTC per 7.5 mL of blood, 0 CTC per 7.5 mL of blood)  Time from\n",
      "primary diagnosis to randomization in months (date of randomization –\n",
      "date of diagnosis)/30.4375  Derived DDR mutational status (positive,\n",
      "negative, unknown) with specific mutations prior to randomization \n",
      "DDR mutational status (positive, negative, unknown) with specific\n",
      "mutations based on blood samples only  DDR mutational status\n",
      "(positive, negative, unknown) with specific mutationsbased on tumor\n",
      "tissue samples onlyThe number of patients in the following categories\n",
      "at the time of randomization will be summarized:  Prior NHT orTaxane\n",
      "and DDR-deficient  Prior NHT or Taxane and non DDR-deficient/unknown\n",
      " No Prior NHT orTaxane and DDR-deficient  No Prior NHT or Taxane and\n",
      "non DDR-deficient/unknown A listing will be provided with the strata\n",
      "(defined above) at the time of randomization as well as based on CRF\n",
      "data with a flag to indicate cases where there are differences between Medical history will be coded using the most current version of MedDRA and summarized\n",
      "\n",
      "6.4.2. Medical History\n",
      "  Medical history will be coded using the most current version of\n",
      "MedDRA and summarized by MedDRA’s SOC and PT. Each patient will be\n",
      "counted only once within each PT or SOC. Summaries will be ordered by\n",
      "primary SOC and PT in descending order of frequency by the\n",
      "experimental treatment arm. Summaries will be provided for all Prior anticancertreatments include systemic therapy, radiation, and surgery.\n",
      "\n",
      "6.4.3. Prior AnticancerTreatments\n",
      "  Prior anticancertreatments include systemic therapy, radiation, and\n",
      "surgery. The number and percentage of patients in each of the\n",
      "following anticancer therapy categories will be tabulated:  Patients\n",
      "with at least one type of prior anticancer systemic treatment\n",
      "including androgen deprivation therapy;  Patients with at least one\n",
      "prior anticancer surgery;  Patients with at least one prior\n",
      "anticancer radiotherapywith “primary treatment”and “salvage” intent; \n",
      "Patients with any prior androgen deprivation therapy. Prior anticancer\n",
      "drug therapy will be summarized as follows based on the number and\n",
      "percentage of patients: o Number of prior anticancer therapy regimens\n",
      "(including androgen deprivation therapy): None/ 1 / 2 / ≥3. The prior\n",
      "anticancerdrugs will be coded in the WHO Drug coding dictionary and\n",
      "will be summarized usingthe number and percentage of patients by\n",
      "preferred term. A patient will be counted only once fora given\n",
      "preferred term, even if he/she received the same medication\n",
      "atcombination with enzalutamidearm. In case of equal frequency,\n",
      "alphabetical order will be used. A summary of the number of patients\n",
      "with the followingprior cancersurgeries will be provided: \n",
      "Prostatectomy,  TURP,  Prostate Biopsy,  Bilateral Orchiectomy, \n",
      "Pelvic Node Dissection,  Ureteral Stent,  Nephrostomy. Specific\n",
      "details on all other surgeries and radiotherapy(primary treatment and Discontinuations from study treatment due to adverse events will be identified as either\n",
      "\n",
      "6.4.4. Study Conduct and Patient Disposition\n",
      "  Discontinuations from study treatment due to adverse events will be\n",
      "identified as either related or not related to study treatment. If\n",
      "causality is missing the event will be considered related to\n",
      "treatment. If multiple events lead to study treatment discontinuation\n",
      "and at least one was considered related, discontinuation will be\n",
      "reported as related to study treatment. COVID-19 Related Disposition\n",
      "Alisting of all patientsaffectedbyCOVID-19will be created. The listing\n",
      "will present subject number identifier byinvestigational site, and a\n",
      "description of COVID-19-related events including:  All protocol Important protocol deviations will be compiled prior to database release and will be\n",
      "\n",
      "6.4.5. Protocol Deviations\n",
      "  Important protocol deviations will be compiled prior to database\n",
      "release and will be summarized by category (n(%)) using the safety\n",
      "population for Part 1 andthe ITT population forPart 2.Categories will\n",
      "be assigned by the study team. In addition, all protocol deviations\n",
      "related to COVID-19 will be presented in a separate listing.6.4.6.\n",
      "Study Treatment Exposure Exposure summaries will be presented using\n",
      "the safety analysis set for each part. Part 1 patients hada starting\n",
      "talazoparib dose of either 1 mg/day or 0.5 mg/dayin combination\n",
      "withenzalutamide 160 mg/day,depending on timing of enrollment. The\n",
      "Part 1 data will be presented separately by the starting talazoparib\n",
      "dose. For part 2, thedailydose of talazoparibis 0.5\n",
      "mg/daygivenorallyin combination with enzalutamide 160 mg/dayat\n",
      "approximatelythesametimeeach day for patients with normal/mild renal\n",
      "impairment. Thestartingtalazoparib dosewill be 0.35mg/dayin\n",
      "combination withenzalutamide 160 mg/dayforpatients with moderaterenal\n",
      "impairment (eGFR 30-59mL/min/1.73m2). Separate summaries will be\n",
      "provided for talazoparib and enzalutamide and will include the\n",
      "following:  Treatment duration (months):\n",
      "Foreachpatient,treatmentdurationis definedas (date of last dose–dateof\n",
      "first dose +1) / 30.4375. Treatment duration will be summarizedboth as\n",
      "a continuous measureandacategorical measure(≤ 3 months, 3 to <6\n",
      "months, 6 to <12 months, ≥ 12 months).  Average dailydose(mg/day):\n",
      "Theaveragedailydoseis definedas the cumulative dosedividedbythe actual\n",
      "number of days on the treatment.  Dose intensity(mg/week):\n",
      "Doseintensity is definedas the cumulativedose dividedbythe treatment\n",
      "duration.  Relative dose intensity (%): Relative dose intensity is\n",
      "defined as the ratio of the actual dose intensity to the planned dose\n",
      "intensity expressed in %. The planned dose intensity will be 3.5 mg\n",
      "(0.5 mg per day for 7 days) for patients without moderate renal\n",
      "impairment and 2.45 mg (0.35 mg per day for 7 days) for patients with\n",
      "moderate renal impairment. RDI (%) = 100x[dose intensity\n",
      "(mg/week)]/[planned dose intensity(mg/week)]. A dose reduction is\n",
      "defined as a non-zero dose that is less than the prior dose.The number\n",
      "andpercentage of patients with at least one dose reductionas well as a\n",
      "breakdown of dose reductions (1 / 2 / 3) will be summarized by\n",
      "treatment arm. Reasons for dose reductions will also be summarized.\n",
      "There could be more than one reason if multiple dose reductions occur\n",
      "forthe same patient,though each reason will be counted only once for\n",
      "each patient. Percentages will be calculated based on the total number\n",
      "of patients in safety analysis set. An dosing interruption is defined\n",
      "a 0mg dose administered. (Note: A dosinginterruption is not considered\n",
      "a dose reduction). The number and percentage of patients with dosing\n",
      "interruptions and the corresponding reasons will be summarized by\n",
      "treatment arm. There could be more than one reasonif multiple\n",
      "dosinginterruption occur forthe same patient,though each reason will\n",
      "be counted only once for each patient. Percentages will be calculated\n",
      "based on the total number of patients in safety analysis set. Time to\n",
      "first interruption (weeks) and time to first reduction (weeks),\n",
      "measured from the date of first dose of study treatment, will be\n",
      "summarized for patients who had at least one interruption or reduction\n",
      "respectively. A summary of duration (days) of dosinginterruptions due\n",
      "to any AEs and for anemia only for each dosinginterruption will be\n",
      "provided,where ‘n’ is the number of dosing interruptions. Apatient can\n",
      "contribute multiple observations, one for each interruption. A summary\n",
      "of the total duration (days) of dosinginterruptions due to AEs for Concomitant medications refer to all medications thatstarted or were ongoing at the time of\n",
      "\n",
      "6.4.7. Concomitant Medications\n",
      "  Concomitant medications refer to all medications thatstarted or were\n",
      "ongoing at the time of randomization , started after randomization and\n",
      "continued during the on-treatment period for up to 28 days after the\n",
      "last dose of all the study treatments as well as those started during\n",
      "the on-treatment period. Concomitant medications will be coded in the\n",
      "WHO Drug coding dictionary and will be tabulated by Anatomical\n",
      "Therapeutic Chemical (ATC) Classification level 2 and preferred term\n",
      "in descending order of frequencyfor the talazoparib in combination\n",
      "with enzalutamidearm. In case of equal frequency regarding drug class\n",
      "(respectively drug name), alphabetical order will be used. A patient\n",
      "will be counted only once fora given drug name, even if he/she\n",
      "received the same medication multiple times. Concomitant non-drug\n",
      "treatments refer to non-drug treatments (radiation and surgery)\n",
      "administered during the on-treatment period. Non-drug treatments will\n",
      "be coded in MedDRA and will be summarized by MedDRA SOC and PT in\n",
      "descending order of frequencyon the talazoparib in combination with\n",
      "enzalutamidearm. Patients will be counted only once per PT even if\n",
      "he/she received the same treatment multiple times. Concomitant\n",
      "medications and non-drug treatments will be summarized by treatment\n",
      "arm for the Part 1 and Part 2 safety populations. Concomitant Subsequent systemic anticancertherapies are defined as therapies collectedon the ‘Follow-\n",
      "\n",
      "6.4.8. Subsequent AnticancerTherapies/Procedures\n",
      "  Subsequent systemic anticancertherapies are defined as therapies\n",
      "collectedon the ‘Follow- up Cancer Therapy’ CRF page. Subsequent\n",
      "anticancer procedures include procedures collected on‘Follow-up\n",
      "Radiation Therapy’marked as curativeor salvage, and ‘Follow-up\n",
      "Surgery’ CRF pages where the date is on or after the date of first\n",
      "dose of study treatment. The number and percentage of patients within\n",
      "each category (medication therapy, radiation therapy, and surgeries)\n",
      "will be provided by treatment arm for thePart 2 ITT Population.\n",
      "Subsequent anticancertherapies and procedures will be listed for Part\n",
      "1 and Part 2. Medications will be coded using the WHO Drug coding\n",
      "dictionary and will be tabulated by preferred term in descending order\n",
      "of frequency.6.5. Safety Summaries and Analyses Unless otherwise\n",
      "specified, summaries of AEs and other safety parameters will provided\n",
      "separately for Part 1 and Part 2 and will be based on the safety\n",
      "population. For Part 1 the data will be analyzed by the starting dose\n",
      "of talazoparib. For Part 2 as it is anticipated that follow-up for the\n",
      "primary endpoint in the DDR-deficient population will be ongoing (i.e.\n",
      "treatment assignment will still be blinded) at the time of the final\n",
      "analysis of rPFS in the all- comers population, summaries will\n",
      "initially be performed only for the all-comers population. At the time\n",
      "of the final rPFS analysis in the DDR-deficient population safety data\n",
      "will be summarized for the combined populations of all-comers and DDR- All analyses will be based on treatment-emergent events unless otherwise specified. AEs not\n",
      "\n",
      "6.5.1. Adverse Events\n",
      "  All analyses will be based on treatment-emergent events unless\n",
      "otherwise specified. AEs not considered treatment-emergent will be\n",
      "flagged in data listings. For Part 1 and Part 2 separately, ahigh-\n",
      "level summary of adverse events will include the number and percent of\n",
      "patients with:  Any AE;  Serious AE;  CTCAE Grade 3-4 AEs;  Grade\n",
      "5 AEs;  AEs leading to dose reductions of talazoparib/placebo;  AEs\n",
      "leading to dose reductions of enzalutamide;  AEs leading to dose\n",
      "reductions of both talazoparib/placebo and enzalutamide;  AEs leading\n",
      "to dosinginterruptions of talazoparib/placebo;  AEs leading to\n",
      "dosinginterruptions of enzalutamide;  AEs leading to dosing\n",
      "interruptions of both talazoparib/placebo and enzalutamide;  AEs\n",
      "leading to permanent discontinuationof talazoparib/placebo;  AEs\n",
      "leading to permanent discontinuationof enzalutamide;  AEs leading to\n",
      "permanent discontinuation of both talazoparib/placebo and\n",
      "enzalutamide. Seriousness, toxicity grade, action taken (interruption,\n",
      "reduction, and withdraw) are as reported by the investigator on the\n",
      "adverse event CRF. Summaries SOC and PT by treatment arm in decreasing\n",
      "frequency will be provided for:  Treatment-Emergent AEs (All\n",
      "Causality); Treatment-Emergent AEs by Maximum CTCAEGrade (All\n",
      "Causality);  Treatment-emergent COVID-19 related AEs (all causality);\n",
      " Treatment-Emergent AEs (Treatment Related);  Treatmen -Emergent AEs\n",
      "by Maximum CTCAE Grade (Treatment Related);  Serious Treatment-\n",
      "Emergent AEs (All Causality);  Serious Treatment-Emergent AEs\n",
      "(Treatment Related); An AEwill be considered treatment related if the\n",
      "investigator considered the event related to one or both of study\n",
      "drugs given in combination. The following summaries of AEs will be\n",
      "provided by decreasing frequency of PT (summaries will not include\n",
      "SOC) in the talazoparib plus enzalutamidearm for Part 2 only: \n",
      "Treatment-Emergent AEs (All Causality) in either treatment arm; \n",
      "Treatment-Emergent AEs (All Causality) by Preferred Term and Maximum\n",
      "CTCAE Grade;  Treatment-Emergent AEs Leading to Dosing Interruptions\n",
      "of Talazoparib(All Causality);  Treatment-Emergent AEs Leading to\n",
      "Dosing Interruptions of Enzalutamide (All Causality);  Treatment-\n",
      "Emergent AEs Leading to Dosing Interruptions of BothTalazoparib and\n",
      "Enzalutamide (All Causality);  Treatment Emergent AEs Leading to Dose\n",
      "Reductions of Talazoparib(All Causality);  Treatment Emergent\n",
      "AEsLeading to Dose Reductions of Enzalutamide (All Causality); \n",
      "Treatment Emergent AEsLeading to Dose Reductions of Both Talazoparib\n",
      "and Enzalutamide (All Causality);  Treatment Emergent AEs Leading to\n",
      "Permanent Withdraw of Talazoparib (All Causality);  Treatment\n",
      "Emergent AEs Leading to Permanent Withdraw of Enzalutamide(All\n",
      "Causality);  Treatment Emergent AEs Leading to Permanent Withdraw of\n",
      "Both Talazopariband Enzalutamide(All Causality);  Treatment Emergent\n",
      "AEs between DDR-deficient patients and non-deficient patients (All\n",
      "Causality);  Treamtment emergent AE between normal/mild vesusmoderate\n",
      "renal impareiment (All Causality) Serious Treatment Emergent AEs\n",
      "(Treatment related). Each patient will be counted only once within\n",
      "each SOC and PT. If a patient has events with missing and non-missing\n",
      "toxicity grades, the maximum non- missing grade will be displayed.\n",
      "Missing grade will only be displayed in the event that only one AEhas\n",
      "been reported for a patient and the grade is missing. Summaries of\n",
      "time to first Grade 3 or 4 event and time to first SAE will also be\n",
      "providedfor the safety populations in Part 2. Patients without an\n",
      "event will be censored as follows:  if the patient has discontinued\n",
      "from study treatment the patient will be censored 28 days afterthe\n",
      "last dose of studytreatment,or before systemic anticancer therapy,\n",
      "whicheveroccurs first, and  if the patient is still on study\n",
      "treatment at the time of analysis the patient will be censored at the See section 3.4.1for a list of AEs of Special Interest.\n",
      "\n",
      "6.5.2. Adverse Events of Special Interest\n",
      "  See section 3.4.1for a list of AEs of Special Interest. For\n",
      "Talazoparib AESIs, separate summaries for each AESI will be provided\n",
      "by maximum toxicity and will include an ‘any event’ row along with a\n",
      "row for each contributing PT in descending order of frequency. Given\n",
      "the observed incidence of hematologic toxicities associated with the\n",
      "use of talazoparib, a summary of hematologic AEs will be provided\n",
      "toshow the incidence of the following cluster terms:  ANEMIA:\n",
      "anaemia, decreased hemoglobin, decreased hematocrit, red blood cell\n",
      "count decreased  NEUTROPENIA: neutropenia and decreased neutrophil\n",
      "count  THROMBOCYTOPENIA: thrombocytopenia and platelet count\n",
      "decreased  LEUKOPENIA: leukopenia or white blood cell count decreased\n",
      " LYMPHOPENIA: lymphopenia or lymphocyte count decreased AESIs for\n",
      "enzalutamide will be summazried by medical event only,not by The frequency (number and percentage) of patients in the safety populationwho died anddeath, will be tabulated based on information from the ‘Notice of Death’ and ‘Survival\n",
      "\n",
      "6.5.3. Deaths\n",
      "  The frequency (number and percentage) of patients in the safety\n",
      "populationwho died anddeath, will be tabulated based on information\n",
      "from the ‘Notice of Death’ and ‘Survival Follow-Up’ CRFs. Date and\n",
      "cause of death will be provided in individual patient data listings\n",
      "with selected dosing information (study treatment received, date of\n",
      "first / last administration, dose, etc.). In addition, if there are ≥\n",
      "10deaths due to COVID-19, a separate death summary will be createdfor Laboratory results will be converted to International System of Units (Système International\n",
      "\n",
      "6.5.4. Laboratory Data\n",
      "  Laboratory results will be converted to International System of Units\n",
      "(Système International d'unités, SI) units for reporting. Quantitative\n",
      "data will be summarized using descriptive statistics (mean, standard\n",
      "deviation, median, quartiles, minimum, and maximum) of actual values\n",
      "and change from baseline for each visit over time (i.e. unscheduled\n",
      "assessments will be excluded). The total number of patients for change\n",
      "from baseline will include all patients who have botha baseline and a\n",
      "value at the postbaseline visit. Baseline will be defined as the last\n",
      "assessment performed on or prior to date of the first dose of study\n",
      "treatment (or prior to randomization for randomized patients). If\n",
      "there are multiple assessments that meet the baseline definition on\n",
      "the same day without the ability to determine which was truly last,\n",
      "then the worst grade will be assigned as the baseline grade. Results\n",
      "collected as strict inequalities (e.g., >10, <10) will be converted to\n",
      "numeric values subtracting a factor of 0.001. Expressions of the form”\n",
      "≥” or “≤” will be converted to the end point. These numeric values\n",
      "will be evaluated for clinically significant abnormalities, but will\n",
      "not be included in calculations of summary statistics. Additionally,\n",
      "laboratory results will be programmatically classified accordingto\n",
      "NCI- CTCAE version 4.03. Non-numerical qualifiers will not be taken\n",
      "into consideration in the derivation of grade (e.g. hypokalemia Grade\n",
      "1 and Grade 2 are only distinguished by a non- numerical qualifier and\n",
      "therefore Grade 2 will not be derived). In summary statistics the\n",
      "number and percentage of patients corresponding to grades that only\n",
      "include non-quantitative criteria will be displayed as a blank or NA\n",
      "(not assessed) rather than 0. If there is any overlap between grade\n",
      "criteria (e.g. CTCAE gradingcriteria for Creatinine Increased –a value\n",
      "can fall into one range based on comparison to upper limit of normal\n",
      "(ULN) and another range based on comparison to baseline), the highest\n",
      "(worst) grade would be assigned to that record. Grade 5 is defined in\n",
      "the CTCAE criteria guidance as an event with an outcome of death.\n",
      "Since laboratory data does not collect an outcome, Grade 5 is not used\n",
      "when programmatically grading laboratory data. Grade 0 or Outside\n",
      "Toxicity Reference (OTR) is not defined specifically byin the CTCAE\n",
      "guidance. However, programmatically this is used as a category to\n",
      "represent those patients who did not meet any of the Grades 1 to 4\n",
      "criteria. If the laboratory value is evaluable for CTCAE criteria\n",
      "grading (numeric value is present, valid units and ranges are present\n",
      "asthe Grade 1-4 criteria for a given laboratorytest, then the value is\n",
      "assigned as Grade 0 or OTR. Abnormalities will be described using the\n",
      "worst grade by scheduled timepoint and overall. Worst grade by\n",
      "scheduled timepoint will be determined using only local laboratory\n",
      "results. Worst overall grade will be determined using both central and\n",
      "local laboratory results from scheduled and unscheduled visits.\n",
      "Several laboratory tests have bi-directional grading criteria defined\n",
      "so that both low (hypo) and high (hyper) values can be graded\n",
      "separately. Each criterion will be summarized separately. In the cases\n",
      "where a value is graded as a Grade 1, 2, 3, or 4 for one of the\n",
      "directions, that value will also be assigned as a Grade 0 for the\n",
      "opposite direction for that test. For example, a value meeting the\n",
      "criteria for Grade 3 Hypercalcemia will be classified as a Grade 0\n",
      "Hypocalcemia. For CTCAE terms that can be derived using one of several\n",
      "laboratory tests, the maximum postbaselinegrade for a given patient\n",
      "and CTCAE term will be the maximum across all possible laboratory\n",
      "tests. Additional laboratory results that are not part of NCI-CTCAE\n",
      "will be presented according to the following categories by scheduled\n",
      "timepoint as well as overall: below normal limit, within normal\n",
      "limits, and above normal limits. In the unlikely event that for a\n",
      "given patient, clinically significant abnormalities are noted in both\n",
      "directions (e.g., > ULNand< Lower Limit of Normal (LLN)), then both\n",
      "abnormalities are counted.Summaries at scheduled timepoints will\n",
      "consider only central laboratory data; however summaries overall will\n",
      "consider both central and local laboratory data. Liver function tests:\n",
      "Alanine aminotransferase (ALT), aspartate aminotransferase (AST),\n",
      "Alkaline Phosphatase (ALP),and total bilirubin (TBILI) are used to\n",
      "assess possible drug induced liver toxicity. The ratios of test result\n",
      "over the ULNwill be calculated and classified for these three\n",
      "parameters during the on-treatment period. Summaries of liver function\n",
      "tests will include the following categories. The number and percentage\n",
      "of patients with each of the following during the on-treatment period\n",
      "will be summarized by treatment arm:  ALT ≥ 3×ULN, ALT ≥ 5xULN, ALT ≥\n",
      "10×ULN, ALT ≥ 20×ULN  AST ≥ 3×ULN, AST ≥ 5xULN, AST ≥ 10×ULN, AST ≥\n",
      "20×ULN  (ALT or AST) ≥ 3×ULN, (ALT or AST) ≥ 5×ULN, (ALT or AST) ≥\n",
      "10×ULN, (ALT or AST) ≥ 20×ULN  TBILI ≥ 2×ULN  Concurrent ALT ≥ 3×ULN\n",
      "and TBILI ≥ 2×ULN  Concurrent AST ≥ 3×ULN and TBILI ≥ 2×ULN \n",
      "Concurrent (ALT or AST) ≥ 3×ULN and TBILI ≥ 2×ULN Concurrent (ALT or\n",
      "AST) ≥ 3×ULN and TBILI ≥ 2×ULN and ALP ≤ 2×ULN or missing Concurrent\n",
      "measurements are those occurring on the same date. Categories will be\n",
      "cumulative, i.e., a patient with an elevation of AST ≥10×ULN will also\n",
      "appear in the categories ≥5×ULN and ≥3×ULN. Liver function elevation\n",
      "and possible Hy’s Law cases will be summarized using frequency counts\n",
      "and percentages. An evaluation of Drug-Induced Serious Hepatotoxicity\n",
      "(eDISH) plot will also be created, with different symbols for\n",
      "different treatment arms, by graphically displaying  peak serum\n",
      "ALT(/ULN) vs peak total bilirubin (/ULN) including reference lines at\n",
      "ALT=3×ULN and total bilirubin=2×ULN.  peak serum AST(/ULN) vs peak\n",
      "total bilirubin (/ULN) including reference lines at AST=3×ULN and\n",
      "total bilirubin=2×ULN. In addition, a listing of all TBILI, ALT, AST\n",
      "and ALP values for patients with a postbaseline TBILI ≥ 2×ULN, ALT≥ Systolicanddiastolic blood pressure (mmHg),heart rate (bpm), and temperature (Celsius)\n",
      "\n",
      "6.5.5. Vital Signs\n",
      "  Systolicanddiastolic blood pressure (mmHg),heart rate (bpm), and\n",
      "temperature (Celsius) will besummarizedat baseline andat all\n",
      "subsequent scheduledtimepoints. Changes from baseline valuewill\n",
      "bepresentedfor all scheduledtime points. All recorded vital signdata\n",
      "will belistedfor Parts 1 and 2. Thenumberandpercentage ofpatients with\n",
      "thefollowingvital signchanges will be presented.The definitions of\n",
      "potentiallyclinicallysignificant abnormalitiesareshown in Table 10.\n",
      "Table 10. PotentiallyClinicallySignificantAbnormalitiesinVitalSigns\n",
      "Parameter CriteriaforPotentiallyClinicallySignificantAbnormalities\n",
      "Systolicbloodpressure Absoluteresult> 180 mmHg andincrease from\n",
      "baseline ≥40 mmHg Absoluteresult< 90 mmHg and decrease from baseline\n",
      ">30 mmHg Diastolic bloodpressure Absoluteresult> 110 mmHg andincrease\n",
      "from baseline ≥30 mmHg Absoluteresult< 50 mmHg and decrease from\n",
      "baseline >20 mmHg ≥ 20 mm HG increase from baseline Heart Rate\n",
      "Absolute result > 120 bpm and increase from baseline > 30 bpm Absolute\n",
      "result < 50 bpm and decrease from baseline >20 bpmTable 10.\n",
      "PotentiallyClinicallySignificantAbnormalitiesinVitalSigns Parameter\n",
      "CriteriaforPotentiallyClinicallySignificantAbnormalities Weight >10%\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "tagged_text = tag_text_with_values(domain_type, extracted_sec1)\n",
    "\n",
    "# Print the tagged text\n",
    "print(tagged_text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pickle\n",
    "import spacy"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "nlp = pickle.load(open('C:/Users/SRIVAA86/OneDrive - Pfizer/Desktop/NLP/ner_nlp_70_30_10_New_oversample.pkl','rb'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "from nltk.tokenize import sent_tokenize\n",
    "import nltk\n",
    "from nltk.stem import WordNetLemmatizer\n",
    "\n",
    "lemmatizer = WordNetLemmatizer()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Anaconda3\\lib\\site-packages\\spacy\\displacy\\__init__.py:215: UserWarning: [W006] No entities to visualize found in Doc object. If this is surprising to you, make sure the Doc was processed using a model that supports named entity recognition, and check the `doc.ents` property manually if necessary.\n",
      "  warnings.warn(Warnings.W006)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">6.1 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">part 1 analysis 6.1.1 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">primary endpoint target safety event specified intable 4will be evaluated in the part 1 safety analysisset .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    table\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " 4 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">target safety event : part 1 ( open- label treatment ) hematologic toxicity any of the following considered possibly or probably related to talazoparib :  grade 4 anemia  grade 4 thrombocytopenia  grade 4 neutropenia ( anc &lt; 500/µl or &lt; 0.5 × 109/l )  grade 3 thrombocytopenia associated with clinically significant bleeding  grade 3 neutropenia or grade 3 thrombocytopenia if daily dosing is interrupted for 7days  febrile neutropenia , defined a anc &lt; 1000/µlwith a single temperature of &gt; 38.3c ( &gt; 101f ) or a temperature of &gt; 38c ( 100.4f ) sustained over a 1-hour period  neutropenic infection ( anc &lt; 1000/µl or &lt; 1.0 × 109/l ) nonhematologic toxicity any grade 3 adverse eventconsidered possibly or probably related to talazoparib excluding the following :  grade 3 laboratory abnormality not considered clinically significant  grade 3 adverse event not considered clinically significant  grade 3 nausea or vomiting that responds to medical intervention within 72hours  grade 3 diarrhea that can be medically managed to grade 2 within 72hours  grade 3 fatigue that improves to grade 2 within 7 day liver toxicity any of the following considered possibly or probably related to talazoparib :  alt or ast &gt; 3× ulnif baseline alt or ast 3×uln  alt or ast &gt; 5×uln ( a lower threshold should be considered if the alt or ast abnormality are accompanied by symptom and sign of hepatitis ) and 2-fold increase above baseline  alt or ast 3×uln and total bilirubin ≥2×uln  total bilirubin &gt; 5×uln toxicity will be classified by severity according to the national cancer institute common terminology criterion for adverse event , version 4 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">a the targeted safety event defined above include some subjective criterion or multiple criterion occurring simultaneously , an assessment of whether or not event met the criterion of being target safety event requiring a reduction in the starting dose for part 2 will be made based on a review of individual patient data , summary of all aes , and exposure.6.1.2 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">secondary endpoint [ pharmacokinetics ] a record-level dataset pharmacokinetic analysis set -talazoparib will includeall talazoparib pk concentration that meet thecriteria below :  pk sample collected at week1  pk sample collected at week 5 , 9 , 13 , and 17 at the same dose level without any dose modification for at least 14 day .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">another record-level dataset pharmacokinetic analysis set -enzalutamidewill includeall enzalutamideconcentrationsthat meet the criterion below :  pk sample collected at week 1  pk sample collected at week 5 , 9 , 13 , and 17 for patient who did not experience any dose reduction or interruption of enzalutamide .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">pharmacokinetic analysis set –talazopariband pharmacokinetic analysis set – enzalutamide will be used for pk parameter derivation and in part 1 , analysis of pk concentration will include sampling at predose , 1 , 2 , 4 , 6 and 24 6.1.2.1 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">pk concentration in part 1 , analysis of pk concentration will include sampling at predose , 1 , 2 , 4 , 6 and 24 hour postdoseat day 1 ( week 1 ) and week 9 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">additionally , blood sample for pk are collected at predoseand 2 hour postdoseat week 5 and predose at week 13 and 17 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">all planned individual patient ’ plasma concentration data will be \n",
       "<mark class=\"entity\" style=\"background: cyan; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    listed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_L</span>\n",
       "</mark>\n",
       " ( pharmacokinetic population ) .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">pk sample obtained beyond 10 % of the planned time will be included in the \n",
       "<mark class=\"entity\" style=\"background: cyan; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    listing\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_L</span>\n",
       "</mark>\n",
       " and could be included in the calculation of pk parameter ( based on discretion of the pharmacokineticist ) , however , will be removed from \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    figure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_F</span>\n",
       "</mark>\n",
       " and table reporting mean concentration per planned sampling time .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">predosepksample collection should occur prior to administration of the investigational product on that day , otherwise will be excluded .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">in all data presentation ( except \n",
       "<mark class=\"entity\" style=\"background: cyan; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    listing\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_L</span>\n",
       "</mark>\n",
       " ) , value below the limit of the assay quantification ( blq ) will be set to zero .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">in \n",
       "<mark class=\"entity\" style=\"background: cyan; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    listing\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_L</span>\n",
       "</mark>\n",
       " blq value will be reported a “ &lt; llq ” , where llq will be replaced with the value for the lower limit of quantification .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">summarystatisticswill beprovidedforplasmaconcentrations of talazopariband enzalutamide and it n-desmethyl metabolite at scheduled visit by time point ( using the pk analysis set for talazoparib or enzalutamide , see section6.1.2 ) .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">plasma concentration value below the limit of quantitation will be treated a zero in the descriptive statistic calculation .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">zero concentration will be considered a missing in geometric mean calculation .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">spaghetti \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    plot\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_F</span>\n",
       "</mark>\n",
       " of individual concentration against actual time postdose ( separate \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    plot\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_F</span>\n",
       "</mark>\n",
       " for each in estimating the pk parameter , blq value at the beginning of the profile will be set toare embedded between blqs , or quantifiable value occurring after two or more blqs , may 6.1.2.2 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">pk parameter in estimating the pk parameter , blq value at the beginning of the profile will be set toare embedded between blqs , or quantifiable value occurring after two or more blqs , may be set to missing at the discretion of the pharmacokineticist .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">actual sampling time , rather than scheduled sampling time , will be used in all computation involving sampling time .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">if the actual time or dose time is missing , the scheduled time may be substituted in order to calculate the pk parameter .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">a appropriate , additional pk parameter may be calculated and reported .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the following pk parameter of talazoparib and enzalutamide and it ndesmethyl metabolite will be summarized usingthe pharmacokinetic population ( specifically using the record-level set called pk analysis set –talazoparib and pk analysis set –enzalutamide ) a appropriate : c , c , t , auc , and cl /f will be summarized by dose and study visit .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">max trough max  s dose-normalized auc , c , and c will be summarized by study visit .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"> max trough the above mentioned pk parameter ( t excluded ) will be summarized by arithmetic max mean , standard deviation and cv , geometric mean , geometric cv , minimum , median , maximum value and the number of evaluable parameter .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the pk characteristic of t will max be described utilizing the number of observation , minimum , maximum and median .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">geometric cv % is defined a sqrt ( exp ( variance of log transformed data ) -1 ) *100 in addition , box and whisker \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    plot\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_F</span>\n",
       "</mark>\n",
       " for individual patient parameter auc , c , and c  max trough by dose and scheduled visit a well a for dose-normalized auc , c , and c by  max trough scheduled visit maybe be presented and overlaid with geometric mean .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">for all presentation , pk data from part 1 and part 2 will be pooled .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">however , separate summary of pk parameter including auc , c , and c by dose level and scheduled  max trough visit in addition to summary of dose-normalized auc , c , and c by scheduled visit  max trough will be \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    generated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_F</span>\n",
       "</mark>\n",
       " for patient in for ctc count , a summary of the mean ( standard deviation ) , median , and range of 6.1.3 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">exploratory endpoint for ctc count , a summary of the mean ( standard deviation ) , median , and range of baseline and postbaselinevalues will be provided for patient in part 1 ctc evaluable population .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">in addition , the number and percentage of patient with ctc count ≥ 5vs .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">&lt; 5 and ctc count &gt; 0vs .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">=0 per 7.5 ml will be presented a well .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the analysis of ctc count conversion from 5 or more ctc per 7.5 ml at baseline to &lt; 5 ctc per 7.5 ml post baselinewill excludepatients with a ctc count &lt; 5 per 7.5 ml at baseline .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the proportion of patient withsuch a conversion will be calculated along with the two-sided 95 % ci using clopper- pearson method ( exact methodfor a binomial proportion ) .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the analysis of ctc count conversion from detectable at baseline to 0 postbaselinewill exclude patient with a ctc count of 0 per 7.5 ml of blood at baseline .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the proportion of patient with sucha conversionwill be calculated along with the two-sided 95 % ciusing clopper-pearson method.the analysis of the proportion of patient with baseline ctc &lt; 5 who show increased ctc postbaselinewill excludepatients with a ctc count of ≥ 5 per 7.5 ml of blood at baseline .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the proportion of patient with such a conversion will be calculated along with the two-sided 95 % ci using the clopper-pearson method .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">a separate analysis plan will be provided to describe analysis of molecular profiling of tumor tissue remaining after genomic testing for eligibility and of saliva and ctdna .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">although not specifically \n",
       "<mark class=\"entity\" style=\"background: cyan; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    listed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_L</span>\n",
       "</mark>\n",
       " a exploratory objective , analysis of efficacy including rpfs , orr in patient with soft tissue measurable disease at baseline , psa response , and time to psa progression may be evaluated during the course of the study and will be reported at the time of the final analysis of rpfs in all-comers , if not sooner .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">derivation will follow the same rule outlined in section 6.2for part 2 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    summary\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " will be descriptive and not inferential .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">specifically summary of time to event endpoint will be limitedto median and rate at specific timepoints of interest .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    summary\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " of response rate will include number and percentage .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    summary\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " will be provided regardless of mutation status or starting dose .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">mutation status ( where available ) 6.2.1 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">primary endpoint -- rpfs 6.2 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">part 2 analysis 6.2.1 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">primary endpoint -- rpfs the primary efficacy analysis will compare rpfs based on bicr between talazoparib in combination with enzalutamide vs. talazoparib-matching placebo in combination with enzalutamide , and will be performed using anone-sided stratified log-rank test forthe all- comer and ddr- deficient population respectively ( subset of the itt population ) .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">a secondary analysis of rpfs based on investigator assessment will also be performed .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">rpfs is defined a the time from the date of randomization to first objective evidence of radiographic progression a assessed in soft tissue per recist1.1 or in bone ( upon subsequent confirmation ) per pcwg3 guideline , or deathdue to any cause , whichever occurs first , and will be summarized in month using the following calculation : rpfs ( month ) = [ date of event/censoring –randomization date +1 ] /30.4375 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the documentationrequiredfor the determination of radiographic progressionis shown in table 5 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    table\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " 5 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">criterion for evidence of radiographic progression date criterion for progression criterion for confirmation criterion for progression of progression documentation of disease detected ( requirement and timing ) progression on ( visit ) [ 1 ] confirmatory scan week9 bone lesion : 2or more new timing : at least 6weeks persistence of at least 2 lesion compared to baseline after progression identified lesion seen at week 9 bone scan by pcwg3 or at week17 visit [ 2 ] and 2 or more new bone lesion on bone scan ( compared to week9 scan ) table 5 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">criterion for evidence of radiographic progression date criterion for progression criterion for confirmation criterion for progression of progression documentation of disease detected ( requirement and timing ) progression on ( visit ) [ 1 ] confirmatory scan soft tissue lesion : no confirmatory scan not applicable progressive disease on ct or required for soft tissue mri by recist1.1 disease progression week17 or bone lesion : 2 or more new timing : at least 6weeks persistent of at least 2 of later lesion on bone scan after progression identified the lesion identified a compared to week9 bone required for bone lesion new compared to week 9 scan observed on bone scan [ 2 ] soft tissue lesion : no confirmatory scan not applicable progressive disease on ct or required for soft tissue mri by recist1.1 disease progression [ 1 ] progression detected by bone scan at an unscheduled visit prior to week 13 will requireconfirmation at least 6 week later following the confirmation criterion outlined in the table for week 9 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">all other unscheduled assessment will follow the confirmation criterion for week 17 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">[ 2 ] confirmation must occur at the next available scan .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">rpfs will be censored in the following scenario : 1 ) the patient will be censoredon the date of the last adequate tumor assessment on or before the data cutoff dateif the patient doe not have radiographic progression and doe not die .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">2 ) the patient will becensored on the date of last adequate tumor assessment prior to the start of new antineoplastic therapy , if thepatient start a new antineoplastic therapy prior to radiographic progressionor death .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">3 ) the patient will be censored onrandomizationdate , if the patient doe not have baseline or postbaselinetumor assessment .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">4 ) the patient will becensoredon the date of the last adequate tumor assessment without evidence of disease progression prior to missed tumor assessment , if the patient miss 2 or more scheduled tumor assessment immediately prior to radiographic progression or death .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">for the purpose of rpfs censoring , apatient will be censored on the date of the last adequate tumor assessment prior to the start of new antineoplastic therapy if the patient start a new antineoplastic therapy prior to radiographic progression or death .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">if a patient ha a curative radiotherapy where the treatment intent is specified a ‘ primary treatment ’ or surgery where the treatment intent is specified a ‘ curative in intent ’ and the surgery outcome is either ‘ resected ’ or ‘ partially resected ’ prior to radiographic progression or death , the patient will also be censored on the date of the last adequate tumor assessment before the radiotherapy or surgery.two or more missed assessment is defined a follows :  if the last adequate tumor assessment prior to the event occurs on or before 70 day from randomization , more than 119 day from that assessment ( two 8-week assessment plus a 7-day assessment window ) to the event ;  if the last adequate tumor assessment prior to the event occurs after 70 day and on or before 126days from randomization , more than 147days from that assessment ( an8-week assessment plus a 12-week assessment plus a 7-day assessment window ) to the event ;  if the last adequate tumor assessment prior to the event occurs after 126days from randomization , more than 175 day from that assessment ( two 12-week assessment plus a 7-day assessment window ) to the event .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">if a patient meet more than onecensoring criterion described above , the patient ’ s rpfs value will be censored atthe earliest censoring date .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the stratified analysis will be based on the following randomization stratification factor : previous treatment with any nht or taxane-based chemotherapy for cspc ( yes vs. no ) ; ddr mutational status ( deficient vs. non- deficient/unknown ) .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the primary stratified analysis will be based on the stratification information recorded in iwrs .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">a secondary stratified analysis based on ddr mutational status derived from clinical database will also be performed .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">especially because ddr status in iwrs can not separate non-deficient and unknown status , derived ddr status from clinical database will be used to identify the non-deficient subpopulation .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">prior to protocol amendment 6 , ddr mutational status for randomization/stratification wa obtained from tumor tissue ( archival or fresh biopsy ) or historical test result ( prior tumor tissue analysis using foundationone test ) .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">starting with protocol amendment 6 , ddr mutational status for randomization stratification wa derived from either tumor tissue ( archival slide or fresh biopsy or historical test result ) or peripheral blood ( liquid biopsy ) prior to randomization .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">if prospective result from bloodand tumor tissue sample are both available , apositive result from eitherwill be considered prospectively ddr-deficient for randomizationstratification .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">retrospectively analyzed screening plasmasamples with result known after randomizationand retrospectively analyzed saliva result will also be incorporated for patient with an unknown ddr status in exploratory analysis .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">for detail see section 5.2.7 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">kaplan-meier \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    curve\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_F</span>\n",
       "</mark>\n",
       " will be used to estimate the time-to-event distribution .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the 50th percentile of kaplan -meier estimate will be used to estimate the median duration of each endpoint .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">a 2-sided 95 % ci based on the brookmeyer-crowley method will be provided for this estimate .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">in addition , the event-free rate and 95 % ci at 12 month , 24 month , and 36 month for each treatment arm will be presented.the stratified hazard ratio ( talazoparib in combination with enzalutamide/control ) and the associated 95 % ci will be estimated using a cox proportional hazard model .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">tie will be handled using the breslowmethod .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">both one-sided and two-sided p-values will be providedin summary table .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">frequency ( number and percentage ) of patient with each event type ( progression [ including type of progression –i.e .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">bone progression , soft tissue progression , bone and soft tissue progression ] or death ) and censoring reason will be presented by treatment arm along with the overall event and censoringrates .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">reason for censoring will be summarized according to the category intable 6 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">if a patient meet multiple definition for censoringat the same visit , the \n",
       "<mark class=\"entity\" style=\"background: cyan; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    list\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_L</span>\n",
       "</mark>\n",
       " will be used to define the hierarchy .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    table\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " 6 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">censoring reason and hierarchy for rpfs hierarchy condition censoring reason 1 no adequate baseline assessment no adequate baseline assessment 2 start of new antineoplastictherapy or select start of new antineoplastictherapy radiotherapy/surgery before event .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">3 event immediately after missing at least two event after missing assessment consecutive assessment 4 no event and withdrawal of consent date ≥ withdrawal of consent randomization dateor end of study ( eos ) = patient refused further follow-up 5 no event and lost to follow-up in any disposition page lost to follow-up 6 no event and eos present or disposition page for no adequate postbaselinetumor any epoch after screening say patient will not assessment continue into any subsequent phase of the study and no adequate postbaselinetumorassessment 7 no event and none of the condition in the prior ongoing without an event hierarchy are met median follow-up time will be estimated according to the kaplan-meier estimate of potential follow-up by the reverse kaplan-meier method .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">an overview forest \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    plot\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_F</span>\n",
       "</mark>\n",
       " of rpfs based on bicr assessment bythe following subgroup will be presented .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">a similar forest plot based on investigator assessment will also be provided .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"> age ( &lt; 70/≥70 )  geographic region ( north america , european union [ eu ] /great britain [ gbr ] , asia , rest of world [ row ] )  easterncooperative oncologygroup ( ecog ) performance status at baseline ( 0 , 1 )  total gleason score at diagnosis ( &lt; 8/≥8 )  type of progression at study entry ( psa only , radiographic progression with or without psa progression )  baseline psa ( &lt; vs. ≥ overall median )  site of metastasis at study entry ( bone only , soft tissue only , both bone and soft tissue , none )  ddr status by iwrs ( ddr-deficient , non-deficient/unknown )  prior taxane or nht the following sensitivity analysis will be performed separately for the all-comers and 6.2.1.1 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">sensitivityanalyses the following sensitivity analysis will be performed separately for the all-comers and ddr-deficient population to explore the robustness ofeach primaryanalysis result .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">some of these sensitivity analysis will be presented in the csr , while the remaining will be presented in other summary document , for example , summary of clinical efficacy and summary of clinical safety .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the sensitivity analysis will be performed following the method described forthe primary analysis with the modification below :  radiographicpfs counting all progression and death a event regardless of missing assessment or timing of the event ( i.e .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">not censoring due to thestart of a new antineoplastictherapy prior to event or due to missed assessment ) based on bicr andinvestigator assessment .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"> radiographicpfs counting study treatment discontinuation , start of a new antineoplastic therapy , andoccurrence of asymptomatic skeletal event a additional event based on bicr and investigator assessment .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">censoring will be similar to that described for the primary analysis , except for the following : o radiographic progression , death , discontinuation of study treatment ( both treatment component ) , start of a new anti-cancer therapy , and a symptomatic skeletal event will all be considered a event .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">rpfs will be calculated a the time interval from the date of randomization to the date of radiographic progression , death , discontinuation of study treatment ( both treatment component ) , start of a new anti-cancer therapy , or a symptomatic skeletal event , whichever occurs first .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"> radiographic pfs by assigning the date ofcensoring and event only at scheduled assessment date based on bicr and investigator assessment : o if aradiographic progression occurs within 7-daywindowof it scheduled assessment time , it will be assigned the scheduled assessment date .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">if a radiographic progression occurs outside the 7-day window and between 2assigned a the radiographic progression date ( e.g. , if a radiographic progressionoccurs between week 25 and 37 , it will be assigned to week 37 ) .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">o in the event of death , the event date will not be adjusted .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">ddr-deficient patient enrolled in china in cohort 1 will be included in the analysis of ddr-deficient patient population .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">a sensitivity analysis of ddr-deficient patient by excluding the ddr- deficient patient enrolled in china in cohort 1 will also be performed .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">in addition , to ass the impact ofcovid-19 , the following sensitivity analysis of rpfs may be performed if covid-19 related death is reported in at least 10patients in the study :  radiographic pfs based on bicr assessment and censoring  death due to covid-19 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"> radiographic pfs based on investigator assessment and censoringdeaths due to covid-19 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">bicr v investigator assessment : a separate summary of the bicr assessment versus investigator assessment will be provided for the all-comers population and for the ddr-deficient population .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">these will include number of concordant and discordant assessment a well a the number of case where a pfs event wa assessed at different timepoints by the bicr and investigator .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the following category will be summarized by treatment arm for each population :  agreement on time and occurrence of rpfs event ( within 28 day ) ( a1 ) ,  agreement on rpfs event but investigator event occurred later ( by &gt; 28days ) ( a2 ) ,  agreement on rpfs event but investigator event occurred earlier ( by &gt; 28days ) ( a3 ) ,  investigator assessment of rpfs event , patient censored in the bicr analysis ( b ) ,  patient censored in the investigator assessment analysis of rpfs , bicr assessment of rpfs event ( c ) , and  agreement on non-occurrence of rpfs event ( d ) .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">a +/-28day window will be used to ass the agreement on timing and occurrence of an rpfs event .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">total event discrepancy rate ( b+c ) /n , early discrepancy rate ( a3+b ) / ( a+b ) , late discrepancy rate ( a2+c ) / ( a2+a3+b+c ) ; and overall discrepancy rate ( a2+a3+b+c ) /n will be calculated where a=a1+a2+a3.6.2.2 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">secondary endpoint each secondary endpoint will be analyzed separately for the all-comers population and o is defined a the time from randomization to the date of death due to any cause .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">patient 6.2.2.1 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">overall survival o is defined a the time from randomization to the date of death due to any cause .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">patient last known to be alive will be censored at the date of last contact .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">o ( month ) = [ date of deathor censoring –randomization date +1 ] /30.4375 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">aone-sided stratifiedlog-rank test will be performed on o in the all-comers population if the null hypothesis of rpfs in the all-comers population is rejected .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">similarly , aone-sided stratified log-rank test of o will be performed in the ddr-deficient population if the null hypothesis of rpfs in the ddr-deficient population is rejected .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the stratified hazard ratio ( talazoparib in combination with enzalutamide/control ) and the associated 95 % ci will be estimated using a cox proportional hazard model .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">tie will be handled using the breslowmethod .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">both one-sided and two-sided p-values will be provided in summary table .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">kaplan- meier estimate will be presented by treatment arm with a summary of associated statistic including the median o with two-sided 95 % ci .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">in addition , the survival rate and 95 % ci at 12months , 24months , 36months , and 48 month for each treatment arm will be presented a well .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">reason for censoring will be summarized according to the category intable 7 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">ifa patient meet multiple definition for censoring , the \n",
       "<mark class=\"entity\" style=\"background: cyan; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    list\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_L</span>\n",
       "</mark>\n",
       " will be used to define the hierarchy .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    table\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " 7 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">censoring reason and hierarchy for o hierarchy condition censoring reason 1 no event and withdrawal of consent date ≥ withdrawal of consent randomization dateor eos= subject refused further follow-up 2 no event and lost to follow-up in any disposition page lost to follow- up 3 no event and none of the condition in the prior alive hierarchy are met frequency ( number and percentage ) of patient with anevent and censoring reason will be presented by treatment arm a follows :  death o death due to covid-19  withdrawal of consent  lost to follow-up ongoing and no death .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">to ass the impact of covid-19 , the following sensitivity analysis of o may be performed by applying the additional censoring rule if covid-19 related death is reported in at orr is defined a the proportion of patient with measurable soft tissue disease at baseline 6.2.2.2 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">objective response per recist 1.1 orr is defined a the proportion of patient with measurable soft tissue disease at baseline with a best overall confirmedsoft tissue response of cr or pr according to recist 1.1 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">soft tissue response must be confirmed by a follow-up radiographic assessment at least 4 week later with no evidence of confirmed bone disease progression on repeat bone scan at least 6 week later per pcwg3 criterion .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">patient without documented cr or pr will be considered non-responders .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">prior to determining the best overall soft tissue response , the date of confirmed bone progression ( if applicable ) will be determined .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">if confirmed bone progression is documented and the soft tissue response at the visit where the bone progression criterion are first met is not pd , the derived soft tissue timepoint response incorporating bone assessment will be pd .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">this derived timepoint response will be used to determining the best overall response ( bor ) .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">an example is provided intable 8 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    table\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " 8 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">incorporation of bone progression into best overall response overall soft example soft tissue tissue number timepoint response bone assessment response considering bone progression ( derived ) 1 week9 cr progression pd criterion met ( pd ) week 17 cr progression pd criterion confirmed 2 week 9 cr progression cr criterion met ( non-pd ) week 17 cr progression cr criterion not confirmed 3 week 9 sd non pd sd week 17 pr progression pdtable 8 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">incorporation of bone progression into best overall response overall soft example soft tissue tissue number timepoint response bone assessment response considering bone progression ( derived ) week 25 pr progression pd criterion confirmed best overall response willbe assessed on patient with measurable disease based on reported overall response at different evaluation timepoints from the date of randomization until documented disease progression ( in soft tissue per recist 1.1 or in bone per pcwg3 guideline ) or start of new antineoplastictherapyor curative radiotherapy where the treatment intent is specified a ‘ primary treatment ’ or surgery where the treatment intent is specified a ‘ curative in intent ’ andthe surgery outcome is either ‘ resected ’ or ‘ partially resected ’ , according to the following rule :  cr = at least two determination of cr at least 4 week apart and documented before progression and start of new antineoplastictherapy  pr = at least two determination of pr or better ( and not qualifying for a cr ) at least 4 week apart and before progression and start of new antineoplastic  sd ( for patient with at least one measurable lesion at baseline ) = at least one sd assessment ( or better and not qualifying for cr or pr ) ≥ 8weeks after date of randomizationand before progression and the start of new antineoplastictherapy  pd = progression ≤ 16weeks after date of randomizationand not qualifying for cr , pr or sd  not evaluable ( ne ) = all other case .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">for investigator assessment , global deterioration of health statuswill not be considered a documented disease progression .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">for patient with measurable soft tissue disease at baseline , objective response rate ( orr ) will be summarizedfor the two treatment arm .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the primary evaluation of orr will be based on bicr overall tumor assessment .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">a secondary evaluation of orr will be based on the investigator assessment using derived response based on recist 1.1 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the frequency ( number and proportion ) of patient with best overall response of cr , pr , sd , progressive disease ( pd ) , and ne ( not-evaluable ) will be tabulated .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">patient with best overall responseof ne will be summarized by reason for having ne status. no adequate baseline assessment  early death ( defined a death prior to 8 week after date or randomization )  no postbaseline assessment due to covid-19 , i.e .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">participant miss tumor assessment visit due to covid-19 pandemic  no postbaselineassessments due to other reason  all postbaselineassessments have overall response ne  new antineoplastictherapy started before first postbaselineassessment  sd of insufficient duration ( &lt; 8 week after date of randomization )  pd too late ( &gt; 16weeks after date of randomization ) special and rare case where the best overall responseis ne due to both early sd and late pd will be classified a ‘ sd of insufficient duration ’ .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">orr by treatment arm will be calculated along with the two-sided 95 % ciusing a cochran– mantel–haenszel test .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the difference in response rate between treatment arm along with bothone-sided and two-sided p-values for thedifference will be provided .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">in addition , for each ddr mutation , for patient with measurable soft tissue disease at baselinewho have an objective response 6.2.2.3 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">duration of soft tissue response for patient with measurable soft tissue disease at baselinewho have an objective response per recist 1.1 , duration of soft tissue response ( dor ) is defined a the time from the date of the first soft tissue response to the first documented objective evidence of progression ( in soft tissue per recist 1.1 or in bone per pcwg3 guideline ) or start of new antineoplastic therapy .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">those patient who did not have a soft tissue response will be excluded from the analysis .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the censoring rule for duration of soft tissue response are a described for rpfs in section 6.2.1 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">dor ( month ) = [ date of event or censoring–first date of cr/pr +1 ] /30.4375 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">kaplan-meier estimate ( product-limit estimate ) will be presented by treatment arm together with a summary of associated statistic including the median dr time with two-sided 95 % ci .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the ci for the median will be \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    calculated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " according to brookmeyer and crowley .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">inferential statistic ( e.g .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">hazard ratio and p-value ) will not be provided for duration of response given that the analysis is performed on the responder only , not the itt population .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">duration of soft tissue response will be reported forboth the all-comers population and the ddr-deficient population .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">in addition , for each ddr mutation , dor by treatment arm may also be explored if there are enough patient with the mutation.6.2.2.4 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">proportion of patient with psa response ≥ 50 % psa response is defined a a decline from baseline psa ( ng/ml ) by at least 50 % .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">a psa response must be confirmed by a second consecutive value at least 3 week later .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">patient without a baseline and at least one post baseline psa assessment will not be analyzed for this endpoint .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">only assessment performed from the date of randomizationuntil confirmed psa progression or start of new anticancer treatment ( defined a systemic anticancer therapy [ other than study treatment ] , or curative radiotherapy where the treatment intent is specified a ‘ primary treatment ’ , or surgery where the treatment intent is specified a ‘ curative in intent ’ and the surgery outcome is either ‘ resected ’ or ‘ partially resected ’ ) , given after the first dose of study treatment will be considered .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the percentage of patient in the itt population with maximum psa decline of at least 50 % will be calculated along with the two-sided 95 % ci .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the difference in response rate between treatment arm along with both one-sided and two-sided p-values for the difference in will be providedusing a cochran–mantel–haenszel test in summary table .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">psa ( ng/ml ) will also be summarized descriptively by visit .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">psa response will be reported forboth the all-comers psa progression is defined a the timefrom the date of randomization to the date of the first 6.2.2.5 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">time to psa progression psa progression is defined a the timefrom the date of randomization to the date of the first psa value demonstrating progression , which is subsequently confirmed .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">if apatient start a new antineoplastic therapy prior to psaprogression , the patient will be censored on the date of last psa assessment prior to the start of a new antineoplastic therapy .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">patient without confirmed psa progression will be censored at the date of the last psa assessment .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">patient without any post baseline assessment will be censored at randomization .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">psa progression ( month ) = [ date of psa progression or censoring –randomization date +1 ] /30.4375 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">for patient with psa decline , the psa progression date is defined a the date that a ≥ 25 % increase and an absolute increase of ≥ 2µg/l ( 2ng/ml ) above the nadir is documented , which is confirmed by a second consecutive value obtained at least 3weeks later .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">early rise ( before week 12 ) shouldbe ignored in determining progression .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">a such , for patient with no psa decline , the psa progression date is defined a the date that a ≥ 25 % increase and an absolute increase of ≥ 2µg/l ( 2ng/ml ) above the baseline is documented after week 12 , which is confirmed by a second consecutive value at least 3 week later .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">psa progression will be analyzedusing a one-sided stratified log-rank test .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">kaplan-meier estimate will be presented by treatment arm with the median and 95 % ci .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">frequency ( number and percentage ) of patient with anevent orcensoring will be presented by treatment arm.time to psa progression will be reported forboth the all-comers population and the ddr- time to initiation of cytotoxic chemotherapy is defined a the time from randomization to the 6.2.2.6 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">time to initiation of cytotoxic chemotherapy time to initiation of cytotoxic chemotherapy is defined a the time from randomization to the first use of cytotoxic chemotherapy .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">cytotoxic chemotherapy will be identified based on a clinical review of all follow-up cancer therapy reported on the follow-up therapy crf page .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">this review will occur prior to data unblinding .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">result will be reported in month ( [ date of event or censoring –randomization ] ) /30.4375 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">patient not starting any cytotoxic chemotherapywill be censored at the date of last contact .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">time to initiation of cytotoxic chemotherapy will be analyzedusing a one-sided stratified log-rank test .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">kaplan-meier estimate will be presented by treatment arm with the median and 95 % ci .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">frequency ( number and percentage ) of patient with anevent orcensoring will be presented by treatment arm .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">time to initiation of cytotoxic chemotherapy will be analyzedforboth the all-comers population and the ddr-deficient time to initiation of antineoplastic therapy is defined a the time from randomization to the 6.2.2.7 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">time to initiation of antineoplastic therapy time to initiation of antineoplastic therapy is defined a the time from randomization to the first use of antineoplastic therapy .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">such therapy include cytotoxic chemotherapy , hormonal chemotherapy , and investigational agent for prostate cancer .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">they will be identified based on a clinical review of all follow-up cancer therapy reported on the follow-up therapy crf page .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">this review will occur prior to data unblinding .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">result will be reported in month ( [ date of event or censoring –randomization ] ) /30.4375 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">patient not starting any antineoplastic therapy will be censored at the date of last contact .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">time to initiation of antineoplastic chemotherapy will be analyzedusing a one-sided stratified log-rank test .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">kaplan-meier estimate will be presented by treatment arm with the median and 95 % ci .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the result will be reported forboth the all-comers population time to the first symptomatic skeletal event is defined a the time from randomization to the 6.2.2.8 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">time to first symptomatic skeletal event time to the first symptomatic skeletal event is defined a the time from randomization to the date of the first symptomatic fracture , surgery to the bone , radiotherapy to the bone , or spinal cord compression a reported on the skeletal related event crf page .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">patient without any symptomatic skeletal event will be censored at the date of the last skeletal event assessment .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">analysis will be in month ( [ date of event or censoring –randomization ] ) /30.4375.time to the first symptomatic skeletal event will be analyzedusing a one-sided stratified log- rank test .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">kaplan-meier estimate will be presented by treatment arm with the median and 95 % ci .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the result will be reported forboth the all-comers population and the ddr-deficient pfs2 is defined a the time from randomization to investigator documented disease 6.2.2.9 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">pfs2 based on investigator assessment pfs2 is defined a the time from randomization to investigator documented disease progression ( psa progression , progression on imaging , or clinical progression ) on the first subsequent antineoplastic therapy for prostate cancer , or death from any cause , whichever occurs first .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">pfs2 ( month ) = [ date of event/censoring –date of randomization +1 ] /30.4375 a patient will be considered to have an event if :  date of documented progression on the first subsequent antineoplastic therapy is provided on follow-up cancer therapy crf page ; or  the patient dy .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">pfs2 will be analyzedusing a one-sided stratified log-rank test .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">kaplan-meier estimate will be presented by treatment arm with the median and 95 % ci .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">both one-sided and two- sided p-values will be provided in summary table .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the censoring andevent date option to be considered for pfs2 along with the corresponding censoring reason and it hierarchy are presented intable 9 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the frequency ( number and percentage ) of patient with an event and censoring reason will be presented by treatment arm .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    table\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " 9 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">outcome , event/censoring date , and reason for censoring for pfs2 scenario date of event/censoring outcome/ censoring reason/ censoring hierarchy no pda and no death date of last adequate censored/ tumor assessmentb no pd by investigator/ documenting no pd 1 no pda and death date of death event ( death ) pda date &gt; ntx1c start date start date of ntx1c censored/ and no death start of new anticancer treatment before pd/ 2 pda date &gt; ntx1c start date date of death event ( death ) and deathtable 9 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">outcome , event/censoring date , and reason for censoring for pfs2 scenario date of event/censoring outcome/ censoring reason/ censoring hierarchy pda date ≤ ntx1c start date documented progression event ( date of documented and documented progression on ntx1 progression on ntx1 ) on ntx1 pda date ≤ ntx1c start date date of death event ( death ) and no documented progression on ntx1 and death pdadate ≤ ntx1c start date date of last contact censored/ and no documented withdraw of consent/ progression on ntx1 and 3 no death and the patient withdrew consent for follow-up pda date ≤ ntx1c start date date of last contact censored/ and no documented lost to follow-up/4 progression on ntx1 and no death and the patient is lost to follow-up pda date ≤ ntx1c start date date of last contact censored/ and no documented ongoing without pfs2 event/ progression on ntx1 and 5 no death and no other condition met a pd is the first pd while on study treatment by investigator assessment per recist v1.1 or per pcwg3 , without considering any censoring rule .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">b if there is no adequate postbaseline assessment , then the censoring date is the date of randomization .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">if the patient ha initiated next-line anticancer treatment , the last adequate postbaseline assessment on or prior to start date of next line anticancer treatment will be considered .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">c ntx1 is the first new anticancer regimen the pfs2results will be reported forboth the all-comers population and the ddr-deficient time to opiate use for prostate cancer pain is defined a the time from date of randomization 6.2.2.10 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">time to opiate use for prostate cancer pain time to opiate use for prostate cancer pain is defined a the time from date of randomization to the date of the first or new opiate medication for prostate cancer painstarted after randomization and will be based on the start date of medication reported on the concomitant medication page of the crf reported with a category of ‘ opioids ’ .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">patient without any opiate use will be censored at the last dose of study treatment.time to opiate use for prostate cancer painwill be analyzedusing a one-sided stratified log- rank test .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">kaplan-meier estimate will be presented by treatment arm with the median and 95 % ci .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the result will be reported forboth the all- all of the pro endpoint described below will be analyzed using the pro analysis set .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">6.2.3 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">pro endpoint all of the pro endpoint described below will be analyzed using the pro analysis set .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">pro endpoint will be analyzedforboth the all-comers time to deterioration in patient-reported pain symptom per bpi-sf 6.2.3.1 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">time to event endpoint time to deterioration in patient-reported pain symptom per bpi-sf patient-reported pain symptom ( per the pain log – bpi-sf question 3 ) will be completed for 7 consecutive day beforeeachstudy visit .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">in addition , the bpi-sf will be completed during each study visit.four or more completed bpi-sf question 3at each visit period ( i.e .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">collectively7 consecutive day prior to each study visit and during study visit ) are required for thepain score for each time periodto be considered evaluable .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">pain score average during each visit period will be calculated and will be used for the analysis of time to deterioration in patient-reported pain symptom .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">analgesic use ( per analgesic log ) is recorded for seven consecutive day prior to each study visit and during each study visit .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the worst world health organization ( who ) analgesic usage score for each visit period ( seven consecutive day prior to each study visit and during study visit ) will be used .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">analgesic use is scored according to who criterion : zero for no use , one for use of non-opiate analgesic ( e.g. , non-steroidal anti-inflammatory drug , acetaminophen , antidepressant , and agent targeting neuropathic pain ) , two for use of weak opiate for moderate pain ( e.g. , codeine and tramadol ) , and three for strong opiate for severe pain ( e.g. , morphine and fentanyl ) .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">time to deterioration in patient-reported pain symptom per bpi-sf is assessed using the average pain score from the bpi-sf question 3 : “ please rate your pain by marking the box beside the number that best describes your pain at it worst in the last 24 hours. ” time to this event is defined a the time from randomization to onset of pain progression , where pain progression is defined a a ≥2 point increase from baseline in the question 3 scorefor two consecutive visit period at least 4 week apart without a decrease in who analgesic usage score .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">if there is a decrease in who analgesic usage score , then it will not be consideredas pain progression even if there is a ≥2 point increase from baseline in the question 3 score .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">patient without observed pain progression at the time of analysis will be censored at the date of last bpi-sf assessment .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">kaplan-meier estimate will be presented together with a summary of associated statisticsfrequency ( number and percentage ) of patient with an event or censoring will be presented .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">time to definitive deterioration in patient-reported global health status/qol per eortc qlq-c30 time to definitive deterioration in patient-reported global health status/qol per eortc qlq-c30is defined a the time fromrandomization to the firstdefinitive deterioration defined a a ≥ 10-point decrease from baseline and no subsequent observation of a &lt; 10-point decrease from baseline .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">patient without a definitive deterioration at the time of analysis will be censored at the date of last eortc qlq-c30assessment .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">kaplan-meier estimate will be presented together with a summary of associated statistic including the median and quartile with two-sided 95 % ci .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">frequency ( number and percentage ) of patient with an event or censoring will be presented .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">time to definitive deterioration in patient-reported disease-specific urinary symptom per eortc qlq-pr25 time to definitive deterioration in patient-reported disease-specific urinary symptom per eortc qlq-pr25 is defined a the time fromrandomization to the firstdefinitive deterioration defined a a ≥ 10-point increase from baseline and no subsequent observation of a &lt; 10point increase from baseline .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">patient without a definitive deterioration at the time of analysis will be censored at thedate of last eortc qlq-pr25 assessment .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">kaplan-meier estimate will be presented together with a summary of associated statistic including the median and quartile with two-sided 95 % ci .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">frequency ( number and percentage ) of patient bpi-sf 6.2.3.2 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">descriptivesummaries and change from baseline bpi-sf descriptive summary for bpi-sfby visit will be provided .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">these include :  for each visit period ( collectively for study visit and the 7 consecutive day prior to each study visit ) , number and percentage of patient who completed all the bpsi-sf question 3 out of a total of 8 ) , ≥4 of the bpi-sf question 3 , and those who did not complete any bpi-sf question 3 will be summarized  descriptive summary of the average score at each visit period for bpi-sf question3 o each pain intensity is a whole number ( 0 through 10 ) and will be summarized a a continuous variable o missing value ( &lt; 4 of8 possible assessment per visit period ) are not included in the summariesdescriptive statistic for change from baseline in patient- reported pain symptom per bpi- sf ( question 3 ) will be summarized for each visit period .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">a graphical display of mean over time a well a mean change from baseline over time will also be provided .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">a longitudinal mixed effect model will also be used to summarize the change from baseline pain symptom score ( bpi-sf question 3 ) across all visit period .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">unless otherwise specified , all scheduled assessment will be used in the analysis , regardless of adherence to study treatment .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">eq-5d-5l health index analysis of the eq-5d health index will consist of descriptive statistic on \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mean\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " and change from baseline , overall change from baselineusing a longitudinal mixed effect model , and graphical display of mean and change from baseline over time .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">in addition , there will be a health status profile analysis consisting of adisplay of the number and percentage of patient in each of the 5response level for each ofthe 5 dimension at each visit .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">eq-5d general health status ( eq-5d va ) analysis of eq-5d va will consist of descriptive statistic on \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mean\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " and change from baseline , overall change from baselineusing a longitudinal mixed effect model , and graphical display of mean and change from baseline over time .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">qlq-c30 analysis of the qlq-c30will consist of descriptive statistic for each scale on \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mean\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " and change from baseline , overall change from baselineusing a longitudinal mixed effect model , time to definitive deterioration , and graphical display of mean and change from baseline over time .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">qlq-pr25 analysis of the qlq-pr25 will consist of descriptive statistic for each scale on \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mean\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " andchanges from baseline , overall change from baselineusing a longitudinal mixed effectsmodel , time to definitive deterioration , and in part 2 , analysis of pk concentration will include sampling at predoseand 2 hour post- 6.2.4 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">pk in part 2 , analysis of pk concentration will include sampling at predoseand 2 hour post- dose at week 3 , 5 and 9 , and pre-dose at week 13 and 17 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the pk analysis forpart 2 of the studywill be similar to those for part 1 of the study .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">for detail see section 6.1.2 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">separate summary of dose-normalized c by scheduled visit trough for ctc endpoint will be analyzedseparately forboth the all-comers population and the ddr- 6.2.5.1 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">ctc conversion rate ctc endpoint will be analyzedseparately forboth the all-comers population and the ddr- deficient population .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">for ctc count , a summary of the mean ( standard deviation ) , median , and range of baseline and postbaselinevalues will be provided for patient in thectc evaluable set .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">in addition , the number and percentage of patient with ctc count ≥ 5 vs. &lt; 5 and ctc count &gt; 0 vs. =0 per 7.5 ml will be presented a well .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">for the analysis of ctc count conversion from 5 or more ctc per 7.5 ml at baseline to &lt; 5 ctc per 7.5 ml post baseline , those patient with a ctc count &lt; 5 per 7.5 ml at baseline will be excluded for this conversion endpoint .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the proportion of patient with a conversion will be calculated along with the two-sided 95 % ciusing the clopper-pearson method .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">for the analysis of ctc count conversion from detectable at baseline to 0 postbaseline , those patient with a ctc count of 0 per 7.5 ml of blood at baseline will be excluded for this conversion endpoint .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the proportion of patient with such a conversionwill be calculated along with the two-sided 95 % ciusing the clopper-pearson method .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">for the analysis of the proportion of patient with baseline ctc &lt; 5 who show increased ctc postbaseline , those patient with a ctc count of ≥ 5 per 7.5 ml of blood at baseline will be excluded from the analysis .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the proportion of patient with such a conversion will be calculated along with the two-sided 95 % ciusing the clopper-pearson method .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the result will be analyzed forboth the all-comers population and the ddr-deficient a separate analysis plan will be written to describe analysis of molecular profiling of tumor 6.2.5.2 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">molecular profiling a separate analysis plan will be written to describe analysis of the concordance of ddr deficiency result ( ddr-deficient/non-deficient/unknown ) will be 6.2.5.3 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">concordance of ddr deficiency result the concordance of ddr deficiency result ( ddr-deficient/non- deficient/unknown ) will be exploredfor the following assay method :  prospective tissue-based test vs. retrospectively analyzed screening blood-based test  prospective blood-based test vs. retrospectively subgroup analysis will be performed if there is a sufficient sample size .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the determination 6.3 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">subgroup analysis subgroup analysis will be performed if there is a sufficient sample size .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the determination of whether or not there is a sufficient samplesize will be defined after enrollment is completethere are ≥ 20 patient within the defined subset and analysis of time to event endpoint will only be performed if there are at least 10 event on each treatment arm within the subgroup .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">deviation from these analysis will be described in the clinical study report .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">some of the subgroup analysis will be presented in the csr , while the remaining will be presented in other summary document , for example , summary of clinical efficacy and summary of clinical safety .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">besides the subgroup analysis presented in the overview forest \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    plot\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_F</span>\n",
       "</mark>\n",
       " described in section6.2.1 , the following additional subgroup analysis will be performed for rpfs by bicr where the subgroup are subset of the all-comers population :  ddr mutational status derived using prospective/retrospective data ( subgroup definition 2-6in section 5.2.7 ) .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"> renal impairment ( moderate , mild , normal )  race ( asian , white , african american , other )  prior nht ( yes , no )  prior docetaxel ( yes , no )  baseline bone protecting agent ( yes , no )  baseline ldh value ( &lt; vs. ≥ median )  baseline hemoglobin value ( &lt; vs. ≥ median )  baseline alp value ( &lt; vs. ≥ median )  baseline ctc count ( &lt; 5 , ≥ 5 )  baseline ctc count ( 0 , &gt; 0 ) similarsubgroup analysis will be performed for cohort 2 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">a subgroup analysis for o will be performed at the time of the final o analysis using the same subgroup specified above for rpfs .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">subgroup analysis of other efficacy parameter and subgroup analysis for part 1 data are not planned .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">key safety output for part 2 will be provided to explore the following subgroup :  renal impairment ( moderate vs.mild vs. normal ) ,  age ( &lt; 70vs .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">≥ 70 ) ,  asian vs. non-asian.normal , mild , and moderate renal impairment are defined based on baseline egfr of ≥90 ml/min/1.73m2 , 60-89 ml/min/1.73m2 , and30-59ml/min/1.73m2 respectively , where egfr willbe captured on the crfs .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">key safety output for part 1 will be provided by startingdose .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">additionally adverse event \n",
       "<mark class=\"entity\" style=\"background: cyan; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    listing\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_L</span>\n",
       "</mark>\n",
       " will consider the dose at the time of the unless otherwise specified , the following summary will be provided separately for the 6.4 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">baseline and other summary unless otherwise specified , the following summary will be provided separately for the safety analysis set of part 1 and for the itt all- comer and ddr-deficient population in part 2 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">for part 1 , select thefollowingdemographic andbaselinedisease characteristicswill besummarized : 6.4.1 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">baseline summary thefollowingdemographic andbaselinedisease characteristicswill besummarized :  age ( continuous and by group : &lt; 65 ; 65- &lt; 75 ; &gt; =75 )  race  asian vs. non-asian  weight  body mass index ( bmi )  geographic region ( northamerica , europe , asia , rest of world )  renal impairment at baseline ( normal , mild , moderate ) , o normal , mild , and moderate are defined based on baseline baseline egfr of ≥90 ml/min/1.73m2 , 60-89 ml/min/1.73m2 , and 30-59ml/min/1.73m2 , respectively ,  histopathological classification  baseline serum psa ( ng/ml )  baseline useof aboneprotecting agent ( yes , no )  gleason score ( low [ 2-4 ] , medium [ 5-7 ] , high [ 8-10 ] )  gleason score ( &lt; =6 , 3+4=7 , 4+3=7 , 8 , 9-10 , not reported )  ecogperformance status  tnm stageat diagnosis  tnm stage at study entry  disease localization at screening : o bone only o soft tissue only o both bone and soft tissue o none distribution of disease at screening : o bone ( includes bone with soft tissue component ) o lymph node o visceral disease ( lung or liver ) o visceral disease ( lung ) o visceral disease ( liver ) o other soft tissue  number of bone metastasis at screening : n ( % ) o 0 o 1-4 o 5-9 o 10-20 o &gt; 20  type of progression at study entry : o psa progression only o bone progression only o soft tissue progression only o psa+ bone or soft tissue o bone+ psa or soft tissue o psa+bone+soft tissue  baselinepain score by bp-sf ( 0-1 ; 2-3 ; &gt; 3 ) ,  baseline ctc count o continuous summary o categorical summary ( ≥ 5 ctc per 7.5 ml of blood , &lt; 5 ctc per 7.5 ml of blood ) o categorical summary ( &gt; 0 ctc per 7.5 ml of blood , 0 ctc per 7.5 ml of blood )  time from primary diagnosis to randomization in month ( date of randomization – date of diagnosis ) /30.4375  derived ddr mutational status ( positive , negative , unknown ) with specific mutation prior to randomization  ddr mutational status ( positive , negative , unknown ) with specific mutation based on blood sample only  ddr mutational status ( positive , negative , unknown ) with specific mutationsbased on tumor tissue sample onlythe number of patient in the following category at the time of randomization will be summarized :  prior nht ortaxane and ddr-deficient  prior nht or taxane and non ddr-deficient/unknown  no prior nht ortaxane and ddr-deficient  no prior nht or taxane and non ddr-deficient/unknown a \n",
       "<mark class=\"entity\" style=\"background: cyan; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    listing\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_L</span>\n",
       "</mark>\n",
       " will be provided with the stratum ( defined above ) at the time of randomization a well a based on crf data with a flag to indicate case where there are difference between medical history will be coded using the most current version of meddra and summarized 6.4.2 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">medical history medical history will be coded using the most current version of meddra and summarized by meddra ’ s soc and pt .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">each patient will be counted only once within each pt or soc .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    summary\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " will be ordered by primary soc and pt in descending order of frequency by the experimental treatment arm .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    summary\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " will be provided for all prior anticancertreatments include systemic therapy , radiation , and surgery .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">6.4.3 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">prior anticancertreatments prior anticancertreatments include systemic therapy , radiation , and surgery .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the number and percentage of patient in each of the following anticancer therapy category will be tabulated :  patient with at least one type of prior anticancer systemic treatment including androgen deprivation therapy ;  patient with at least one prior anticancer surgery ;  patient with at least one prior anticancer radiotherapywith “ primary treatment ” and “ salvage ” intent ;  patient with any prior androgen deprivation therapy .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">prior anticancer drug therapy will be summarized a follows based on the number and percentage of patient : o number of prior anticancer therapy regimen ( including androgen deprivation therapy ) : none/ 1 / 2 / ≥3 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the prior anticancerdrugs will be coded in the who drug coding dictionary and will be summarized usingthe number and percentage of patient by preferred term .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">a patient will be counted only once forum given preferred term , even if he/she received the same medication atcombination with enzalutamidearm .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">in case of equal frequency , alphabetical order will be used .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">a summary of the number of patient with the followingprior cancersurgeries will be provided :  prostatectomy ,  turp ,  prostate biopsy ,  bilateral orchiectomy ,  pelvic node dissection ,  ureteral stent ,  nephrostomy .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">specific detail on all other surgery and radiotherapy ( primary treatment and discontinuation from study treatment due to adverse event will be identified a either 6.4.4 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">study conduct and patient disposition discontinuation from study treatment due to adverse event will be identified a either related or not related to study treatment .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">if causality is missing the event will be considered related to treatment .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">if multiple event lead to study treatment discontinuation and at least one wa considered related , discontinuation will be reported a related to study treatment .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">covid-19 related disposition alisting of all patientsaffectedbycovid-19will be created .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the \n",
       "<mark class=\"entity\" style=\"background: cyan; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    listing\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_L</span>\n",
       "</mark>\n",
       " will present subject number identifier byinvestigational site , and a description of covid-19-related event including :  all protocol important protocol deviation will be compiled prior to database release and will be 6.4.5 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">protocol deviation important protocol deviation will be compiled prior to database release and will be summarized by category ( n ( % ) ) using the safety population for part 1 andthe itt population forpart 2.categories will be assigned by the study team .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">in addition , all protocol deviation related to covid-19 will be presented in a separate listing.6.4.6 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">study treatment exposure exposure summary will be presented using the safety analysis set for each part .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">part 1 patient hada starting talazoparib dose of either 1 mg/day or 0.5 mg/dayin combination withenzalutamide 160 mg/day , depending on timing of enrollment .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the part 1 data will be presented separately by the starting talazoparib dose .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">for part 2 , thedailydose of talazoparibis 0.5 mg/daygivenorallyin combination with enzalutamide 160 mg/dayat approximatelythesametimeeach day for patient with normal/mild renal impairment .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">thestartingtalazoparib dosewill be 0.35mg/dayin combination withenzalutamide 160 mg/dayforpatients with moderaterenal impairment ( egfr 30-59ml/min/1.73m2 ) .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">separate summary will be provided for talazoparib and enzalutamide and will include the following :  treatment duration ( month ) : foreachpatient , treatmentdurationis definedas ( date of last dose–dateof first dose +1 ) / 30.4375 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">treatment duration will be summarizedboth a a continuous measureandacategorical measure ( ≤ 3 month , 3 to &lt; 6 month , 6 to &lt; 12 month , ≥ 12 month ) .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"> average dailydose ( mg/day ) : theaveragedailydoseis definedas the cumulative dosedividedbythe actual number of day on the treatment .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"> dose intensity ( mg/week ) : doseintensity is definedas the cumulativedose dividedbythe treatment duration .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"> relative dose intensity ( % ) : relative dose intensity is defined a the ratio of the actual dose intensity to the planned dose intensity expressed in % .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the planned dose intensity will be 3.5 mg ( 0.5 mg per day for 7 day ) for patient without moderate renal impairment and 2.45 mg ( 0.35 mg per day for 7 day ) for patient with moderate renal impairment .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">rdi ( % ) = 100x [ dose intensity ( mg/week ) ] / [ planned dose intensity ( mg/week ) ] .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">a dose reduction is defined a a non-zero dose that is le than the prior dose.the number andpercentage of patient with at least one dose reductionas well a a breakdown of dose reduction ( 1 / 2 / 3 ) will be summarized by treatment arm .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">reason for dose reduction will also be summarized .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">there could be more than one reason if multiple dose reduction occur forthe same patient , though each reason will be counted only once for each patient .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    percentage\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " will be calculated based on the total number of patient in safety analysis set .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">an dosing interruption is defined a 0mg dose administered .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">( note : a dosinginterruption is not considered a dose reduction ) .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the number and percentage of patient with dosing interruption and the corresponding reason will be summarized by treatment arm .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">there could be more than one reasonif multiple dosinginterruption occur forthe same patient , though each reason will be counted only once for each patient .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    percentage\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " will be calculated based on the total number of patient in safety analysis set .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">time to first interruption ( week ) and time to first reduction ( week ) , measured from the date of first dose of study treatment , will be summarized for patient who had at least one interruption or reduction respectively .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">a summary of duration ( day ) of dosinginterruptions due to any aes and for anemia only for each dosinginterruption will be provided , where ‘ n ’ is the number of dosing interruption .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">apatient can contribute multiple observation , one for each interruption .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">a summary of the total duration ( day ) of dosinginterruptions due to aes for concomitant medication refer to all medication thatstarted or were ongoing at the time of 6.4.7 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">concomitant medication concomitant medication refer to all medication thatstarted or were ongoing at the time of randomization , started after randomization and continued during the on-treatment period for up to 28 day after the last dose of all the study treatment a well a those started during the on-treatment period .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">concomitant medication will be coded in the who drug coding dictionary and will be tabulated by anatomical therapeutic chemical ( atc ) classification level 2 and preferred term in descending order of frequencyfor the talazoparib in combination with enzalutamidearm .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">in case of equal frequency regarding drug class ( respectively drug name ) , alphabetical order will be used .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">a patient will be counted only once forum given drug name , even if he/she received the same medication multiple time .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">concomitant non-drug treatment refer to non-drug treatment ( radiation and surgery ) administered during the on-treatment period .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">non-drug treatment will be coded in meddra and will be summarized by meddra soc and pt in descending order of frequencyon the talazoparib in combination with enzalutamidearm .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">patient will be counted only once per pt even if he/she received the same treatment multiple time .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">concomitant medication and non-drug treatment will be summarized by treatment arm for the part 1 and part 2 safety population .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">concomitant subsequent systemic anticancertherapies are defined a therapy collectedon the ‘ follow- 6.4.8 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">subsequent anticancertherapies/procedures subsequent systemic anticancertherapies are defined a therapy collectedon the ‘ follow- up cancer therapy ’ crf page .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">subsequent anticancer procedure include procedure collected on ‘ follow-up radiation therapy ’ marked a curativeor salvage , and ‘ follow-up surgery ’ crf page where the date is on or after the date of first dose of study treatment .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the number and percentage of patient within each category ( medication therapy , radiation therapy , and surgery ) will be provided by treatment arm for thepart 2 itt population .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">subsequent anticancertherapies and procedure will be \n",
       "<mark class=\"entity\" style=\"background: cyan; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    listed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_L</span>\n",
       "</mark>\n",
       " for part 1 and part 2 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">medication will be coded using the who drug coding dictionary and will be tabulated by preferred term in descending order of frequency.6.5 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">safety summary and analysis unless otherwise specified , summary of aes and other safety parameter will provided separately for part 1 and part 2 and will be based on the safety population .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">for part 1 the data will be analyzed by the starting dose of talazoparib .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">for part 2 a it is anticipated that follow-up for the primary endpoint in the ddr-deficient population will be ongoing ( i.e .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">treatment assignment will still be blinded ) at the time of the final analysis of rpfs in the all- comer population , summary will initially be performed only for the all-comers population .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">at the time of the final rpfs analysis in the ddr-deficient population safety data will be summarized for the combined population of all-comers and ddr- all analysis will be based on treatment-emergent event unless otherwise specified .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">aes not 6.5.1 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">adverse event all analysis will be based on treatment-emergent event unless otherwise specified .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">aes not considered treatment-emergent will be flagged in data \n",
       "<mark class=\"entity\" style=\"background: cyan; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    listing\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_L</span>\n",
       "</mark>\n",
       " .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">for part 1 and part 2 separately , ahigh- level summary of adverse event will include the number and percent of patient with :  any ae ;  serious ae ;  ctcae grade 3-4 aes ;  grade 5 aes ;  aes leading to dose reduction of talazoparib/placebo ;  aes leading to dose reduction of enzalutamide ;  aes leading to dose reduction of both talazoparib/placebo and enzalutamide ;  aes leading to dosinginterruptions of talazoparib/placebo ;  aes leading to dosinginterruptions of enzalutamide ;  aes leading to dosing interruption of both talazoparib/placebo and enzalutamide ;  aes leading to permanent discontinuationof talazoparib/placebo ;  aes leading to permanent discontinuationof enzalutamide ;  aes leading to permanent discontinuation of both talazoparib/placebo and enzalutamide .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">seriousness , toxicity grade , action taken ( interruption , reduction , and withdraw ) are a reported by the investigator on the adverse event crf .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    summary\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " soc and pt by treatment arm in decreasing frequency will be provided for :  treatment-emergent aes ( all causality ) ;  treatment-emergent aes by maximum ctcaegrade ( all causality ) ;  treatment-emergent covid-19 related aes ( all causality ) ;  treatment-emergent aes ( treatment related ) ;  treatmen -emergent aes by maximum ctcae grade ( treatment related ) ;  serious treatment- emergent aes ( all causality ) ;  serious treatment-emergent aes ( treatment related ) ; an aewill be considered treatment related if the investigator considered the event related to one or both of study drug given in combination .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the following summary of aes will be provided by decreasing frequency of pt ( summary will not include soc ) in the talazoparib plus enzalutamidearm for part 2 only :  treatment-emergent aes ( all causality ) in either treatment arm ;  treatment-emergent aes ( all causality ) by preferred term and maximum ctcae grade ;  treatment-emergent aes leading to dosing interruption of talazoparib ( all causality ) ;  treatment-emergent aes leading to dosing interruption of enzalutamide ( all causality ) ;  treatment- emergent aes leading to dosing interruption of bothtalazoparib and enzalutamide ( all causality ) ;  treatment emergent aes leading to dose reduction of talazoparib ( all causality ) ;  treatment emergent aesleading to dose reduction of enzalutamide ( all causality ) ;  treatment emergent aesleading to dose reduction of both talazoparib and enzalutamide ( all causality ) ;  treatment emergent aes leading to permanent withdraw of talazoparib ( all causality ) ;  treatment emergent aes leading to permanent withdraw of enzalutamide ( all causality ) ;  treatment emergent aes leading to permanent withdraw of both talazopariband enzalutamide ( all causality ) ;  treatment emergent aes between ddr-deficient patient and non-deficient patient ( all causality ) ;  treamtment emergent ae between normal/mild vesusmoderate renal impareiment ( all causality )  serious treatment emergent aes ( treatment related ) .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">each patient will be counted only once within each soc and pt .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">if a patient ha event with missing and non-missing toxicity grade , the maximum non- missing grade will be displayed .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">missing grade will only be displayed in the event that only one aehas been reported for a patient and the grade is missing .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    summary\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " of time to first grade 3 or 4 event and time to first sae will also be providedfor the safety population in part 2 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">patient without an event will be censored a follows :  if the patient ha discontinued from study treatment the patient will be censored 28 day afterthe last dose of studytreatment , or before systemic anticancer therapy , whicheveroccurs first , and  if the patient is still on study treatment at the time of analysis the patient will be censored at the see section 3.4.1for a \n",
       "<mark class=\"entity\" style=\"background: cyan; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    list\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_L</span>\n",
       "</mark>\n",
       " of aes of special interest .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">6.5.2 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">adverse event of special interest see section 3.4.1for a \n",
       "<mark class=\"entity\" style=\"background: cyan; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    list\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_L</span>\n",
       "</mark>\n",
       " of aes of special interest .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">for talazoparib aesis , separate summary for each aesi will be provided by maximum toxicity and will include an ‘ any event ’ row along with a row for each contributing pt in descending order of frequency .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">given the observed incidence of hematologic toxicity associated with the use of talazoparib , a summary of hematologic aes will be provided toshow the incidence of the following cluster term :  anemia : anaemia , decreased hemoglobin , decreased hematocrit , red blood cell count decreased  neutropenia : neutropenia and decreased neutrophil count  thrombocytopenia : thrombocytopenia and platelet count decreased  leukopenia : leukopenia or white blood cell count decreased  lymphopenia : lymphopenia or lymphocyte count decreased aesis for enzalutamide will be summazried by medical event only , not by the frequency ( number and percentage ) of patient in the safety populationwho died anddeath , will be tabulated based on information from the ‘ notice of death ’ and ‘ survival 6.5.3 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">death the frequency ( number and percentage ) of patient in the safety populationwho died anddeath , will be tabulated based on information from the ‘ notice of death ’ and ‘ survival follow-up ’ crfs .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">date and cause of death will be provided in individual patient data \n",
       "<mark class=\"entity\" style=\"background: cyan; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    listing\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_L</span>\n",
       "</mark>\n",
       " with selected dosing information ( study treatment received , date of first / last administration , dose , etc . ) .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">in addition , if there are ≥ 10deaths due to covid-19 , a separate death summary will be createdfor laboratory result will be converted to international system of unit ( système international 6.5.4 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">laboratory data laboratory result will be converted to international system of unit ( système international d'unités , si ) unit for reporting .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">quantitative data will be summarized using descriptive statistic ( mean , standard deviation , median , quartile , minimum , and maximum ) of actual value and change from baseline for each visit over time ( i.e .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">unscheduled assessment will be excluded ) .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the total number of patient for change from baseline will include all patient who have botha baseline and a value at the postbaseline visit .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">baseline will be defined a the last assessment performed on or prior to date of the first dose of study treatment ( or prior to randomization for randomized patient ) .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">if there are multiple assessment that meet the baseline definition on the same day without the ability to determine which wa truly last , then the worst grade will be assigned a the baseline grade .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">result collected a strict inequality ( e.g. , &gt; 10 , &lt; 10 ) will be converted to numeric value subtracting a factor of 0.001 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">expression of the form ” ≥ ” or “ ≤ ” will be converted to the end point .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">these numeric value will be evaluated for clinically significant abnormality , but will not be included in calculation of summary statistic .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">additionally , laboratory result will be programmatically classified accordingto nci- ctcae version 4.03 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">non-numerical qualifier will not be taken into consideration in the derivation of grade ( e.g .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">hypokalemia grade 1 and grade 2 are only distinguished by a non- numerical qualifier and therefore grade 2 will not be derived ) .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">in summary statistic the number and percentage of patient corresponding to grade that only include non-quantitative criterion will be displayed a a blank or na ( not assessed ) rather than 0 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">if there is any overlap between grade criterion ( e.g .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">ctcae gradingcriteria for creatinine increased –a value can fall into one range based on comparison to upper limit of normal ( uln ) and another range based on comparison to baseline ) , the highest ( worst ) grade would be assigned to that record .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">grade 5 is defined in the ctcae criterion guidance a an event with an outcome of death .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">since laboratory data doe not collect an outcome , grade 5 is not used when programmatically grading laboratory data .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">grade 0 or outside toxicity reference ( otr ) is not defined specifically byin the ctcae guidance .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">however , programmatically this is used a a category to represent those patient who did not meet any of the grade 1 to 4 criterion .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">if the laboratory value is evaluable for ctcae criterion grading ( numeric value is present , valid unit and range are present asthe grade 1-4 criterion for a given laboratorytest , then the value is assigned a grade 0 or otr .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">abnormality will be described using the worst grade by scheduled timepoint and overall .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">worst grade by scheduled timepoint will be determined using only local laboratory result .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">worst overall grade will be determined using both central and local laboratory result from scheduled and unscheduled visit .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">several laboratory test have bi-directional grading criterion defined so that both low ( hypo ) and high ( hyper ) value can be graded separately .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">each criterion will be summarized separately .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">in the case where a value is graded a a grade 1 , 2 , 3 , or 4 for one of the direction , that value will also be assigned a a grade 0 for the opposite direction for that test .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">for example , a value meeting the criterion for grade 3 hypercalcemia will be classified a a grade 0 hypocalcemia .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">for ctcae term that can be derived using one of several laboratory test , the maximum postbaselinegrade for a given patient and ctcae term will be the maximum across all possible laboratory test .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">additional laboratory result that are not part of nci-ctcae will be presented according to the following category by scheduled timepoint a well a overall : below normal limit , within normal limit , and above normal limit .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">in the unlikely event that for a given patient , clinically significant abnormality are noted in both direction ( e.g. , &gt; ulnand &lt; lower limit of normal ( lln ) ) , then both abnormality are counted.summaries at scheduled timepoints will consider only central laboratory data ; however summary overall will consider both central and local laboratory data .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">liver function test : alanine aminotransferase ( alt ) , aspartate aminotransferase ( ast ) , alkaline phosphatase ( alp ) , and total bilirubin ( tbili ) are used to ass possible drug induced liver toxicity .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the ratio of test result over the ulnwill be calculated and classified for these three parameter during the on-treatment period .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    summary\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " of liver function test will include the following category .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">the number and percentage of patient with each of the following during the on-treatment period will be summarized by treatment arm :  alt ≥ 3×uln , alt ≥ 5xuln , alt ≥ 10×uln , alt ≥ 20×uln  ast ≥ 3×uln , ast ≥ 5xuln , ast ≥ 10×uln , ast ≥ 20×uln  ( alt or ast ) ≥ 3×uln , ( alt or ast ) ≥ 5×uln , ( alt or ast ) ≥ 10×uln , ( alt or ast ) ≥ 20×uln  tbili ≥ 2×uln  concurrent alt ≥ 3×uln and tbili ≥ 2×uln  concurrent ast ≥ 3×uln and tbili ≥ 2×uln  concurrent ( alt or ast ) ≥ 3×uln and tbili ≥ 2×uln concurrent ( alt or ast ) ≥ 3×uln and tbili ≥ 2×uln and alp ≤ 2×uln or missing concurrent measurement are those occurring on the same date .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    category\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_T</span>\n",
       "</mark>\n",
       " will be cumulative , i.e. , a patient with an elevation of ast ≥10×uln will also appear in the category ≥5×uln and ≥3×uln .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">liver function elevation and possible hy ’ s law case will be summarized using frequency count and percentage .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">an evaluation of drug-induced serious hepatotoxicity ( edish ) \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    plot\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_F</span>\n",
       "</mark>\n",
       " will also be created , with different symbol for different treatment arm , by graphically displaying  peak serum alt ( /uln ) v peak total bilirubin ( /uln ) including reference line at alt=3×uln and total bilirubin=2×uln .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\"> peak serum ast ( /uln ) v peak total bilirubin ( /uln ) including reference line at ast=3×uln and total bilirubin=2×uln .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">in addition , a \n",
       "<mark class=\"entity\" style=\"background: cyan; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    listing\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">R_L</span>\n",
       "</mark>\n",
       " of all tbili , alt , ast and alp value for patient with a postbaseline tbili ≥ 2×uln , alt≥ systolicanddiastolic blood pressure ( mmhg ) , heart rate ( bpm ) , and temperature ( celsius ) 6.5.5 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">vital sign systolicanddiastolic blood pressure ( mmhg ) , heart rate ( bpm ) , and temperature ( celsius ) will besummarizedat baseline andat all subsequent scheduledtimepoints .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">change from baseline valuewill bepresentedfor all scheduledtime point .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">all recorded vital signdata will belistedfor part 1 and 2 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">thenumberandpercentage ofpatients with thefollowingvital signchanges will be presented.the definition of potentiallyclinicallysignificant abnormalitiesareshown in table 10 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">table 10 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">potentiallyclinicallysignificantabnormalitiesinvitalsigns parameter criteriaforpotentiallyclinicallysignificantabnormalities systolicbloodpressure absoluteresult &gt; 180 mmhg andincrease from baseline ≥40 mmhg absoluteresult &lt; 90 mmhg and decrease from baseline &gt; 30 mmhg diastolic bloodpressure absoluteresult &gt; 110 mmhg andincrease from baseline ≥30 mmhg absoluteresult &lt; 50 mmhg and decrease from baseline &gt; 20 mmhg ≥ 20 mm hg increase from baseline heart rate absolute result &gt; 120 bpm and increase from baseline &gt; 30 bpm absolute result &lt; 50 bpm and decrease from baseline &gt; 20 bpmtable 10 .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">potentiallyclinicallysignificantabnormalitiesinvitalsigns parameter criteriaforpotentiallyclinicallysignificantabnormalities weight &gt; 10 %</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# text = \"\"\n",
    "# sent_tokenize\n",
    "sentence = sent_tokenize(extracted_sec1)\n",
    "for sen in sentence:\n",
    "    word_list = nltk.word_tokenize(sen)\n",
    "    lem_line= ' '.join([lemmatizer.lemmatize(w.lower()) for w in word_list])\n",
    "    doc=nlp(lem_line)\n",
    "    color={'R_T':'pink', 'R_L':'cyan', 'R_F':'violet'}\n",
    "    options={'ents':['R_T','R_L','R_F'],'colors':color}\n",
    "    spacy.displacy.render(doc,style='ent',jupyter=True,options=options)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
